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Abstract 
Multiple  myeloma  (MM)  remains  essentially  incurable  by  conventional  anti-tumour 
therapy,  although  the  median  survival  time  has  increased  to  5  years  in  those  who 
respond  well  to  autologous  (auto)  haematopoietic  stem  cell  transplant  (HSCT).  In 
a  small  number  of  patients  with  MM,  long-term  disease-free  survival  has  been 
achieved  by  harnessing  the  immune  phenomenon,  "graft-versus-tumour"  effect, 
induced  during  allogeneic  haemopoietic  stem  cell  transplantation.  This  has 
prompted  many  investigators  to  examine  ways  in  which  a  patient's  own  immune 
system  can  be  more  effectively  directed  against  their  disease,  with  the  ultimate 
aim  of  tumour  eradication.  However,  the  MM  is  associated  with  a  number  of 
cytokines  and  chemokines  such  as  CCL3,  IL-6,  IL-10,  VEGF,  and  TGFß  that  have 
immunosuppressive  effects  on  the  host,  and  drive  disease  progression 
The  BDCA  antibodies  allowed  reliable  measurement  of  dendritic  cell  (DC)  subsets 
and  B  cell  numbers  in  the  blood  of  normal  subjects,  and  patients  with  MM 
throughout  the  disease  course.  The  numbers  of  blood  myeloid  DC  (BmDC)  and 
blood  plasmacytoid  DC  (BpDC)  are  low  throughout  the  course  of  the  disease,  and 
only  improve  for  a  short  period  of  time  following  autologous  HSCT.  Thalidomide 
therapy  of  patients  with  relapsed  disease  was  associated  with  an  increase  in 
BmDC1  and  BpDC  numbers. 
Monocytes,  mobilised  at  the  time  of  stem  cell  collection,  were  used  to  produce 
mature  DC  (matDC)  from  MM  patients  and  normal  donors  (ND).  The  matDC 
produced  from  MM  patients  were  of  poorer  quality  as  compared  to  those  from  ND, 
despite  using  combinations  of  GM/IL-4,  GM/IL-13,  X4  and  MIMIC  in  the  production 
process.  The  combinations  that  contained  the  X4  maturation  cocktail  produced  the 
best  quality  matDC. Dr  Simon  J  Harrison,  2005  3 
Pre-stimulation  of  MM  T  cells  with  T  cell  stimulation  beads  and  IL-2  enhanced  their 
proliferative  response  to  IL-2  and  matDC+IL-2,  but  blocked  proliferation  in 
response  to  matDC  alone.  Pre-stimulation  also  blocked  T  cell  cytokine  secretion  in 
response  to  DC  alone.  Despite  this,  pre-stimulated  matDC  primed  T  cells  from  MM 
patients  produced  the  best  killing  of  MM  tumour  cell  targets,  followed  by  un- 
stimulated  matDC  primed  TC,  with  un-stimulated  matDC  primed  TC  from  ND 
producing  poor  cytolytic  effects. 
The  fluorescent  chemokine  uptake  assay  was  a  sensitive  and  specific  method  for 
detecting  chemokine  receptor  activity,  and  was  able  to  track  changes  during  DC 
development  and  maturation.  CCL3  uptake  was  low  on  MM  monocytes.  Uniquely, 
mobilised  monocytes  also  demonstrated  some  CCR7  activity,  as  indicated  by 
CCL19  uptake.  This  expression  was  confirmed  by  RT-PCR.  CCR7  activity  was 
best  on  ND  matDC  matured  with  the  X4  cytokine  cocktail,  and  significantly  lower 
on  matDC  from  MM  patients.  CCR8  expression  was  significantly  higher  on  MM 
monocytes  and  matDC  than  on  ND  cells,  suggesting  that  they  may  be  more 
sensitive  to  the  immunosuppressive  effects  of  CCL1. 
In  summary,  the  DC/  T  cell  system  is  abnormal  in  MM  patients.  Despite  this,  it  is 
possible  to  produce  antigen  loaded  mature  MoDC  from  MM  patients.  When 
combined  with  T  cell  pre-stimulation  and  IL-2  expansion,  these  DC  are  capable  of 
inducing  anti-MM  cytotoxic  T  cells,  which  exhibit  considerable  anti-MM  cytolytic 
activity.  However,  the  DC  from  MM  patients  still  display  abnormal  chemokine 
receptor  expression,  which  may  inhibit  their  capacity  to  migrate  to  lymph  nodes  in- 
vivo  in  order  to  generate  these  cytotoxic  T  cell  responses. 
These  observations  will  aid  in  the  optimisation  of  DC  based  immune  therapies  for 
MM,  and  suggest  that  a  combined  immunotherapy  approach  using  pre-stimulated Dr  Simon  J  Harrison,  2005 
T  cells,  MM  Ag  primed  DC  and  IL-2  may  produced  better  clinical  responses  in  MM 
patients. Dr  Simon  J  Harrison,  2005 
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16 1.  Introduction  and  Aims 
1.1  Multiple  Myeloma 
Multiple  myeloma  (MM)  is  a  clonal  B-cell  malignancy  characterised  by  an  excess 
of  mature  plasma  cells  in  the  bone  marrow  (BM),  in  association  with  a  monoclonal 
protein  in  serum  and/or  urine,  decreased  normal  immunoglobulin  (Ig)  levels,  renal 
failure  and  lytic  bone  disease.  It  has  an  incidence  of  around  4/100,000  in 
Caucasians  and  a  median  age  of  onset  of  70yrs,  with  the  vast  majority  of  patients 
presenting  with  fatigue,  recurrent  infections,  bone  pain  or  pathological  fractures. 
MM  remains  essentially  incurable  by  conventional  anti-tumour  therapy  and  the 
median  survival  time  is  3yrs.  However,  this  may  be  extended  to  5yrs  with  modern 
induction  therapy  and  a  good  response  to  autologous  (auto)  haemopoietic  stem 
cell  transplantation  (HSCT)  (Attal  and  Harousseau  1999,  Child,  et  a/  2003).  The 
diagnostic  criteria  for  MM  and  the  other  members  of  the  group  of  disorders  known 
as  the  monoclonal  gammopathies  were  reviewed  recently  (International  Myeloma 
Working  2003). 
Monoclonal  gammopathy  of  uncertain  significance  (MGUS)  is  a  pre-malignant 
condition  affecting  1%  of  people  <50yrs  and  up  to  3%  of  >70yrs.  Patients  must 
have  a  monoclonal  protein  <30g/l  and  <10%  plasma  cells  in  the  bone  marrow 
(BM).  Patients  with  MGUS  progress  to  MM  or  a  related  disorder  at  a  rate  of  1  %/yr. 
Most  MGUS  patients  have  detectable  clonal  abnormalities,  and  it  is  thought  that 
disease  progression  is  the  result  of  accumulating  genetic  abnormalities  within  the 
plasma  cell  clone.  Smouldering  MM  is  defined  as  the  presence  of  a  paraprotein  of 
30g/l  and/or  >10%  BM  plasma  cells,  with  none  of  the  other  diagnostic  features  of 
MM.  Currently  there  is  no  evidence  that  treatment  at  this  stage  alters  the  disease 
course,  but  a  number  of  on  going  clinical  studies  hope  to  answer  this  question. Dr  Simon  J  Harrison,  2005  Chapter  1-18 
MM  can  be  diagnosed  by  the  presence  of  >  10%  infiltrate  of  plasma  cells  in  the 
BM,  in  the  presence  of  a  monoclonal  paraprotein  in  serum  or  urine,  and  evidence 
of  end  organ  damage,  such  as  hypercalcaemia,  renal  failure,  anaemia  and  bong 
destruction  (CRAB).  A  small  number  of  patients  have  no  detectable  paraprotein, 
but  meet  the  other  diagnostic  criteria,  and  this  is  called  non-secretory  MM.  A 
number  of  disease  prognostic  markers  have  been  defined;  raised  serum  ß2- 
microglobulin;  low  serum  albumin;  deletion  of  chromosome  13  or  it's  long  arm; 
t(4;  14)  and  t(14;  16)  translocations,  and  they  form  the  basis  of  the  new 
International  Staging  System  (Greipp,  et  al  2005).  As  the  disease  progresses,  the 
neoplastic  plasma  cell  induces  a  number  of  changes  in  the  BM  microenvironment 
(Figure  1-5);  increased  angiogenesis;  suppression  of  cell  mediated  immunity 
(discussed  later);  paracrine  signalling  loops  with  stromal  cells  which  induce  tumour 
cell  proliferation  and  resistance  to  drugs  such  as  Dexamethasone. 
The  treatment  of  MM  can  be  divided  into  3  phases,  induction,  consolidation  and 
maintenance.  If  patients  are  not  eligible  for  auto  HSCT,  then  a  simple  induction 
regime  of  monthly  oral  Melphalan  and  Predinisolone  until  the  paraprotein  level 
stops  falling,  despite  further  therapy  i.  e.  plateau  is  reached,  is  the  treatment  of 
choice  because  of  the  low  rate  of  side  effects.  Unfortunately,  Melphalan  is  toxic  to 
stem  cells,  so  younger  fitter  patients  who  will  go  on  to  have  autologous  stem  cells 
collected  need  to  avoid  it  and  other  alkylating  agents  prior  to  harvest.  A  number  of 
alternatives  have  been  the  subject  of  clinical  trials,  such  as  high  dose 
Dexamethasone,  VAD  (intravenous  Vincristine,  Dexamethasone  and  Doxorubicin), 
Z-Dex (oral  Idarubicin  and  Dexamethasone)  and  CTD  (oral  Cyclophosphamide, 
Thalidomide  and  Dexamethasone)  (MRC  sponsored  Myeloma  IX  study) 
(Alexanian,  et  al  1992,  Cook,  et  a/  2004,  Garcia-Sanz,  et  a/  2002).  Although  VAD 
and  CTD  seem  to  have  superior  response  and  complete  remission  rates,  there  is Dr  Simon  J  Harrison,  2005  Chapterl-19 
currently  no  evidence  that  they  are  associated  with  improved  long-term  survival. 
Following  'induction'  therapy,  patients  go  on  to  have  auto  stem  cells  collected  for 
use  in  auto  HSCT  consolidation. 
As  already  discussed,  the  role  of  auto  HSCT,  conditioned  with  200mg/m2  of 
Melphalan,  is  well established.  However,  a  number  of  groups  have  explored  the 
use  of  sequential  or  tandem  auto  HSCT,  and  have  shown  an  improvement  in  EFS 
and  OS  (Attal,  et  a!  2003,  Barlogie,  et  a!  1997).  The  use  of  sequential  auto  and  NM 
allogeneic  (alto)  HSCT  is  also  the  subject  of  clinical  trails.  The  role  of  maintenance 
therapy  following  transplant  is  controversial.  At  present,  there  is  no  convincing 
evidence  to  support  it's  use,  but  a  number  of  studies  (including  Myeloma  IX)  are 
exploring  the  use  of  thalidomide  following  auto  HSCT.  Overall  MM  patients  have  a 
relatively  poor  outlook  compared  to  other  low  grade  lymphoproliferative  disorders. 
This  has  prompted  the  development  of  a  number  of  experimental  compounds  and 
treatment  modalities 
1.2  Allogeneic  Haematopoietic  Stem  Cell  Transplantation 
The  immune  system  is  capable  of  eradicating  malignancies.  The  first  evidence  that 
cancer  cells  were  susceptible  to  immune  attack  emerged  in  the  early  1960's  from 
the  animal  models  used  for  HSCT  (Mathe,  et  al  1965).  This  was  first  demonstrated 
in  human  HSCT  in  the  late  1980's  with  the  observation  that  patients  who  survive  T 
cell  replete  alto  HSCT  have  a  lower  relapse  rate  compared  to  auto,  syngeneic  or  T 
cell  depleted  alto  HSCT  (Gale,  et  al  1989,  Hughes,  et  al  1989).  This  "graft-versus- 
tumour"  effect  has  also  been  demonstrated  using  steady  state  unprimed  donor 
lymphocyte  infusions  (DLI)  to  treat  relapse  following  alto  HSCT  and  in  the  setting 
of  minimal  residual  disease  (Kolb,  et  al  1990). Dr  Simon  J  Harrison,  2005  Chapterl-20 
The  use  of  alto  HSCT  in  the  treatment,  of  MM  has  resulted  in  a  higher  rate  of 
molecular  remission,  with  lower  rates  of  relapse  and  disease  progression  as 
compared  to  patients  treated  with  auto  HSCT  (Bensinger,  et  al  1996,  Corradini,  et 
a!  1999).  Those  patients  who  survive  1  year  have  significantly  improved  disease- 
free  survival  (Bjorkstrand,  et  a!  1996).  This  is  partly  related  to  the  intensity  of  the 
chemo-radiotherapy  conditioning  regimen,  but  it  is  also  a  result  of  the  graft-versus- 
myeloma  (GVM)  effect  (Perez-Simon,  et  al  2003,  Tricot,  et  a11996,  Verdonck,  et  al 
1998).  However,  these  improvements  in  disease  control  are  achieved  at  the 
expense  of  higher  treatment-related  morbidity/mortality  in  the  first  year  and  have 
prompted  the  experimental  use  of  potentially  less  toxic  NM  HSCT  (Crawley,  et  'l1 
2005b,  Garban,  et  al  2001,  Perez-Simon,  et  al  2003,  Singhai,  et  a/  2000).  The 
close  relationship  between  Graft-versus-host  disease  (GvHD)  and  GVM  in 
published  studies  suggests  that  donor  alto-reactive  T  cells  directed  against  minor 
histocompatibility  antigens  (Ags)  present  on  both  normal  and  myeloma  cells 
mediates  the  latter  effect.  The  successful  use  of  DLI  in  some  cases  of  MM  that 
relapse  following  allo-HSCT  has  led  to  increased  interest  in  the  possibility  that 
other  forms  of  immune  therapy  might  be  effective  in  this  disease  (Lokhorst,  et  al 
1997,  Lokhorst,  et  a!  2000).  However,  the  doses  of  T  cells  required  to  induce  these 
remissions  are  higher  in  MM  than  in  other  DLI  responsive  diseases  such  as 
chronic  myeloid  leukaemia  (CML)  (Verdonck,  et  al  1998),  and  are  associated  with 
an  increased  incidence  of  GVHD  (Huff  and  Jones  2002,  Salama,  et  a/2000).  This 
may  be  partly  explained  by  the  influence  of  the  malignant  clone  on  the  function  of 
the  immune  effector  cells  resulting  from  both  passive  and  active  suppression, 
although  it  is  possible  that  MM  tumour  Ags  are  less  immunogenic  compared  with 
those  on  other  malignant  cells,  as  MM  is  associated  with  several  defects  in  the 
host's  immune  system  (Cook  and  Campbell  1999). Dr  Simon  J  Harrison,  2005  Chapter  1-21 
MM  tumour  cells  produce  a  number  of  immunologically  active  agents  that  can 
modulate  the  immune  response  such  as  transforming  growth  factor-bete  (TGF-ß) 
(Cook,  eta!  1999),  interleukin-10  (IL-10)  (Brown,  et  a/  2004),  Fas  liganc  (FasL) 
(Villunger,  et  al  1997),  vascular  endothelial  growth  factor  (VEGF)  (Oyarpa,  et  al 
1998)  and  MUC-1  (Agrawal,  et  a11998,  Gimmi,  et  a11996,  Treon,  et  a/  1998).  It  is 
postulated  that  by  producing  these  agents  the  tumour  cell  modifies  both  the 
microenvironment  to  support  growth  and  differentiation  of  the  clone,  and  the  holt 
immune  response  to  prevent  tumour  rejection.  This  duality  of  function  is important 
in  understanding  the  possible  interactions  of  the  malignant  clone  with  the  tumour- 
bearing  host,  especially  if  we  are  to  design  immunotherapy  strategies  that  will 
achieve  their  true  potential  and  result  in  improved  survival  in  MM. 
In  an  attempt  to  boost  the  GVM  effect  Kwak  et  al  have  demonstrated  the 
successful  transfer  of  myeloma  idiotype-specific  immunity  from  an  actively 
immunised  bone  marrow  donor  to  a  recipient  with  MM,  demonstrating  MHC  class 
I-restricted  CD8+  T  cell  recognition  of  freshly  isolated,  recipient  myeloma  tumour 
cells  (Kwak,  et  al  1995,  Yiwen,  et  al  2000).  It  still  remains  to  be  seen  whether  the 
GVM  effect  can  be  separated  from  GVHD.  However,  there  is  evidence  that  a 
patients  own  immune  system  may  play  an  important  role  in  the  control  of  their 
disease  . 
It  has  been  shown  that  T  cells  specific  for  MM  associated  Ags  such  as 
Mucin-1  (MUC-1  or  CD227)  (Beckhove,  et  ao  idiotype  protein  (Yi,  et  a11995)  and 
NY-ESO-1  (van  Rhee,  et  al  2005b)  are  present  in  the  peripheral  blood  of  MM 
patients.  Joshua's  group  have  shown  that  the  presence  of  expanded  T  cell  clones 
at  any  time  during  the  disease  course  is  associated  with  prolonged  overall  survival 
(Brown,  et  al  1997,  Raitakari,  et  a!  2003). 
Immunotherapeutic  strategies  attempt  to  utilise  the  immune  system  for  disease 
control  and  they  have  mainly  been  tested  in  the  setting  of  relapsed  or  resistant Dr  Simon  J  Harrison,  2005  Chapter  1-22 
disease.  The  use  of  such  strategies  in  the  setting  of  minimal  residual  disease 
following  conventional  chemotherapy  or  HSCT  offers  an  increased  potential  for 
tumour  cell  control  by  adoptively  transferring  immune  effectors  at  a  timt  when  they 
are  likely  to  have  most  impact  (Hsu,  et  al  1997,  Stevenson,  et  a!  2004). 
1.3  Cellular  Immunotherapy 
Discovered  by  Steinman  and  others  in  the  1970's  (Steinman,  et  al  1975,  Steinmpn 
and  Cohn  1973,  Steinman  and  Cohn  1974,  Steinman,  et  al  1974),  dendritic  cellq 
(DC)  have  been  identified  as  the  sentinels  of  the  immune  system.  As  a  result  it  has 
become  theoretically  possible  to  direct  the  immune  response  against  a  specific 
chosen  (tumour)  Ag  towards  immunity  or  tolerance  (Matzinger  and  Guerder  1989). 
It  is  important  to  consider  how  the  different  components  of  the  immune  system 
(DC,  T  cells  and  natural  killer  (NK)  cells)  develop  and  interact  in-vivo  and  how  this 
may  be  altered  in  patients  with  MM.  Subsequently  we  will  consider  how  cells  of  the 
immune  system  may  be  manipulated  ex  vivo  to  overcome  any  MM  tumour  cell 
suppressive  effects  and  eradicate  the  malignant  clone. 
1.3.1  In-vivo  DC  development 
DC  precursors  are  derived  from  the  bone  marrow  haematopoietic  stem  cell  (HSC), 
differentiating  into  two  phenotypically  distinct  populations.  Myeloid  DC  (mDC) 
classically  arise  from  the  common  myeloid  progenitor  and  myelomonocytic 
precursors,  are  characterised  by  the  surface  phenotype  of  CD11c++/  CD1237/ 
CD1  c+,  and  tend  to  induce  Th1  responses.  Plasmacytoid  DC  (pDC)  arise  from  the 
common  lymphoid  progenitor,  are  CD110  CD123'+,  and  induce  Th2  responses. 
However,  factors  such  as  the  strength  of  the  T  cell  receptor/MHC  class  II 
interaction,  Ag  density  and  the  microenvironment,  are  also  important  in  the 
balance  between  mounting  a  Thl  or  Th2  T  cell  response.  Recent  studies  also Dr  Simon  J  Harrison,  2005  Chapterl-23 
suggest  that  the  system  for  DC  generation  may  exhibit  more  plasticity  than 
previously  thought,  in  that  both  myeloid  and  lymphoid  DC  may  arise  from  either 
myeloid  or  lymphoid  progenitors  (Shigematsu,  et  al  2003).  DC  precursor  and 
circulating  blood  DC  migrate  into  peripheral  tissues,  such  as  skin,  portal  triads, 
mucosa  and  lung,  driven  by  their  expression  of  CCR2  and  CXCR4  (Figure  1-1 
and  1-3).  Here  they  down  regulate  CCR2  and  up  regulate  CCR6,  which  seems  to 
be  important  for  (i)  DC  circulation  to  lymphoid  tissue  like  Peyer  patches  via 
constitutive  expression  of  CCL20  and  (ii)  may  play  a  role  in  the  induction  of 
tolerance  to  self  Ags.  Immature  DC  also  express  CCR1,  CCR5  and  CXCR2,  which 
allows  them  to  migrate  towards  areas  of  inflammation  via  increased  levels  of 
CCL3,  CCL5,  CXCL8  and  CCL20,  which  may  be  inducibly  expressed  in  other 
tissues  during  an  inflammatory  response  (Austyn  and  Larsen  1990).  The  iDC 
actively  sample  the  environment  by  phagocytosis  and  process  Ag  from  bacteria, 
viruses  and  apoptotic  bodies  (Albert,  et  al  1998,  Hengel,  et  al  1987,  Svensson,  et 
al  1997),  presenting  them  in  the  context  of  MHC  class  I  and  II  molecules.  To 
mature,  iDC  require  a  second  `danger'  signal  such  as  interferon  (IFN)  a  or  y, 
interleukin-1  ß  or  microbial  compounds  such  as  bacterial  lipopolysaccharide  (LPS) 
(Matzinger  1998).  During  the  ensuing  terminal  differentiation,  DC  down  regulate 
their  phagocytic  and  Ag  processing  functions,  up  regulate  expression  of  MHC 
class  I  and  Il,  costimulatory  and  adhesion  molecules  (O'Neill  and  Bhardwaj  2005). 
Dendritic  cell  maturation  also  down  regulates  CCR1,  CCR5  and  CCR6  and  up 
regulates  CCR7  and  CCR8  expression,  thus  becoming  sensitive  to  CCL1,  CCL19 
and  CCL21,  which  are  constitutively  expressed  in  lymph  nodes  (Qu,  et  a/  2004). 
The  mature  DC  (matDC)  then  rapidly  migrate  to  the  secondary  lymphoid  tissues 
via  the  afferent  lymphatic  system,  attracted  by  chemokines  such  as  CCL19  and 
CCL21  (Chan,  et  al  1999,  Dieu,  et  al  1998),  where  they  efficiently  present  Ag  to  T 
cells,  and  induce  an  immunogenic  response.  If  iDC  encounter  Ag  in  the  absence Dr  Simon  J  Harrison,  2005  Chapterl-24 
of  Inflammation,  they  partially  up  regulate  CCR7  but  do  not  up  regulate  co- 
stimulatory  molecules,  and  constitutively  migrate  to  LN  to  induce/maintain 
tolerance  (Matzinger  1998).  Naive  and  central  memory  T  cells  also  express  CCR7, 
thus  chemokine  expression  brings  DC  and  T  cells  into  close  proximity  for  Ag 
presentation  to  occur. 
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Figure  1-1  In-Vivo  DC  generation,  migration  and  maturation  pathways 
DC  arise  in  the  bone  marrow  and  migrate  from  the  BM  to  peripheral  tissues  via  the 
blood.  Here,  iDC  encounter  Ag,  mature  and  migrate  to  lymph  nodes  via  the 
lymphatics,  and  present  Ag  to  naive  T  cells.  Effector  (cytotoxic)  T  cells  then 
migrate  to  peripheral  tissues  via  the  blood. 
1.3.2  Chemokines  and  their  role  in  DC  trafficking 
Chemokines  (CHEMOtatic  cytoKINES)  were  originally  defined  as  proteins 
manufactured  by  cells  and  tissues  that  stimulate  movement  and  activation  of 
immune  cells  to  the  area  where  the  chemokine  is  produced  and  their  subsequent 
activation.  However,  there  is  now  a  considerable  body  of  evidence  to  show  that Dr  Simon  J  Harrison,  2005  Chapterl-25 
the  biological  effects  mediated  by  chemokines  are  far  more  complex.  Virtually  all 
cell  types,  including  tumour  cells,  have  the  potential  to  express  chemokjnes  and 
chemokine  receptors  and  this  expression  may  have  a  direct  impact  on  tumour  cell 
growth,  angiogenesis  and  metastases  (Vicari  and  Caux  2002).  At  the  same  time 
the  chemokine  expression  pattern  of  the  tumour  may  have  a  direct  bearing  on  the 
host  immune  system's  ability  to  mobilise  monocytes,  DC,  T  cells  and  NK  cells 
against  the  tumour.  The  chemokine  balance  within  the  patient  and  the  tumour  May 
be  crucial  in  determining  the  type  of  immune  response  that  is  mounted,  in  that  the 
tumour  may  shift  the  balance  from  an  immunogenic  response  in  to  a  tolerogenic 
response  by  the  expression  of  a  different  chemokine  `signature`. 
aICXC  subfamily 
ELRCXC  CC 
cxc  cC 
1ICC  subfamily 
cc  cc 
cc  cc  cc 
cxc  cccc 
TM  CT 
1C  subfamily 
cc 
SICX3C  subfamily  TM  CT 
cxxxc  cc 
Figure  1-2  General  structure  of  chemokine  gene  super-family  members. 
Schematic  representation  of  the  conserved  cysteine  signature  residues  present  in 
the  primary  amino  acid  structure  that  distinguish  members  of  the  chemokine  gene 
super-family  in  to  four  basic  subfamilies,  which  can  be  subdivided  based  on  the 
presence  or  absence  of  additional  cysteine  residues  and  ELR  (glutamic  acid, 
leucine  and  arginine)  motifs.  (Reproduced  by  kind  permission  Dr  S.  McColl, 
Chemokine  Biology  Lab,  University  of  Adelaide) 
Chemokines  are  a  large  family  of  proteins,  with  considerable  structural  homology 
based  on  conserved  cysteine  residues  and  the  binding  capacity  to  particular  G 
protein-coupled  receptors  (GPCR)  (Zlotnik  and  Yoshie  2000).  They  have  been 
divided  in  to  4  major  sub-groups  based  on  the  relative  position  of  conserved Dr  Simon  J  Harrison,  2005  Chapterl-26 
cysteine  residues:  CC;  CXC,  XC  and  CX3C  (also  known  as  ß,  a,  y  and  6 
respectively)  with  CC  and  CXC  being  by  far  the  most  common.  In  addition 
Chemokines  can  be  functionally  classified  into  two  groups  based  on  whether  they 
are  expressed  in  a  constitutive/homeostatic  or  inducible  fashion.  The 
nomenclature  for  chemokines  is  confusing.  There  are  over  40  members  of  the 
human  chemokine  family  and  a  large  number  have  several  different  names,  as  a 
consequence  of  being  described  by  different  groups  at  different  times.  In  an 
attempt  to  rationalise  this,  a  new  system  to  standardise  chemokine  ligand 
nomenclature,  was  introduced  after  the  1998  Gordon  Research  Conference  on 
Chemotactic  Cytokines  (Zlotnik  and  Yoshie  2000)  (Table  1-1). 
Sytematic  name  Original  names  Sytematic  name  Original  names 
CCL1  1-309  CXCL1  Gro  a 
CCL2  MCP-1,  MCAF  CXCL2  Gro  P 
CCL3  MIP-la  CXCL3  Gro  y 
CCL4  MIP-1  ß  CXCL4  PF4 
CCL5  RANTES  CXCL5  ENA-78 
CCL7  MCP-3  CXCL6  GCP-2 
CCL8  MCP-2  CXCL7  NAP-2 
CCL11  Eotaxin-1  CXCL8  IL-8 
CCL13  MCP-4  CXCL9  MIG 
CCL14  HCC-1  CXCL10  IP-10 
CCL15  HCC-2,  Lknl,  MIP-16  CXCL11  I  TAC 
CCL16  HCC-4,  LEC  CXCL12  SDF-I 
CCL17  TARC  CXCL13  BLC,  BCA  1 
CCL18  MIP-4,  PARC,  DC-CK1  CXCL14  BRAK 
CCL19  MIP-3ß,  ELC  CXCL16  CXCL16 
CCL20  MIP-3a,  LARC 
CCL21  SLC,  6Ckine  CX3CL1  Fractalkine 
CCL22  MDC,  STCP-1 
CCL23  MPIF-1  XCL1  Lymphotactin 
CCL24  MPIF-2,  Eotaxin-2  XCL2  SCM-1  ß 
CCL25  TECK 
CCL26  Eotaxin-3 
CCL27  CTACK,  ILC 
CCL28  MEC 
Table  1-1  Human  chemokine  systematic  nomenclatures. 
No  human  equivalent  of  mouse  CCL6,  CCL9,  CCL10,  CCL12,  CXCL15  has  been 
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The  function  of  chemokines  on  target  cells  is  mediated  by  binding  to  their 
corresponding  receptors:  CCR,  CXCR,  XCR  and  CX3CR,  which  are  members  of 
the  huge  G-protein  coupled  seven  transmembrane  domain  receptor  superfamily, 
The  complexity  of  this  system  is  further  increased  by  promiscuity,  by  wlýich 
chemokines  can  bind  to  a  number  of  different  receptors  and  receptors  can  bind  p 
number  of  different  ligands  (Table  1-2).  The  result  is  that  there  are  many  possible 
biological  read  outs  based  on  the  balance  of  the  receptor/chemokine  expression 
patterns. 
Chemokine  receptors  Human  chemokine  ligands  Ligand  expression 
CCR1  CCL3-  5,7,14,15,16,23  Inducible 
CCR2  CCL2,5,7,8,13,16  Inducible 
CCR3  CCL3,7,8,11,13,15,24,26,28  Inducible 
CCR4  CCL17,22  Constitutive  /  Inducible 
CCR5  CCL3-  5,8,16  Inducible 
CCR6  CCL20  Constitutive  /  Inducible 
CCR7  CCL19,21  Constitutive 
CCR8  CCL1  Inducible 
CCR9  CCL25  Constitutive 
CCR10  CCL27,28  Constitutive  /  Inducible 
CCR11/CCX  CKR  CCL19,21,25,  CXCL13  ?  Decoy 
CXCR1  CXCL1,6,8  Inducible 
CXCR2  CXCL1-  3,5,6,8  Inducible 
CXCR3  CXCL4,9,10,11  Inducible 
CXCR4  CXCL12  Constitutive 
CXCR5  CXCL13  Constitutive 
CXCR6  CXCL16 
CX3CR1  CX3CL1  Inducible 
XCR1  XCL1,2 
D6  CCL2-  5,7,8,11,13,14,17,22  Decoy 
DARC  CCL3,5,7,11,13,14,17,  CXCLI-  4,7,8,  Decoy/  Buffer 
Table  1-2  Summary  of  the  known  human  chemokine  receptors  and  their 
ligands 
At  the  International  Union  of  Pharmacology,  XXX,  2002,  Update  on  chemokine 
receptor  nomenclature  meeting,  the  putative  receptor  CCR11  was  disqualified 
(Murphy  2002)  because  although  high  affinity  binding  to  CCL19,  CCL21  and 
CCL25  was  identified,  there  was  no  detectable  signalling  or  induction  of 
chemotaxis.  This  placed  it  in  a  group  of  `silent  receptors  along  with  D6  and  DARC. Dr  Simon  J  Harrison,  2005  Chapterl-28 
By  altering  the  expression  of  chemokine  receptor  genes  during  differentiation  and 
maturation,  cells  such  as  DC  and  T  cells  are  able  to  track  from  the  bone  marrow, 
to  peripheral  tissues  and  lymph  nodes  under  the  influence  of  homeostatic  ligands. 
Inflammatory  processes  up-regulate  inducible  CCRs  on  leukocytes,  inducing 
chemotaxis  towards  pro-inflammatory  CCLs,  such  as  CCL3,  produced  during  the 
inflammatory  response  (Figure  1-3). 
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Figure  1-3  DC  migration  and  chemokine  receptor  expression 
DC  precursors  and  blood  DC  migrate  into  peripheral  tissues,  driven  by  their 
expression  of  CCR2  and  CXCR4.  Here  they  down  regulate  CCR2  and  up  regulate 
CCR6.  Immature  DC  also  express  CCR1,  CCR5  and  CXCR2,  allowing  them  to 
migrate  towards  areas  of  inflammation  via  increased  levels  of  CCL3,  CCL5, 
CXCL8  and  CCL20,  inducibly  expressed  in  other  tissues  during  an  inflammatory 
response.  Dendritic  cell  maturation  down  regulates  CCR1,  CCR5  and  CCR6  and 
up  regulates  CCR7  and  CCR8  expression,  becoming  sensitive  to  CCL1,  CCL19 
and  CCL21,  which  are  constitutively  expressed  in  lymph  nodes.  If  iDC  encounter 
Ag  in  the  absence  of  Inflammation,  they  partially  up  regulate  CCR7  and 
constitutively  migrate  to  LN  to  induce/maintain  tolerance.  Naive  and  central 
memory  T  cells  also  express  CCR7,  thus  chemokine  expression  brings  DC  and  T 
cells  into  close  proximity  for  Ag  presentation  to  occur  (Gunn  2003,  Vicari,  et  at 
2004). Dr  Simon  J  Harrison,  2005  Chapterl-29 
Gene  expression,  mRNA  stability,  receptor  trafficking  and  desensitisation  regulate 
the  expression  of  chemokine  receptors  on  the  cell  surface.  Desensitisation  may 
occur  as  the  result  of  one  of  two  mechanisms.  Either,  binding  of  the  ligand  to  the 
receptor  leads  to  internalisation  of  the  ligand-receptor  complex  and  the  cell  is 
refractory  to  subsequent  internalisation,  despite  continued  surface  receptor 
expression.  Alternatively,  ligands  bind  to  receptors  and  induce  desensitisation  of 
another  receptor  by  transactivation.  These  processes  are  known  respectively  as 
homologous  and  heterologous  desensitisation.  As  with  the  cytokine  system,  the 
chemokine  system  is  further  complicated  by  the  expression  of  a  number  of  atypical 
CCRs  (decoy  receptors)  by  the  vascular  and  lymphoid  endothelia.  The  D6 
(Jamieson,  et  a!  2005)  and  CCR11/  CCX  CKR  (personal  communication  R.  J.  B. 
Nibbs)  receptors  bind  CCLs  with  high  affinity,  which  are  internalised  and 
degraded.  However,  internalisation  is  not  associated  with  detectable  signalling, 
chemotaxis,  receptor  desensitisation  or  reduced  re-circulation  to  the  cell  surface 
(Weber,  et  al  2004).  In  contrast,  DARC  (Duffy  antigen  receptor  for  chemokines) 
may  act  as  a  chemokine  buffer  by  binding  CCLs  present  at  high  concentrations, 
preventing  leukocyte  desensitisation,  but  maintaining  a  background  homeostatic 
level  (Comerford  and  Nibbs  2005). 
Until  recently,  trafficking  of  matDC  to  lymph  nodes  was  thought  to  be  mediated  via 
expression  of  CCR7  (Ohl,  et  al  2004).  However,  there  is  recent  evidence  from  a 
transplant  model  using  CCR7  deficient  mice  to  suggest  that  CCR7  is  not  essential 
for  graft  rejection  (Beckmann,  et  al  2004).  Interestingly,  other  groups  have 
suggested  that  CCR8  may  also  be  important  for  matDC  migration  (Qu,  et  al  2004) 
and  co-localisation  of  both  effector  and  regulatory  T  cells  (Sebastiani,  et  a!  2002). 
Inflammatory  cytokines  such  as  TNFa  and  IL-1  P,  and  the  Pathogen  Associated 
Molecular  Patterns  (PAMPs),  which  signal  through  TLRs,  are  traditionally  thought Dr  Simon  J  Harrison,  2005  Chapter  1-30 
of  as  the  main  agents  responsible  for  inducing  DC  maturation.  However,  it  is 
becoming  clear  that  chemokines  may  also  influence  DC  maturation.  It  has  been 
shown  that  T.  Gondii  derived  cyclophilin  is  able  to  induce  IL-12  production  by 
signaling  through  CCR5  (Aliberti,  et  a12000,  Aliberti,  et  a!  2003).  More  recently  it 
has  been  suggested  that  CCL19  and  CCL21  play  a  role  in  DC  maturation  as  well 
as  migration  (Marsland,  et  a/  2005).  In  this  study  it  was  shown  that  the  number  of 
migrating  DC  isolated  from  mice  genetically  deficient  in  CCL21  and  CCL19  (pit/plt) 
(Paucity  of  Lymph  node  T  cell  mutation)  following  Ag  priming  with  FITC  conjugated 
OVA  protein  and  an  LPS  maturation  signal  was  significantly  reduced.  The 
migrating  DC  expressed  a  partially  mature  phenotype,  HLA  class  II  was  normally 
up  regulated,  CD40  was  slightly  reduced,  while  expression  of  CD80  and  86  was 
markedly  reduced  compared  to  wild  type  mice.  Marsland  et  al  also  showed  that  if 
CCL21  or  CCL19  was  produced  in  a  eukaryotic  system,  rather  than  the  normal 
prokaryotic  systems  used  by  the  majority  of  commercial  suppliers,  they  were  100 
times  more  potent  at  inducing  DC  migration.  They  also  indicated  that  these  forms 
of  CCL21  and  CCL19  were  able  to  induce  DC  maturation,  i.  e.  increased 
expression  of  CD86,  CD80,  CD40  and  increased  production  of  IL-1  P  and  IL-12 
(and  TNFa  in  the  case  of  CCL19).  These  results  suggest  that  small  glycosylation, 
structural  or  conformational  changes  in  CCLs  may  radically  alter  their  in-vitro 
potency,  which  may  be  crucial  in  the  production  of  DC  for  clinical  use. 
Dendritic  cells  produce  large  numbers  of  different  chemokines  at  the  various 
stages  of  maturation.  For  example,  iDC  are  able  to  produce  the  inflammatory 
chemokines  IL8,  CXCL10,  CCL3,  CCL4  and  CCL5,  which  increases  the 
recruitment  of  neutrophils,  monocytes  and  perhaps  NK  cells  to  sites  of  infection 
and  inflammation.  Whilst  matDC  produce  CCL17,  CCL18,  CCL19  and  CCL22  to 
attract  T  and  B  lymphocytes  within  the  lymph  node  in  a  paracrine  fashion. Dr  Simon  J  Harrison,  2005  Chapterl-31 
As  already  discussed,  MM  induces  a  state  of  immunosuppression  by  the  secretion 
of  cytokines  such  as  IL-6,  IL-10  and  TGF3.  It  should  therefore  come  as  no  surprise 
that  tumours  manipulate  the  chemokine  system  as  well  (Byrne  and  Halliday  2002, 
Vicari  and  Caux  2002).  The  migration  of  DC  into  tumours  is  usually  driven  by  the 
expression  of  CCL3,  CCL4,  MCPs  and  CCL5,  which  also  recruit  monocytes  and 
macrophages.  Once  inside  the  tumour,  DC  are  presented  with  Ag  in  the  form  of 
apoptotic  bodies,  in  the  absence  of  a  danger  signal.  In  this  type  of  environment, 
iDC  are  able  to  up  regulate  CCR7  expression,  but  not  co-costimulatory  molecules 
(Gallucci,  et  al  1999,  Sauter,  et  a/  2000).  This  effect  is  enhanced  by  the 
production  of  IL-10  and  TGF(3  by  tumour  infiltrating  macrophages,  'which  block  DC 
maturation.  Thus  partially  mature  DC  migrate  to  lymph  nodes,  deliver  a  tolerogenic 
signal  to  the  immune  system  and  induce  the  production  of  TH2  and  T  regs. 
The  effects  of  the  chemokine  system  are  not  restricted  to  the  immune  system,  with 
CCL3  and  CCL4  playing  predominant  roles  in  driving  the  increased  osteoclast 
activity  that  causes  MM  bone  disease.  CCL3  and  CCL4  are  present  at  higher 
concentrations  in  the  serum  and  bone  marrow  of  MM  patients,  and  correlate  with 
the  severity  of  bone  disease  and  prognosis,  continuing  to  rise  as  the  disease 
progresses  (Abe,  et  a/  2002,  Choi,  et  a/2000,  Hashimoto,  et  a/  2004,  Magrangeas, 
et  a12003,  Terpos,  et  a!  2003).  Interestingly,  CCR1  and  CCR5  are  also  expressed 
by  MM  plasma  cells,  where  they  reportedly  mediate  cell  survival,  proliferation  and 
migration  (Lentzsch,  et  al  2003,  Oyajobi,  et  a12003),  and  induce  MM  cell 
adherence  to  BM  stroma,  cellular  interactions  that  lead  to  the  production  of 
osteolytic  factors  by  the  stroma  (Figure  1-5)  (Michigami,  et  a/  2000). 
It  is  clear  that  if  we  hope  to  use  the  immune  system  to  eradicate  malignant 
diseases  such  as  MM,  a  greater  understanding  will  be  needed  about  the  influence 
of  chemokines  on  normal  DC  development  and  trafficking,  and  how  this  can  be Dr  Simon  J  Harrison,  2005  Chapter  1-32 
altered  by  malignant  disease.  The  results  thus  far  from  cellular  immuno!  herapy 
trials  have  been  disappointing.  One  of  the  reasons  for  this  is  that  mature  DC 
administered  in  these  types  of  studies  fail  to  migrate  to  secondary  lymphoid 
tissues  in  significant  numbers  (Blocklet,  et  a12003,  Triozzi,  et  a!  2000).  The 
chemokine  system  also  plays  a  role  in  the  clinical  manifestations  of  MM,  and 
interfering  in  these  pathways  may  have  significant  therapeutic  potential. 
1.3.3  Antigen  Cross  Presentation. 
CD8+  T  cells  require  Ag  to  be  presented  by  MHC  class  I  molecules  to  elicit  a  CTL 
response.  It  was  originally  thought  that  only  endogenous  Ag  processed  in  the 
cytoplasm  of  the  Ag  presenting  cell  (APC)  could  gain  access  to  this  process, 
whereas  Ag  from  both  endogenous  and  exogenous  sources  can  be  loaded  onto 
MHC  class  II  molecules.  It  was  later  found  that  DC  could  present  Ag  acquired  from 
phagocytosed  apoptotic  bodies  and  present  this  in  the  context  of  HLA  class  I,  thus 
generating  CTL  responses  (Albert,  et  al  1998,  Ronchetti,  et  al  1999).  This  process 
has  become  known  as'cross  presentation',  although  the  in-vivo  phenomenon  was 
originally  described  as  'cross  priming'  by  Bevan  over  20  years  ago  (Bevan  1976). 
Various  mechanisms  to  explain  how  DC  achieve  this  process  have  been 
proposed,  including  recycling  of  MHC  class  I  molecules  exchanging  peptide  for 
those  being  newly  formed  in  the  endosome,  translocation  of  Ag  from  the  cell 
surface  to  the  cytosol  and  the  passage  of  Ags  from  the  endosome  to  the  cytosol, 
which  seem  to  be  used  mostly  by  DC  (Moron,  et  al  2003).  The  Ags  are  then 
processed  by  the  proteosome  and  transported  to  the  endoplasmic  reticulum  (ER) 
by  transporter  associated  with  Ag  processing  (TAP)  molecules  where  they  can 
bind  to  MHC  class  I  molecules.  However,  it  has  been  suggested  that  rather  than 
being  released  directly  into  the  cytosol,  the  Ags  may  remain  in  the  phagosome 
which  may  either  fuse  to,  or  carry  elements  of,  the  ER  (Guermonprez,  et  a/  2003). Dr  Simon  J  Harrison,  2005  Chapter  1-33 
The  required  TAP,  proteosomes  and  MHC  class  I  may  then  be  recruited  (Houde, 
et  a!  2003).  Other  groups  have  speculated  that  there  may  be  a  specific  transport 
mechanism  in  DC,  which  efficiently  transports  phagocytosed  Ag  into  the  cytosol  for 
processing  (Rodriguez,  et  al  1999).  Using  mechanisms  such  as  these,  myeloid  DC 
are  able  to  induce  strong  CTL  responses  to  exogenous  (tumour)  Ag. 
1.3.4  Dendritic  cell,  T  cell  interactions 
DC  have  the  unique  ability  to  present  Ag  to  naive  T  cells.  Techniques  such  as  2- 
photon  imaging  of  lymph  nodes  have  shown  that  this  process  follows  an  orderly 
progression.  Within  two  hours  of  DC  migration  T  cell  behaviour  changes  from  a 
random  stochastic  nature,  to  making  short-lived  contacts  with  multiple  DC 
dendrites.  During  the  next  14  hours  T  cells  form  stable  clusters  around  DC  before 
breaking  down  into  dynamic  swarms,  and  by  24  hours,  T  cells  proliferate  and 
migrate  out  of  the  node  (Miller,  et  al  2004).  Elegant  studies  such  as  these  provide 
further  evidence  that  the  'immune  synapse'  is  a  dynamic,  orderly  process. 
Effective  priming  of  naive  T-  cells  induces  clonal  expansion  and  differentiation  into 
effector  and  memory  cells.  This  is  achieved  via  the  engagement  of  the  T  cell 
receptor  (TCR)/HLA-I/II/Ag,  CD40  /  CD40  Ligand  (CD40L)  and  CD28/CD80 
complexes  and  the  secretion  of  IL-7,  IL-12  and  perhaps  IL-2  (Granucci,  et  al 
2001).  CD4+  T-  cell  help  is  required  at  the  time  of  priming  to  generate  CD8+ 
effector  cells,  and  is  mediated  by  CD40/CD40L  engagement,  which  induces  DC 
production  of  IL-12.  This  CD40  licensing  of  DC  may  also  be  induced  by  CD40L  on 
some  apoptotic  bodies  (Propato,  et  a/  2001).  The  CD40/CD40L  interaction  seems 
particularly  important  in  that  CD40  ligation  alone  is  sufficient  to  drive  the 
maturation  of  DC  (Caux,  et  al  1994),  and  allows  matDC  to  prime  CD8'  cytotoxic  T Dr  Simon  J  Harrison,  2005  Chapter  1-34 
cells  (CTL)  without  further  CD4+  T  cell  help.  Of  the  many  other  factors  important  in 
the  T  cell  response,  the  maturity  of  the  DC  is  one  of  the  most  important. 
Immature  DC  induce  `abortive  proliferation'  of  T  cells,  i.  e.  initial  proliferation  but 
short-term  survival  and  perhaps  clonal  deletion.  Mature  DC  induce  T  cell  survival 
and  differentiation  by  displaying  Ag  in  the  context  of  the  appropriate  co-stimulatory 
molecules  (Dhodapkar,  et  a/  2001,  Jonuleit,  et  al  2001  b,  Liu,  et  al  2001).  Thus  it  is 
crucial  that  DC  achieve  a  fully  mature  state  if  they  are  to  be  used  as  an  anti-cancer 
therapy.  This  may  also  partly  explain  how  the  tumour  is  able  to  evade  detection  by 
the  immune  system  at  an  early  stage  when  novel  tumour  Ags  may  be  encountered 
by  APC  in  the  absence  of  an  inflammatory,  pro-maturation  environment  (danger 
signal).  Thus  APC  remain  in  an  immature  state  and  a  tolerogenic  response  may 
be  generated  (Matzinger  1998). 
1.3.5  How  can  DC  be  produced/obtained  for  clinical  use? 
Circulating  blood  mDC  and  pDC  (Figure  1-4)  can  be  collected  using  apheresis 
machines  and  enriched  with  magnetic  cell  separation  protocols  in  a  similar  manner 
to  CD34+  stem  cells  (Fearnley,  et  al  1997,  Lopez,  et  a!  2003).  These  cells  are 
present  at  very  low  concentrations  in  peripheral  blood  (Dzionek,  et  al  2000, 
MacDonald,  et  a12002)  but  the  number  of  circulating  DC  can  be  dramatically 
increased  using  FLT-3  (Maraskovsky,  et  al  1996,  Morse,  et  a/  2000). 
This  is  a  relatively  inexpensive  and  straight  forward  process,  however,  the  yield  of 
cells  is  still  relatively  modest  and  there  is  conflicting  evidence  relating  to  whether 
circulating  DC  are  functionally  normal  in  patients  with  MM  (Brown,  et  al  2001, 
Ratta,  et  a!  2002).  Brown  et  al  have  previously  reported  that  circulating  DC  from 
MM  patients  fail  to  up  regulate  CD80  and  86  in  response  to  CD40L,  which  may  be Dr  Simon  J  Harrison,  2005  Chapter  1-35 
corrected  by  co-culture  with  IL-12,  IFN-y  or  anti-TGF-ß  antibodies,  suggesting  that 
TGF-ß1  and  IL-10  are  implicated  in  causing  this  defect  (Brown,  et  a!  2001). 
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Figure  1-4  Potential  cell  sources  for  the  production  DC  intended  for  clinical 
use. 
Alternatively,  DC  may  be  generated  from  either  CD34+  HSC  (34+DC)  (Caux,  et  al 
1992)  or  from  monocytes  (MoDC)(Zhu,  et  al  2000).  34+DC  were  first  produced 
using  a  cytokine  cocktail  containing  GM-CSF  and  TNFa  (Reid,  et  al  1992, 
Santiago-Schwarz,  eta!  1992).  Many  groups  have  subsequently  refined  this  by 
adding  cytokines  such  as  FLT-3,  SCF  and  IL-4  (Evans,  et  al  2000,  Strunk,  et  al 
1996).  The  DC  generated  by  these  methods  have  a  mature  myeloid  phenotype, 
low  phagocytic  activity,  and  express  high  levels  of  co-stimulatory  molecules  such 
as  CD40,  CD80,  CD83  and  CD86  (Ferlazzo,  et  a!  2000).  They  are  also  able  to 
induce  an  Ag  specific  cytotoxic  response  from  naive  T  cells  (Caux,  et  al  1995). Dr  Simon  J  Harrison,  2005  Chapter  1-36 
Unfortunately,  patients  must  first  undergo  HSC  mobilisation  with  either  3-CSF 
alone,  or  in  combination  with  chemotherapy.  Also,  the  methods  by  which  34+DC 
can  be  loaded  with  Ag,  such  as  transfection  or  fusion  with  tumour  cells,  are  not 
straight  forward  and  are  further  discussed  below. 
DC  may  be  generated  from  monocytes  (MoDC)  isolated  from  peripheral  blood 
mononuclear  cells  (PBMC)  separated  by  either  plastic  adherence  or  positive 
selection  of  CD14+  cells  using  immunomagnetic  beads.  In-vitro  culture  of  MoDC 
occurs  classically  in  three  stages.  Immature  DC  are  produced  by  culture  with  IL-4 
and  GM-CSF  for  5  to  10  days.  These  cells  are  CD1a'/CD1c+/CD147/CD86+  and 
HLA-DRand  they  have  a  high  phagocytic  capacity,  which  facilitates  Ag  uptake.  A 
number  of  groups  have  substituted  IL-13  for  IL-4  at  this  stage  to  produce 
functional  iDC  which  may  have  a  more  stable  phenotype  compared  to  those 
generated  with  IL-4  (Boyer,  et  al  1999,  Morse,  et  al  1999a). 
The  next  stage  in  the  process  is  to  load  iDC  with  Ag.  Normal  iDC  are  phagocytic, 
so  they  can  be  simply  'fed'  Ag  as  a  purified  naked  form,  coated  with  liposome, 
crude  tumour  lysate,  tumour  derived  heat  shock  protein  (HSP),  whole  apoptotic 
tumour  cells,  antibody  coated  tumour  cells  or  genetically  modified  Ag  (Mylovenge, 
idiotype-GM-CSF  fusion,  Dendreon.  ),  as  summarised  in  Table  1-1  (Galea-Lauri, 
et  a!  2004). co 
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However,  there  is  some  evidence  that  DC  from  patients  with  malignancy  (CIVIL  and 
MM)  have  reduced  phagocytic  capacity  due  to  cytoskeletal  abnormalities,  reduced 
processing  capacity  for  exogenous  Ag  and  reduced  chemokine  induced  migratign 
(Dong,  et  al  2003,  Ratta,  et  a!  2002).  There  are  at  least  three  approaches  that 
may  circumvent  this  problem.  The  first  is  the  generation  of  DC  from  a  malignant 
precursor  cell.  This  is  well  characterised  in  myeloid  malignancies  such  as  acute 
and  chronic  myeloid  leukaemia  (AML  and  CML),  and  there  have  been  recent 
reports  of  the  generation  of  DC-like  cells  from  patients  with  acute  lymphoid 
leukaemia  (ALL)  (Blair,  et  al  2001).  These  cells  appear  to  have  the  ability  to 
stimulate  naive  T  cells,  although  whether  they  function  as  efficiently  as  normal  DC 
is  still  open  to  debate.  At  present  there  is  no  evidence  that  MM  plasma  cells  can 
be  converted  into  more  efficient  APC. 
The  next  approach  is  to  generate  normal  matDC  (maturation  is  discussed  below) 
and  then  fuse  them  with  tumour  cells  by  either  electroporation  or  pegylation 
(Gong,  et  a12002,  Hao,  et  a12004,  Raje,  et  a/  2004).  These  approaches  make  the 
assumption  that  the  resulting  fusion  or  malignant  DC  retain  normal  function. Such 
cells  must  also  express  all  of  the  relevant  tumour  Ags,  in  a  state  that  the  immune 
system  is  able  to  recognise  as  abnormal,  so  that  a  cytotoxic  response  is  mounted 
rather  than  inducing  tolerance.  The  final  approach  is  to  again  generate  normal 
matDC  but  then  transfect  them  with  tumour-associated  Ags,  such  as  MM  idiotype 
protein  (Id)  or  NY-ESO-1  (van  Rhee,  et  a!  2005b)  using  viral  vectors  (i.  e. 
adenovirus  and  lentivirus).  It  is  possible  to  achieve  high  rates  of  transfection  but 
these  approaches  have  been  hampered  by  viral  effects  on  DC  function  and  recent 
reports  of  leukaemic  transformation  in  2/9  boys  undergoing  gene  therapy  for  X- 
linked  severe  combined  immunodeficiency  due  to  the  activation  of  the  oncogene Dr  Simon  J  Harrison,  2005  Chapter  1-39 
LMO2  (Hacein-Bey-Abina,  et  a/  2003a,  Hacein-Bey-Abina,  et  al  2003b, 
McCormack  and  Rabbitts  2004). 
Usually,  iDC  are  converted  into  matDC  after  Ag  loading,  using  various 
combinations  of  cytokines  and  inflammatory  stimulants.  Classically,  tumour 
necrosis  factor  alpha  (TNFa)  (Thurnher,  et  al  1997)  or  monocyte  conditioned 
medium  (Romani,  eta!  1996)  are  used,  but  many  other  compounds  and 
combinations  are  described  including  poly  (I:  C),  CD40Ligand  ,  prostaglandin  E2, 
IL-1ß  and  IL-6  to  name  but  a  few.  Mature  DC  up  regulate  surface  expression  of  the 
co-stimulatory  molecules  CD80,  CD83,  CD40,  HLA  class  I  and  II,  lose  their 
phagocytic  ability,  increase  their  migratory  capacity  to  lymph  nodes  via  increased 
CCR-7  and  become  much  more  efficient  at  inducing  responses  from  naive  T  cells 
(De  Vries,  et  a!  2003a,  De  Vries,  et  a!  2003b,  Tarte,  et  a!  2000). 
The  production  of  MoDC  (and  34+DC)  is  costly,  labour  intensive  and  requires  auto 
cells  to  be  generated  for  each  individual  patient.  Recently  groups  have  been 
looking  at  speeding  up  the  process  of  producing  matDC  from  1-2  weeks  down  to  2 
days  (Fast  DC)  (Dauer,  et  al  2003,  Xu,  et  a/  2003),  which  may  more  closely 
represent  what  is  happening  physiologically  during  the  inflammatory  response  and 
has  the  added  benefits  of  being  quicker  and  less  labour  intensive. 
Unfortunately,  the  MM  tumour  cells  are  actively  producing  cytokines  (IL-6,  IL-10, 
TGF-ß  and  VEGF)  that  interfere  with  this  process  at  many  points,  resulting  in  DC 
being  produced  in  fewer  numbers,  that  are  functionally  abnormal  and  fail  to  mature 
with  appropriate  stimulation  (Brown,  et  ao  (Figure  1-5).  When  functionally  normal 
matDC  are  generated,  it  will  be  critical  to  choose  the  correct  Ag(s)  and  adjuvants Dr  Simon  J  Harrison,  2005  Chapter  1-40 
with  which  to  prime  the  immune  response  for  clinical  use.  A  number  of  groups 
have  started  clinical  trials  looking  at  the  use  of  DC  as  treatment  for  MM. 
Effector  T  cells 
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Figure  1-5  Interaction  of  MM  with  the  adaptive  cellular  immune  system 
In  MM  there  is  a  complex  interaction  between  the  malignant  plasma  cell,  bone 
marrow  stroma  and  the  immune  system.  The  tumour  and  stromal  cells  interact  via 
adhesion  and  cytokines,  such  as  IL-6,  VEGF  and  TNFa  to  induce  tumour  cell 
proliferation,  migration,  survival  and  drug  resistance,  as  well  as  blood  vessel 
proliferation.  IL-6  also  blocks  the  conversion  of  monocytes  into  iDC,  VEGF,  IL-10 
and  TGFß  prevent  DC  maturation,  and  TGFß  also  induces  T  cell  anergy. 
1.3.6  T  regulatory  cells  (TRg  cells) 
There  is  a  growing  body  of  evidence  that  as  well  as  providing  immunogenic  'help' 
to  the  immune  system,  CD4+  T  cell  are  also  important  negative  regulators  of  the 
immune  response.  Many  of  these  effects  are  mediated  by  a  subset  of  cells  known 
as  naturally  occurring  CD4+/CD25+  regulatory  T  (TReg)  cells,  which  compose  5- 
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10%  of  all  circulating  CD4+  T  cell  in  adults  (Asano,  eta!  1996,  Sakaguchi,  eta! 
1995).  Unfortunately,  this  picture  is  further  complicated  by  the  interaction  of  iDC 
and  naive  T  cells,  which  may  cause  T  cell  depletion,  anergy,  and  the  induction  of 
other  sub-sets  of  CD4+  and  CD8+  regulatory  T  cell  which  secrete  IL-10  and  TGF-ß 
(Dhodapkar,  et  a12001,  Jonuleit,  et  a12001  a). 
TReg  cells  are  produced  in  the  thymus  by  positive  selection  of  CD4*cells  with  TCR 
that  have  intermediate  affinity  for  MHC  class  II-self  Ag  complexes,  and  exert  their 
immunomodulatory  effects  in-vitro  in  a  cell  contact  dependent  manner,  although 
there  is  some  in-vivo  evidence  that  immuosuppressive  cytokines  may  also  be 
involved.  TRe9  cells  play  a  role  in  maternal  tolerance  to  the  foetus  (Aluvihare,  et  al 
2004),  tolerance  following  transplantation  (Wood  and  Sakaguchi  2003)  and  they 
have  been  implicated  in  impeding  natural  anti-tumour  immunity  and 
immunotherapy  (Sakaguchi,  et  a/2001).  One  of  the  proposed  mechanisms  for 
these  observations  is  the  interaction  between  TReg  cell  CTLA-4  and  iDC  B7-1  and 
B7-2  which  induces  the  up-regulation  of  indolemine  2,3-dioxygenase  (IDO)  on  the 
DC  (Mellor,  et  a/  2003).  These  IDO-DC  inhibit  T  cell  proliferation,  induce  T-  cell 
apoptosis  (Munn,  et  al  2002)  and  large  numbers  of  these  cells  have  been  found  in 
the  tumour-draining  lymph  nodes  of  patients  with  malignancies  (Munn,  et  a!  2002). 
The  group  from  Dana  Faber  recently  reported  a  significant  increase  in 
CD4+/CD25+  TReg  in  MM  patient  samples  compared  to  normal  donors  (23±4%  vs. 
6±3%)  (Prabhala,  et  al  2004).  They  found  that  the  proliferation  of  T  cells  depleted 
of  TReg  cells  was  significantly  lower  in  MGUS  (n=9,  SI=12±2)  and  MM  (n=9, 
SI=28±8)  compared  with  normal  donors  (n=9,  SI=74±9,  p<0.01),  and  LPS  was 
unable  to  overcome  suppression  of  T  cell  proliferation  by  TRg  cells  in  MGUS 
(49%)  and  MM  (24%)  compared  to  normal  controls  (110%).  These  observations Dr  Simon  J  Harrison,  2005  Chapterl-42 
suggest  that  TRe9  cells  may  play  a  role  in  the  immune  dysfunction  seen  in  MM 
patients. 
1.3.7  Natural  killer  (NK)  cells 
NK  cells  are  part  of  the  evolutionarily  older  innate  immune  system.  In  contrast  to  T 
cells,  NK  cells  do  not  require  pre-activation  or  immunisation  in  order  to  recognise 
and  kill  targets  such  as  tumour  cells  or  virally  infected  cells.  NK  cells  arise  from  the 
haematopoietic  stem  cell  (HSC)  and  develop  under  the  influence  of  IL-2  and/or  IL- 
15,  acquiring  effector  functions  such  as  lytic  ability  and  cytokine  production  (IFN-y, 
TNF,  IL-10,  IL-13,  Lymphotoxin-ß,  and  GM-CSF)  (Williams,  eta!  1997).  Mature  NK 
cells  (CD94+  and  KIR+)  seed  to  the  periphery  where  they  expand,  are  recruited  to 
tumours  or  sites  of  infection  (Salazar-Mather,  et  al  1998,  Smyth,  et  al  2000),  where 
they  develop  into  either  specialised  cytokine  producers  (CD94+{,  CD56++-  KIR+, 
CD25+,  CCR-7+  and  c-KIT+)  or  cytotoxic  cells  (CD56+,  KIR++,  and  CD94+). 
NK  cells  recognise  abnormal  cells  via  a  number  of  mechanisms,  of  which  the 
"missing  self  hypothesis"  is  the  best  understood  (Ljunggren  and  Karre  1990). 
Tumour  and  virus-infected  cells  may  lose  or  down  regulate  MHC  class  I 
expression  in  an  attempt  to  prevent  Ag  presentation  and  evade  recognition  by 
CD8+  cytotoxic  T  cells.  NK  cells  detect  this  via  surface  receptors,  which  under 
normal  circumstances  engage  the  MHC  class  I  molecules  and  deliver  an  inhibitory 
signal  to  prevent  NK  cells  attacking  normal  healthy  cells.  There  are  at  least  two 
types  of  MHC  class  I  inhibitory  receptors  which  either  recognise  a  highly 
conserved  element  in  the  HLA  class  I  signal  peptide  bound  by  HLA-E  molecules 
(CD94:  NKG2A  heterodimer)  (ViIches  and  Parham  2002),  or  detect  down 
regulation  of  particular  sub-groups  via  killer  Ig  like  receptors  (KIR).  KIR  binding  to Dr  Simon  J  Harrison,  2005  Chapterl  -43 
HLA  class  I  molecules  is  similar  to  T  cell  receptor  binding  of  HLA-Ag  complexes, 
with  faster  binding  and  detachment  kinetics  which  may  facilitate  efficient 
surveillance  of  the  MHC  class  I  repertoire. 
More  recently  activating  receptors  have  been  identified  on  NK  cells  (Bauer,  et  a! 
1999,  Diefenbach,  et  a/  2002,  Gilfillan,  et  a/  2002).  NKG2D  recognises  structures 
such  as  MHC  class  I  chain-related  molecule  (MIC)  A  and  B,  expressed  at  a 
significant  level  when  cells  are  stressed  or  become  transformed,  promoting  the 
rejection  of  abnormal  cells  (Groh,  et  a!  1996).  This  effect  may  be  circumvented  by 
abnormal  cells  producing  soluble  MIC,  which  induces  down  regulation  of  NKG2D 
(Groh,  et  al  1996).  The  ligands  for  the  Natural  Cytotoxicity  Receptors  (NKp46, 
NKp30  and  NKp44)  have  yet  to  be  identified,  but  the  process  appears  to  be  MHC 
independent. 
There  are  reports  of  natural  NK  cytotoxicity  to  normal  (Ferlazzo,  et  a!  2002)  and 
auto  Ag-pulsed  DC  in  patients  with  MM  (Zheng,  et  a!  2002).  Immature  DC  are 
efficiently  targeted  by  NK  cells  whilst  matDC  are  protected  by  the  up-regulation 
HLA  class  I  (HLA-E).  The  interaction  between  NK  cells  and  DC  at  sites  of 
inflammation  is  complex  and  was  reviewed  recently  by  Ferlazz  and  Münz 
(Ferlazzo  and  Munz  2004).  DC  are  able  to  activate  NK  cells  via  IL-12  and  perhaps 
IL-18  (Andrews,  et  a/  2003)  although  there  is  some  evidence  that  cell  contact  is 
required  via  engagement  of  NKG2D/MICA  and  B.  During  this  interaction  DC 
maturation  is  stimulated  by  IFN-a  released  by  the  NK  cell.  Why  should  NK  cells  kill 
iDC  whilst  at  the  same  time  inducing  DC  maturation  and  homing  to  lymph  nodes? 
It  has  been  suggested  that  this  paradox  is  a  control  mechanism  used  during 
infective  episodes.  Both  results  of  DC/NK  cell  interaction  result  in  the  depletion  of Dr  Simon  J  Harrison,  2005  Chapterl  -44 
DC  at  sites  of  inflammation.  While  this  may  deprive  DC  trophic  pathogens  of  their 
host,  it  may  also  be  an  important  feed  back  mechanism  to  prevent  excessive 
production  of  pro-inflammatory  cytokines  by  limiting  recruitment  of  iDC  to  the 
matDC  pool  (Moretta,  et  al  2003). 
Myeloma  cells  are  susceptible  to  NK  cell  lysis  (Frohn,  et  a/  2002)  and  there  is 
evidence  to  suggest  that  the  number  and  state  of  activation  of  NK  cells  is 
increased  in  MM.  These  cells  have  inherent  anti-MM-cytotoxic  activity  and  drugs 
such  as  thalidomide  may  further  augment  this  effect  (EL-Sherbiny,  et  at  2003, 
Frohn,  et  a!  2002,  Gonzalez,  et  al  1992,  Zheng,  et  a/  2002).  These  observations 
provide  evidence  that  there  is  an  active  interface  between  the  innate  and  adaptive 
arms  of  the  immune  response  that  could  be  harnessed  in  future  anti-MM  NK  cell 
and  DC  based  therapies. 
As  our  understanding  of  how  the  immune  system  regulates  itself  improves,  we 
should  be  better  able  to  manipulate  it  to  produce  more  effective  immune  therapies. 
The  next  section  will  review  the  use  of  immunotherapeutic  strategies  in  the 
treatment  of  MM. 
1.4  Anti-tumour  vaccines  in  Multiple  Myeloma 
Vaccination  is  the  most  effective  intervention  modern  medicine  has  developed, 
and  has  almost  eradicated  diseases  such  as  Small  Pox  and  Poliomyelitis.  An  ideal 
anti-tumour  vaccine  would  be  produced  from  a  tumour-associated  Ag  (TAA)  that  is 
only  expressed  on  tumour  cells  but  is  shared  between  different  patients  and Dr  Simon  J  Harrison,  2005  Chapterl-45 
tumour  types.  It  should  be  highly  immunogenic,  be  able  to  produce  both  humoral 
and  cellular  immune  responses  and  it  should  be  essential  for  tumour  cell  survival, 
thus  not  susceptible  to  mutation  or  deletion.  As  yet,  such  `ideal'  TAA  have  yet  to 
been  identified  in  any  malignant  disease.  In  B  cell  malignancies,  the  only 
compounds  that  come  close  to  this  ideal  are  the  Id  proteins  produced  by  the  clope 
of  tumour  cells.  Unfortunately,  these  molecules  are  specific  to  each  individual 
patient,  requiring  the  vaccine  to  be  tailor-made  for  each  patient  and  are  thus 
labour  intensive  and  very  expensive  to  produce.  Furthermore,  Id  are  weakly 
immunogenic  when  administered  in-vivo  and,  in  the  case  of  MM,  expressed  at  low 
levels  on  the  surface  of  the  tumour  cells.  However,  it  has  been  shown  that  anti-Id 
antibody  and  T  cells  are  present  in  the  blood  of  MM  patients  (Yi,  et  al  1995),  and 
experimental  data  shows  that  the  anti-Id  immune  response  is  able  to  kill  MM 
tumour  cells  in-vitro  and  in  animal  models  (Li,  et  al  2000,  Wen,  et  a!  2001).  A 
number  of  different  strategies  have  been  employed  to  produce  an  effective  Id 
vaccine.  These  have  employed  the  use  of  DNA,  purified  Id  protein  or  light  and 
heavy  chain  variable  regions  (VH  and  VL),  which  can  then  be  linked  to  molecules 
such  as  KLH  or  cytokines  like  IL-2,  IL-12  or  GM-CSF  in  order  to  render  them  more 
immunogenic  (King,  et  al  1998,  Osterborg,  et  al  1998,  Rasmussen,  et  al  2003, 
Stritzke,  et  a/  2003).  DNA  acts  as  a  natural  vaccine  adjuvant.  Bacterial  DNA  is 
even  more  potent,  due  to  the  20-fold  increase  in  CpG  motifs,  recognised  by 
molecules  such  as  the  Toll-like  receptor  9  (TLR-9)  present  on  cells  of  both  the 
innate  and  adaptive  immune  system  (Hemmi,  et  al  2000). 
A  number  of  studies  in  both  MM  and  B  cell  lymphoma  have  demonstrated  that  it  is 
possible  to  use  these  vaccines  to  boost  the  immune  system  but  the  clinical  results 
so  far  have  been  largely  disappointing,  although  most  series  have  been  too  small Dr  Simon  J  Harrison,  2005  Chapter  1-46 
to  produce  statistically  significant  results.  Coscia  et  al  reported  that  despite 
inducing  anti-Id  antibodies  and  skin-prick  sensitivity  in  MM  patients  in  first  CR 
following  high  dose  chemotherapy,  the  residual  tumour  burden  was  not  eliminated 
(Coscia,  et  al  2004).  This  is  in  contrast  to  the  study  reported  by  Bendanoi,  in  which 
Id  protein  vaccination  was  able  to  clear  circulating  tumour  cells  in  8  of  11  patients 
who  were  otherwise  in  remission  following  chemotherapy  for  follicular  lymphoma 
(FL)  (Bendandi,  et  al  1999).  The  group  in  Southampton  have  developed  a  DNA 
fusion  vaccine  which  contains  the  VH  and  VL  genes  of  the  Id  protein  assembled 
as  a  single-chain  (Fv)  sequence.  To  enhance  T  cell  help,  this  has  been  fused  to 
either  the  fragment  C  (FrC)  sequence,  a  non-toxic  part  of  the  Clostridium  tetani 
toxin  (Spellerberg,  et  al  1997),  or  a  plant  viral  protein  coat  (PVCP)  sequence 
(Savelyeva,  et  al  2001).  This  scFv-FrC  fusion  gene  vaccine  has  been  used  in 
clinical  trials  in  patients  with  FL  and  MM  (King,  et  a/  1998).  Antibody  responses  to 
FrC  were  seen  in  8  of  10  FL  patients  treated,  with  5  patients  having  detectable  T 
cell  responses  to  Id  (Stevenson,  et  a!  2004).  The  trial  in  MM  patients  is in  it's  very 
early  stages,  but  some  immune  and  clinical  responses  have  been  reported 
(Stevenson,  et  a!  2004).  This  platform  continues  to  be  modified  in  order  to  induce 
greater  CD8+  mediated  immunity  by  increasing  Ag  presentation  via  MHC  class  I.  In 
a  similar  approach  to  Kwak  et  al  (Kim,  et  al  2003),  Stephenson  is  also  conducting 
a  clinical  trial  of  vaccinating  normal  donors  prior  to  collection  of  DLI  for  use  in  MM 
patients  who  relapse  following  Allo  HSCT  (Stevenson  2003). 
A  novel  approach  has  been  taken  by  Cell Genesys  with  the  GVAX®  myeloma 
vaccine.  Irradiated,  auto  MM  cells  are  administered  with  K562  cells,  genetically 
engineered  to  produce  GM-CSF.  Twenty  two  patients  have  been  enrolled  in  the 
phase  I/II  trial,  and  17  patients  have  received  at  least  one  vaccination.  Interim  data Dr  Simon  J  Harrison,  2005  Chapter  1-47 
presented  at  ASH  2004  demonstrated  that  chemotherapy  followed  by  ajito  HSCT 
and  vaccination  resulted  in  six  complete  responses,  five  partial  responses,  threq 
patients  with  stable  disease  and  two  patients  with  progression  (Borrello,  et  al 
2004).  Three  patients  with  early  progression  after  transplantation  then 
demonstrated  potential  antitumor  activity  following  initiation  of  vaccination,  as 
measured  by  reductions  in  the  myeloma-associated  circulating  protein  (M-spikel  of 
92  percent,  37  percent  and  25  percent.  Treatment  with  GVAX®  myeloma  vaccine 
to  date  has  been  well  tolerated,  with  only  self-limiting  skin  rashes  (2  patients)  aqd 
colitis  (1  patient)  reported. 
1.5  Dendritic  Cell  vaccination  in  Multiple  Myeloma 
Immunotherapy  in  MM  may  be  more  effective  if  it  is  delivered  via  professional  Ag 
presenting  cells  such  as  DC.  A  number  of  studies  have  examined  the  use  of  DC 
that  have  been  pulsed  with  tumour-derived  Id  protein  or  peptides  (Dabadghao,  et 
a11998,  Reichardt,  et  a11999,  Ridgway  2003,  Tarte,  et  a11997,  Titzer,  et  a12000, 
Zeis,  et  al  1998).  It  has  been  shown  that  moDC  pulsed  with  purified  patient- 
specific  Id  can  serve  as  cellular  vaccine  for  MM  patients  after  high  dose  therapy 
and  auto  PBSCT  (Lim  and  Bailey-Wood  1999,  Liso,  et  al  2000,  Reichardt,  et  al 
1999,  Yi,  et  an.  In  the  study  by  the  Stanford  group,  26  patients  were  immunized 
with  Id  pulsed  DC  derived  from  auto  monocytes  under  serum-free  conditions  and 
vaccines  consisting  of  mature  DCs  (HLA-DR+/CD83'/CD80+/CD54+/CD86+, 
median  number  of  5x106  DC/injection)  were  administered  without  serious  adverse 
events.  Four  patients  have  demonstrated  Id-specific  T  cell  proliferative  responses 
and  2  patients  demonstrated  the  induction  of  Id-specific  T  cell  cytotoxicity  (Liso,  et 
al  2000,  Reichardt,  et  a/  1999).  As  all  patients  received  Id/KLH  boosters  post- Dr  Simon  J  Harrison,  2005  Chapter  1-48 
vaccination,  it  is  not  surprising  that  24  of  26  patients  developed  KLH-specific  T  Gell 
responses  after  2  to  3  ld/KLH  booster  injections.  This  protocol  has  been  further 
developed  in  Tubingen,  by  the  addition  of  SC  GM-CSF,  250ug/m2,  as  an  adjuvant 
to  vaccination.  Two  of  twelve  patients  developed  T  cell  proliferative  response  and 
one  patient  formed  aT  cell  cytotoxic  response  (Reichardt,  et  al  2003). 
Investigators  from  Arkansas  have  also  modified  this  approach  by  giving  Id/KLH 
loaded  DC  by  weekly  intranodal  injection  for  4  weeks,  each  followed  by  low  dose 
SC  IL-2  (5x105  IU/injection)  (Yi,  et  an.  7/8  patients  developed  T  cell  responses  and 
all  enhanced  the  anti-idiotypic  B  cell  response.  The  serum  paraprotein  fell  by  30% 
in  one  patient  and  five  others  continue  to  have  stable  disease  with  longer  follow-up 
required.  This  group  is  also  examining  the  use  of  MM  tumour  cells  lysates  as  a 
source  of  Ag  for  DC  priming  (Szmania,  et  al,  Wen,  et  a12002)  whilst  Kim  et  al  are 
investigating  the  use  of  in-vitro  priming  of  alto  donor  T  cells  with  tumour  Id  pulsed 
DC  (Kim,  et  al  2003). 
There  is  some  evidence  that  the  route  of  DC  administration,  as  well  as  their  state 
of  maturation,  may  influence  the  ability  of  DC  to  migrate  and  induce  an  immune 
response.  It  has  been  shown  than  DC  given  by  intra  dermal  injection  (IDI)  are 
three  times  more  effective  at  migrating  to  lymph  nodes  than  those  given  by 
subcutaneous  injection  (SCI),  while  matDC  are  eight  times  better  than  iDC) 
(Ridolfi,  et  a/  2004).  Intra  tumour  injection  of  DC  may  result  in  sequestration  of  DC 
(Feijoo,  et  a12005)  mediated  by  CXCL8. 
Dendritic  cell  based  Id  vaccination  of  MM  patients  is  feasible  and  can  induce  Id 
specific  immune  responses  in  MM  patients.  However,  the  clinical  effectiveness  of 
such  vaccinations  in  MM  still  needs  to  be  proven.  These  therapies  may  need  to  be Dr  Simon  J  Harrison,  2005  Chapter  1-49 
'boosted'  with  adjuvants  or  other  tumour-specific  peptides  in  conjunction  with  Id- 
pulsed  DC.  Such  an  approach  has  been  taken  by  Dendreon  with  the  Mylovenge 
DC  vaccine,  which  uses  Id  protein  fused  with  GM-CSF,  and  is  currently  in  phase  II 
trials  (Rice  and  Hart  2002).  On-going  studies  in  this  area  will  shed  further  light  op 
the  use  of  DCs  as  cellular  vaccines  but  clearly  this  is  an  area  worthy  of  further 
investigation. 
1.6  T  cells  and  reversal  of  tumour  induced  immune 
suppression 
The  effects  of  the  tumour  cell  population  and  associated  microenvironment  in  MM 
is  well  described  (Cook  and  Campbell  1999).  It  has  been  known  for  many  years 
that  patients  with  MM  are  immuosuppressed,  being  more  prone  to  infections 
(Glenchur,  et  al  1959,  Perri,  et  al  1981,  Zinneman  and  Hall  1954),  and  MM  is less 
responsive  to  normal  T  cells  when  given  as  DLI  to  treat  relapse  post  alto  HSCT 
compared  to  other  diseases  such  as  CML  (Verdonck,  et  al  1998).  This  is  at  least 
partly  due  to  MM  tumour  cells  secreting  immunologically  active  compounds  such 
as  IL-6,  IL-10,  VGEF  and  TGFI  among  many  others.  It  has  been  shown  that 
multiple  myeloma  cell  lines  and  freshly  isolated  myeloma  cells  from  patients 
produce  excess  TGF-ß,  and  that  this  agent  is  responsible,  at  least  in  part,  for 
suppressing  T  cell  responses  against  tumour  cells  (Campbell,  et  al  2001,  Cook,  et 
al  1999).  Using  the  natural  inhibitor  to  TGF-ß,  latency  associated  peptide  (LAP), 
the  TGF-ß  suppressive  effect  against  T  cells  has  been  shown  to  be  specific  and 
mediated  through  the  inhibition  of  IL-2  autocrine  pathways  in  the  T  cells 
(Campbell,  et  al  2001,  Cook,  et  al  1999).  Ex-vivo  activation  with  using  anti-CD3 
monoclonal  antibody  (MoAb)  in  the  presence  of  exogenous  IL-15  is  able  to Dr  Simon  J  Harrison,  2005  Chapterl  -50 
overcome  this  inhibition  and,  crucially,  the  IL-2  autocrine  pathways  are  reinstated 
in  T  cells,  rendering  them  resistant  to  further  TGF-ß  suppression  (Campbell,  et  al 
2001).  Such  a  strategy  may  be  employed  to  reinstate  T  cell  effector  function  in 
patients  with  MM,  however  we  have  demonstrated  that  these  cells  may  be 
rendered  cytokine  dependant  and  fail  to  respond  to  Ag's  presented  by  DC  in  the 
absence  of  IL-2/IL-15  (unpublished  data). 
Other  groups  have  identified  that  the  T  cell  Vß  TCR  diversity  in  MM  patients  is 
severely  skewed  after  auto  HSCT  (Mariani,  et  al  2001)  and  that  there  is  a 
significant  association  between  survival  and  lymphocyte  recovery  post  auto  HSCT. 
In  the  Xcellerate  T  cell  trial  (Vij,  et  al)  T  cells  are  activated  with  anti-CD3  and  anti- 
CD28  MoAb  coated  beads  and  infused  IV  three  days  following  stem  cell  infusion. 
Initial  results  suggest  that  this  process  partially  corrects  the  skewing  of  the  Vß 
TCR  repertoire  and  also  rapidly  corrects  the  lymphocyte  count  following  auto 
HSCT.  It  has  been  previously  shown  that  patients  with  MM  who  have  less 
restriction  of  the  T  cell  receptor  Vß  repertoire  have  a  better  prognosis  (Brown,  et  al 
1997).  At  present  there  is  little  evidence  that  the  cells  manipulated  by  the 
Xcellerate  process  have  any  specific  anti-tumour  activity.  However,  the  presence 
of  expanded  T-  cell  clones  is  associated  with  prolonged  overall  survival  (Brown,  et 
at  1997,  Raitakari,  et  at  2003,  Sze,  et  at  2003),  and  MM  Ag  specific  T  cells 
circulating  in  the  peripheral  blood  of  MM  patients  have  been  identified  (Beckhove, 
et  a/  2003,  van  Rhee,  et  al  2005b,  Yi,  et  a!  1995).  These  cells  could  now  be 
isolated  from  the  peripheral  blood  of  Myeloma  patients  using  immunomagnetic  or 
flowcytometric  methods,  expanded  ex-vivo  using  some  of  the  methods  described 
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It  has  been  known  for  some  time  that  immunosuppression  with  cycloph9sphamide 
may  increase  the  effectiveness  of  adoptively  transferred  anti-tumour  T  cells 
(Rosenberg,  et  al  1994b),  and  recently  it  has  been  shown  that  specific  depletion  of 
CD4+  CD25+  TR  cells  by  anti-CD25  antibodies  increases  the  efficiency  of  the  anti- 
tumour  immune  response  of  tumour  bearing  animals,  although  the  tumours  are  pot 
completely  rejected  (Jones,  et  al  2002,  Vela-Ojeda,  et  al  2005).  It  is  possible  to 
enhance  this  effect  by  using  CD25  depletion  along  with  matDC  vaccination 
(Sutmuller,  et  al  2001). 
1.7  Humoral  immunotherapy 
1.7.1  Monoclonal  antibodies 
Tumour-directed  monoclonal  antibody  (MoAb)  therapy  has  been  the  "holy  grail"  of 
many  Haemato-oncologists  since  the  1970's.  With  the  development  of  compounds 
such  as  Rituximab  (anti-CD20),  Campath-1  H  (anti-CD52)  and  Myelotarg  (anti- 
CD33),  the  potential  has  developed  into  a  viable  treatment  for  lymphoma  and 
leukaemia.  This  form  of  immunotherapy  is  now  beginning  to  be  investigated  in  the 
context  of  MM.  One  major  hurdle  in  this  area  has  been  the  selection  of  a  suitable 
surface  Ag  that  would  permit  the  generation  of  a  MoAb  with  satisfactory  specificity 
and  sensitivity  for  the  targeting  of  the  malignant  cell  resulting  in  its  destruction. 
Potential  candidate  molecules  include  CD38,  CD138  (syndecan-1),  CD54  (ICAM), 
CD40,  VEGF  (Yang,  et  a!  2003a)  and  the  un-clustered  surface  type  II 
transmembrane  glycoprotein,  HMI 
. 
24.  The  use  of  anti-CD20  MoAb  is limited  by 
the  fact  that  CD20  is  expressed  on  <20%  of  fresh  myeloma  cells.  Despite  the 
success  of  anti-CD20  MoAb  in  follicular  lymphoma  (McLaughlin,  et  al  1998, 
Zinzani,  et  an,  diffuse  high-grade  lymphoma  (Coiffier,  et  al  1998)  and Dr  Simon  J  Harrison,  2005  Chapter  1-52 
Waldenstrom's  macroglobulinaemia  (Dimopoulos,  et  a12002,  Gertz,  et  p/  2003),  to 
date  the  experience  in  myeloma  is limited  (Lim,  et  a12004,  Musto,  et  a!  12003, 
Treon,  et  a12001),  although  it  may  have  a  role  against  the  MM  `stem  cell'  as 
discussed  later. 
The  use  of  anti-CD38  MoAb  in  clinical  trials  to  date  has  been  limited  though  sonde 
clinical  efficacy  has  been  demonstrated  (Ellis,  et  a/  1995).  Initial  difficulties 
associated  with  human-anti-mouse  antibodies  (HAMA)  have  largely  been 
temporised  with  the  use  of  a  humanised  variant. 
One  advance  in  respect  to  improving  efficacy  is  the  engineering  of  MoAb  as 
carriers  of  toxin  genes.  Workers  in  the  Mayo  Clinic  have  generated  single-chain 
variable  fragments  (scFv)  that  represent  the  linkage  of  the  carboxyl  terminus  of 
one  variable  region  (IgH)  with  the  amino  terminus  of  the  other  (IgL),  using 
nucleotides  that  encode  a  series  of  hydrophilic  peptides  which  retain  the  original 
antibody  specificity  (Chen,  et  a/  1995).  The  investigators  have  attached  diphtheria 
toxin-A  plasmid  DNA  to  a  scFv  directed  against  CD38,  which  is internalised  into 
the  Ag-expressing  cell  by  receptor-mediated  endocytosis.  Using  this  technology, 
in-vitro  and  animal  studies  have  demonstrated  cell  suicide  by  expression  of  the 
diphtheria  toxin-A  and  the  investigators  intend  to  directly  target  plasma  cells  using 
tissue-specific  transcriptional  regulatory  elements  (e.  g.  Ig  heavy  chain  enhancer) 
to  limit  non-specific  cell  killing.  The  translation  into  clinical  trials  is  eagerly  awaited 
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1.8  Immunologically  active  drugs 
1.8.1  Thalidomide  and  it's  analogues 
Thalidomide  has  been  successfully  used  to  treat  patients  with  relapsed/resistant 
myeloma  (Singhal,  et  al  1999).  While  thalidomide  may  act  as  an  anti-angiogenic 
factor  in  myeloma,  several  other  potential  mechanisms  of  action  have  been 
proposed.  Firstly,  thalidomide  may  directly  inhibit  tumour  cell  growth  and 
differentiation,  mediated  by  reduced  cell  adhesion  interactions  and  inhibition  of 
cytokine  secretion  (e.  g.  TNF-a)  or  through  free-radical  generation  and  apoptosis, 
either  directly  or  in  response  to  drugs  such  as  dexamethasone.  Secondly, 
thalidomide  may  inhibit  the  activity  of  vascular  endothelial  growth  factor  (VEGF) 
and  basic  fibroblast  growth  factor  (bFGF-2),  which  act  as  growth  and  survival 
factors  for  myeloma  cells.  Thirdly,  thalidomide  may  act  by  promoting  a  Th1  T  cell 
response  resulting  in  the  secretion  of  interferon-y  and  IL-2.  Whether,  one  or  all  of 
these  mechanisms  mediate  the  clinical  effects  of  thalidomide  in  myeloma  remains 
to  be  clarified.  Several  thalidomide  analogues  are  in  the  early  phases  of  clinical 
development  aiming  to  either  inhibit  cytokines  (phosphodiesterase  4  inhibitors)  or 
induce  immunomodulation  (IMiDs),  with  fewer  side-effects  (Corral,  eta!  1999). 
There  is  tremendous  future  potential  in  the  use  of  thalidomide  or  its  analogues  and 
studies  such  as  the  MRC  Myeloma  IX  aim  to  assess  the  efficacy  of  thalidomide  in 
combination  with  induction  chemotherapy  and  as  a  maintenance  strategy  following 
Auto  HSCT. Dr  Simon  J  Harrison,  2005 
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IL-2  is  a  central  regulator  of  immune  responses  mainly  produced  by  activated 
CD4+1e  T  cells.  However,  transformed  T  cells,  B-cells,  leukaemia  cells,  LAK  cells 
(lymphokine-activated  killer  cells)  NK-cells  and  DC  may  also  secrete  IL-2.  IL-2  iq  a 
growth  factor  for  all  T  cell  subpopulations,  inducing  Ag-unspecific  proliferation  of  T 
cells  by  inducing  cell  cycle  progression  in  resting  cells,  and  clonal  expansion  of 
activated  T-lymphocytes.  IL-2  also  promotes  the  proliferation  of  activated  NK  cells 
and  B-cells  (but  this  requires  the  presence  of  additional  factors,  for  example,  IL-4). 
The  observation  that  leukocytes  cultured  in  IL-2  were  able  to  lyse  tumour  cells 
(Grimm,  et  al  1982,  Lotze,  et  al  1981)  ultimately  led  to  IL-2  being  administered  to 
patients  with  melanoma  ,  renal  cell  carcinoma  and  B-cell  lymphoma  (Lotze,  et  al 
1986,  Rosenberg,  et  a11987,  Rosenberg,  et  a11985)  with  a  number  of  complete 
and  partial  remissions  being  reported  (Yang,  et  al  2003b).  IL-2  has  no  direct  effect 
on  tumours,  as  high  concentrations  don't  inhibit  tumour  cell  growth  in-vitro  and  the 
anti-tumour  properties  are  mediated  by  the  cellular  immune  system  i.  e.  NK  and  T 
cells.  Investigators  such  as  Rosenberg  have  combined  the  use  of  immune  effector 
cells  (tumour  infiltrating  lymphocytes)  and  IL-2  in  the  search  for  more  potent 
therapies  (Dudley,  et  a/  2002). 
Intravenous  IL-2  is  a  toxic  therapy.  The  major  side  effects  include  hypotension, 
capillary  leak  syndrome,  organ  dysfunction  and  a  treatment  related  mortality  of 
1.5%.  This  has  prompted  investigators  to  reduce  the  dose  and  change  to  the 
subcutaneous  route  of  administration.  Although  there  is  debate  as  to  whether  this 
reduces  the  efficacy  of  IL-2  therapy  (Ravaud,  et  al  1994,  Yang,  et  al  2003b),  Kiss 
et  al  have  reported  that  low  dose  SC  IL-2  (1  Mu  BiD  for  1  week,  2Mu  BiD  for  3 Dr  Simon  J  Harrison,  2005  Chapter  1-55 
weeks)  induced  a  complete  remission  of  relapsed  Hodgkin's  disease  following 
sibling  alto  HSCT  complicated  by  acute  skin  GVHD  (Kiss,  et  al  2003).  Whilst 
Slavin  et  al  have  reported  long  term  remissions  using  in-vitro  activation  of  DLI  and 
SC  IL-2  for  the  treatment  of  relapsed  leukaemia  following  Allo  HSCT  that  was 
unresponsive  to  DLI  alone  (Slavin,  et  al  1996). 
These  observations  suggest  that  IL-2  may  be  a  useful  adjuvant  to  cellular 
immunotherapy  of  MM  by  providing  continuing  stimulation  of  the  immune  system 
following  the  administration  of  immune  effector  cells.  IL-2  could  also  be  given 
following  alto  HSCT  in  place  of,  or  in  addition  to  DLI  to  boost  any  immune 
mediated  effect. 
1.9  Efficacy  measurements  in  immunotherapy  trials 
Progress  in  the  understanding  of  the  basic  mechanisms  involved  in  generating 
immune  responses  to  tumour  Ags  has  never  been  greater.  However,  there  is  a 
lack  of  accurate,  reproducible  and  readily  transferable  measurements  of  efficacy  to 
assess  the  immune  responses  generated  in  the  context  of  tumour  immunotherapy. 
The  role  of  efficacy  measurements  in  association  with  immunotherapy  trials  is 
fundamental  to  the  full  assessment  of  such  novel  strategies.  It  has  been  assumed 
that  current  treatment  modalities  are  themselves  curative  in  patients  who  achieve 
long-term  disease-free  survival.  The  role  of  an  auto  anti-tumour  immune  response 
remains  to  be  clarified.  It  has  been  shown  that  it  is  an  auto  immune  response  to 
the  residual  disease  that  prevents  relapse  in  acute  leukaemias  (Lowdell,  et  al 
1999,  Lowdell  and  Koh  2000,  Lowdell,  et  al  1997)  and  the  data  suggests  that  the 
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whether  there  is  an  anti-tumour  immune  response,  albeit  inadequate,  allows  one 
to  construct  and  test  hypotheses  about  how  it  may  be  enhanced  or  indiced  when 
absent.  Such  hypotheses  inevitably  lead  on  to  the  design  of  appropriate  assays  of 
immune  function  during  and  after  administration  of  the  immunological  iriterventign 
under  trial. 
Measurements  of  immune  function  have  been  notoriously  unreliable  and  poorly 
reflect  the  true  status  of  the  patient.  However,  recent  advances  in  measurements 
of  cell  activation,  cytokine  production  and  cell-mediated  cytotoxicity  have  radically 
changed  the  reproducibility  of  such  experiments.  The  identification  of  relevant 
peptides  from  tumour-associated  Ags  is  allowing  the  construction  of  peptide/HLA 
tetramers,  which  can  be  used  to  enumerate  and  analyse  the  function  of  Ag- 
specific  T  cells  (Howard,  et  a/  1999).  In  all  such  assays  it  remains  important  that 
the  true  measure  of  a  relevant  immune  response  is  not  that  the  patient  or  animal 
model  can  be  demonstrated  to  have  responded  to  the  vaccine  but  rather  that  the 
response  is  measurable  against  the  primary  tumour.  This  is  plainly  easier  said 
than  done.  Nonetheless  it  should  be  an  aim  at  the  outset  of  research  so  that  the 
primary  tumour  is  collected  and  stored  in  an  appropriate  manner  at  presentation 
for  use  in  later  experiments.  Clearly,  robust,  reproducible  and  relevant  out  come 
measurements  of  immune  function  are  essential  to  determine  the  efficacy  of  any 
immunotherapy  intervention. 
1.10  Combination  immunotherapy 
In  view  of  the  disappointing  clinical  response  seen  thus  far  in  immunotherapy 
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effective  if  used  in  combination.  Shimizu  showed  that  immune  responses  to  a 
tumour  lysate-pulsed  DC  vaccine  could  be  increased  by  the  addition  of  IL-2  in  a 
murine  sarcoma  model  [146].  Yi  et  al  have  reported  the  use  of  SC  low  gose  IL-2 
five  days  following  administration  of  idiotype-pulsed  DC.  Anti-idiotype  T  cell 
responses  developed  in  four  and  B  cell  responses  in  all  five  patients,  including  9 
50%  reduction  in  M-protein  in  one  patient  (Shimizu,  et  al  1999,  Yi,  et  a/  2002). 
Whilst  in  a  murine  model,  81  %  of  animals  treated  with  Id  vaccine,  plus  FLT-3 
ligand  (FLT-3L)  and  IL-2  survived  more  than  180  days  compared  to  none  give  the 
individual  therapies,  and  27%  and  41  %  given  Id  plus  IL-2  or  FLT-3L  respectively 
(Zeis,  et  al  2002).  Another  approach  has  been  taken  by  the  group  in  South 
Carolina,  who  have  combined  Rituximab  and  low  dose  SC  IL-2  in  NHL. 
Responses  correlated  with  NK  cell  numbers  and  the  addition  of  11-2  resulted  in  an 
increase  in  Ag  dependant  T  cell  cytotoxicity  in  responders  (Gluck,  et  an.  However, 
some  of  the  most  promising  results  to  date  have  come  from  the  NIH,  where  the 
combination  of  vaccination,  adoptive  transfer  of  T  cells  and  IL-2  therapy  resulted  in 
some  long  term  cures  in  a  mouse  melanoma  model  (Overwijk,  et  a!  2003). 
1.11  Discussion 
The  field  of  cancer  immunotherapy  stands  at  a  threshold.  There  have  been  great 
advances  in  the  understanding  of  the  immune  system  and  how  it  can  be 
manipulated,  and  in  a  number  of  diseases,  immune  based  therapies  are 
beginning  to  realise  their  potential.  The  use  of  antibody  therapy,  such  as 
Rituximab,  in  combination  with  conventional  chemotherapy  for  the  treatment  of 
lymphoma  has  resulted  in  improved  disease  responses  and  is  becoming  standard 
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immunotherapy  for  the  treatment  of  post-transplant  lymphoproliferative  disorder 
(PTLD)  (Bollard,  et  al  2003).  PTLD  is  a  complication  of  HSCT  or  solid  organ 
transplantation,  associated  with  regimes  that  contain  antibodies  such  as  anti- 
lymphocyte  or  anti-thymocyte  globulin,  which  generate  more  profound  cellular 
immunodeficiency  than  those  that  do  not  contain  such  antibodies.  This  may  alloyv 
uncontrolled  expansion  of  Epstein-Barr-virus  (EBV)-infected  B  cells.  These 
infected  B  cells  express  the  full  spectrum  EBV  latent  Ags,  which  are  well 
characterised  and  highly  immunogenic,  and  there  appears  to  be  no  additional 
immune  suppression  associated  with  the  malignant  clone.  Adoptively  transferred 
auto  or  HLA  class  I  matched  EBV-specific  T  cells  are  able  to  restore  cellular 
immunity,  eradicating  the  disease  without  the  need  for  conventional 
chemotherapy.  However,  whilst  we  can  consistently  generate  auto  cellular  and 
humoral  anti-MM  immune  responses  in-vitro  and  in-vivo,  they  have  yet  to  be 
translated  into  effective  clinical  tools  capable  of  inducing  sustained  disease 
responses.  We  have  also  yet  to  show  that  the  anti-MM  immune  effects  seen 
following  alto  HSCT  can  be  separated  from  those  due  to  major  and  minor  histo- 
incompatibility.  If  immunotherapy  of  MM  is  to  develop  into  an  effective  therapy,  a 
number  of  crucial  questions  still  need  to  be  answered: 
What  are  the  most  effective  anti-MM  Ag's,  can  they  be  used  alone,  or  are 
they  more  effective  in  combination? 
A  number  of  new  and  old  target  Ags  are  currently  under  investigation.  Of  these 
molecules,  Id  protein  is  the  most  widely  studied.  We  await  with  interest  the  results 
of  studies,  such  as  those  from  Southampton,  which  look  at  combining  Id  with 
adjuvant  compounds  to  increase  the  potency  of  the  anti-MM  immune  response. 
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development  for  the  treatment  of  MM  (Chiriva-Internati,  et  a/  2003,  Rew,  et  al 
2003).  Most  MM  immunotherapeutic  strategies  are  directed  at  mature  MM  cell  Ags 
and  will  thus  be  effective  against  the  bulk  of  the  tumour  cells,  however,  as  with 
other  targeted  therapies  such  as  Glivec  in  CML,  this  approach  has  the  potential  to 
leave  these  tumour  stem  cells  unscathed,  resulting  in  disease  relapse  (Brick,  et  al 
2005).  MM  tumour  cells  are  classically  thought  of  as  mature  plasma  cells 
(CD45+"e/CD19.  ve/CD56+"e/CD138+1e/CD38+1e),  with  a  low  proliferative  index. 
However,  as  with  other  leukaemia's,  there  may  be  a  small  population  of  'tumour 
stem  cells'  (CD45+1e/  CD19+1e/  CD22+"e/  CD138""e)  that  retain  the  capacity  to  self- 
renew  and  proliferate  (Matsui,  et  a!  2004).  These  cells  are  able  to  repopulate 
nod/scid  mice  and  if  removed  by  purging  with  Rituximab,  the  MM  fails  to  engraft 
(Jones  2003,  Matsui,  et  a/  2004).  It  may  be  a  mistake  to  select  MM  Ags  that  may 
only  be  present  on  the  non-self-renewing  cells  in  a  bid  to  get  good  clinical 
responses,  when  we  need  to  direct  our  efforts  at  the  cells  that  contribute  to 
relapse,  thus  improving  long  term  survival.  Further  studies  of  the  putative  MM 
stem  cell  are  warranted.  Examining  their  phenotypic  and  genotypic  characteristics 
may  identify  novel  immunotherapeutic  targets.  It  remains  to  be  seen  whether  a 
single  Ag  can  effectively  eradicate  MM  in-vitro.  Approaches  that  combine  multiple 
Ags,  such  as  tumour  lysate  or  apoptotic  tumour  cells,  have  the  theoretical 
advantage  of  being  less  likely  to  induce  the  MM  clone  to  delete  the  target  Ag,  a 
phenomenon  known  as  Ag  escape. 
Can  simple  vaccination  induce  an  effective  anti-MM  response  or  do  we  need 
to  deliver  the  Ag(s)  via  professional  APC  generated  ex-vivo? 
At  present,  immunotherapy  of  MM  is  developing  along  two  main  themes,  the  more 
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In  the  future  it  may  be  possible  to  combine  these  two  approaches  by  pre- 
conditioning  the  site  of  vaccination  with  growth  factors  and  chemokines  in  order  to 
recruit  APC.  Efficient  trafficking  of  these  Ag  loaded  APC  to  LN  could  then  be 
induced  by  vaccines  containing  adjuvants  designed  to  promote  maturation  and 
migration  of  APC.  This  type  of  approach  would  avoid  all  the  inherent  costs  and 
risks  of  having  to  collect  cells  and  then  ex-vivo  generate  Ag  loaded,  mature  APC, 
for  each  individual  patient.  In  addition,  humoral  as  well  as  cellular  immune 
responses  may  be  induced. 
How  does  the  MM  tumour  cell  evade  immune  surveillance? 
The  evidence  to  date  indicates  that  the  MM  tumour  cell  is  able  to  disable  the 
immune  system  at  multiple  crucial  points  (Figure  1-5)  We  are  beginning  to 
understand  this  interplay  between  the  malignant  cell  and  the  immune  system  of 
the  tumour-bearing  host.  This  is  prompting  researchers  to  devise  strategies  that 
overcome  the  immunosuppressive  effects  of  the  MM  tumour  cell,  such  as  T  cell 
pre-activation,  in  order  to  increase  the  effectiveness  of  immune  therapy  against 
the  malignant  clone. 
Can  immunotherapies  be  effective  when  used  alone,  or  are  they  best  used  in 
combination  in  the  treatment  of  MM? 
In  view  of  the  hostile  in-vivo  environment  induced  by  the  MM  tumour  cell,  and  the 
disappointing  clinical  response  seen  thus  far  in  immunotherapy  trials  in  MM,  it  is 
our  view  that  immune  therapies  may  be  more  effective  if  used  in  combination.  A 
number  of  groups  are  examining  the  effectiveness  of  combinations  of 
immunotherapy,  such  as  Id  pulsed  DC  and  IL-2,  CTL  and  IL-2,  and  antibody 
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prime  the  immune  system,  pre-stimulation  of  T  cells  to  correct  tumour  induced 
anergy,  followed  up  with  low  dose  subcutaneous  IL-2  to  maintain  the  activation  of 
the  immune  system.  As  previously  discussed  a  number  of  groups  are  examining 
the  use  of  combinations  such  as  the  adoptive  transfer  of  Ag  specific  T  cells  and  IL- 
2,  and  Ag-loaded  DC  and  IL-2. 
Until  we  can  answer  these  questions,  effective  immunotherapy  in  myeloma  will 
remain  a  possibility  not  a  probability.  The  on-going  basic  and  translational 
research  is  encouraging,  but  the  proof  of  principal  in  the  clinical  arena  remains  to 
be  demonstrated.  The  design  of  good  clinical  trials  will  be  crucial,  as  is  optimal 
immunological  monitoring  to  measure  what,  if  any,  effect  such  strategies  will  have 
on  the  host's  immune  system.  As  with  other  biological  therapies  in  haemato- 
oncology,  it  is likely  that  these  immune-based  therapies  will  achieve  their 
maximum  effect  when  the  tumour  burden  is  reduced  to  a  minimum.  Thus,  immune 
strategies  against  MM  are  likely  to  be  useful  adjuncts  to  conventional  chemo- 
radiotherapy  and  auto  HSCT. 
1.12  Aims 
The  following  aims  will  be  dealt  with  in  turn,  within  the  relevant  Results  Chapter. 
1.  To  establish  and  validate  that  the  BDCA  assay  can  be  used  to  measure 
mDC1,  pDC,  mDC2  and  B  lymphocytes  in  ND  and  MM  patients. 
2.  To  determine  whether  the  number  of  circulating  DC  subsets  are  abnormal 
in  MM  patients,  and  whether  they  change  during  the  course  of  the  disease 
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3.  To  establish  the  method  DC  production  using  mobilised  monocytes  from 
ND  and  MM  patients. 
4.  To  determine  whether  the  cytokine  combinations  used  during  DC 
production  influence  the  quality  of  the  DC  produced  from  ND  ant  MM 
patients. 
5.  To  determine  whether  pre-stimulation  of  T  cells  from  MM  patients  alters 
their  interaction  with  matDC,  resulting  in  improved  T  cell  proliferation  and 
cytolytic  activity. 
6.  To  determine  whether  the  Luminex  system  can  detected  differences  in  the 
level  of  cytokines  produced  during  the  DC/T  cell  interaction,  in  cells  derived 
from  ND  and  MM  patients  using  different  cytokine  combinations. 
7.  To  establish  and  validate  the  fluorescent  chemokine  uptake  assay. 
B.  To  determine  the  chemokine  receptor  activity  on  cells  from  ND  and  MM 
patients  during  MoDC  development  and  maturation. 
Each  chapter  begins  with  a  short,  focused  introduction  to  the  data  and  culminates 
in  a  brief  discussion  of  the  findings. Dr  Simon  J  Harrison,  2005  Chapter  2-63 
2.  Materials  and  Methods 
2.1  Ethical  approval  and  informed  consent 
All  primary  human  material  was  collected  with  the  approval  of  the  Local  Research 
and  Ethics  Committee,  North  Glasgow  University  Hospitals  Division.  Written 
informed  consent  was  obtained  from  each  patient  and  donor  prior  to  obtaining 
samples. 
2.2  Cell  handling  and  culture 
2.2.1  Media 
PBS/Alba;  Phosphate  buffered  saline  (PBS)  (Sigma,  Poole,  Dorset  UK)  and  0.5% 
Alba  (4.5%  human  albumin  solution,  SNBTS,  Edinburgh,  UK). 
PBS/Alba/EDTA;  PBS  (Sigma)  and  0.5%  Alba  and  2mM  EDTA  (Sigma). 
TC  medium;  RPMI  1640  media  (Sigma)  supplemented  with  5%  human  AB  serum 
(SNBTS),  2%  L-glutamine  (Sigma)  and  2%  penicillin-streptomycin  (Sigma). 
DC  medium;  RPMI  1640  media  (Sigma)  supplemented  with  2%  human  AB  serum, 
2%  L-glutamine  (Sigma)  and  2%  penicillin-streptomycin  (Sigma). 
Serum  free  (SF)  medium:  RPMI  1640  media  (Sigma)  supplemented  with,  2%  L- 
glutamine  (Sigma)  and  2%  penicillin-streptomycin  (Sigma). 
Cryopreservation  medium;  10%  DMSO  (Quest  Biomedical,  Solihull,  UK)/Alba Dr  Simon  J  Harrison,  2005  Chapter  2-64 
DAMP  thawing  solution;  calcium  and  magnesium  free  D-PBS  (Sigma),  0.5%  Alba, 
2.5mM  MgCI2  (Sigma),  1OU/ml  pulmozyme  (Roche  Products  Ltd,  Welwyn  Gardgn 
City,  UK) 
FAGS-Fix  solution;  PBS,  1%  paraformaldehyde  (Sigma)  and  0.5%  Alba. 
2.2.2  Cytokines  and  chemokines 
All  cytokines  were  purchased  from  PeproTec  EC  (London,  UK),  with  the  exception 
of  IL-6  and  GM-CSF  (Stem  Cell  Technologies,  Vancouver,  Canada).  All  cytokines 
were  re-constituted  as  per  the  manufacturers  instructions,  and  stored  at  -80°C  ýt  a 
concentration  of  1-10mg/m! 
All  chemokines  used  in  these  experiments  were  kind  gifts  from  Dr  R.  J.  B.  Nibbs, 
Glasgow  University. 
2.2.3  Cell-lines 
All  cell  culture  work  was  performed  in  a  laminar  flow  cabinet  using  aseptic 
technique.  All  tissue  culture  flasks  and  plates  were  purchased  from  Corning  life 
Sciences  (Koolhovenlaan,  Netherlands). 
MM  cell  lines  were  obtained  from  previously  cryopreserved  stocks  at  our  institution 
or  purchased  from  The  European  Collection  of  Cell  Cultures  (ECACC,  Porton 
Down,  Salisbury,  Wiltshire,  UK).  All  MM  cell  lines  were  maintained  in  suspension 
culture  in  15mis  of  TC  medium,  in  75cm2  tissue  culture  flasks  Cultures  were 
maintained  at  37°C  in  a  5%  CO2  atmosphere.  On  reaching  an  approximate  cell 
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The  HEK293  cell  line,  wild  type  or  stably  transfected  to  express  either  D6  or  CCR7 
(kind  gifts  from  R.  J.  B.  Nibbs,  Glasgow  University)  were  cultured  at  37°C,  5%  CO21 
in  75cm2  tissue  culture  flasks,  and  DMEM  (Sigma)  supplemented  with  10%  FCS 
(Sigma),  plus  1%  streptomycin  and  penicillin  (Sigma),  and  4mM  glutamine 
(Sigma).  The  cells  were  adherent  and  had  a  doubling  time  of  24-36  hours.  Cells 
were  passaged  when  they  became  confluent  on  the  bottom  of  the  flask.  The 
supernatant  was  removed  by  gentle  pipetting  and  the  cells  were  washed  twice  with 
PBS.  Five  mis  of  0.25%  trypsin  was  added  to  each  flask,  which  was  gently 
agitated  until  the  cells  lifted  off  the  bottom  of  the  flask.  Twenty  mis  of  DMEM,  10% 
FCS  was  added  and  the  cells  recovered  by  centrifugation  at  1200  rpm,  washed 
twice  and  plated  out  at  a  1:  10  dilution.  The  transfected  cells  were  normally 
maintained  in  selection  culture,  but  this  was  not  necessary  for  short-term  culture, 
i.  e.  less  than  7  days. 
2.2.4  Harvesting  cells  collected  by  apheresis 
Normal  donors  and  MM  patients  had  stem  cells  mobilised  for  therapeutic  use  as 
per  the  normal  referring  unit  policy.  Usually,  ND  received  G-CSF  1  Opg/kg  by 
subcutaneous  injection  (SCI)  for  5  days,  and  MM  patients  were  conditioned  with 
cyclophosphamide  1-6gm/m2  on  day  0,  commenced  G-CSF  5-1Opg/kg  SCI  on  day 
4,  and  collected  around  day  +10,  when  the  peripheral  blood  CD34+  cell  count  was 
greater  than  20  cells/pl.  All  subjects  had  cells  collected  using  COBE®  Spectral"' 
continuous  flow  Apheresis  System  (Gambro  BCT,  Lakewood,  Co,  USA)  and  the 
standard  stem  cell  collection  program  by  staff  of  the  Apheresis  Unit,  Glasgow 
Royal  Infirmary.  The  cells  for  therapeutic  use  were  collected  into  a  bag,  which  was 
then  heat  sealed  and  removed  for  processing.  The  tubing  on  the  collection  side  of 
the  collection  side  of  the  closed  circuit  was  heat  sealed  and  removed  from  the 
machine  and  processed  within  4  hours  of  collection. Dr  Simon  J  Harrison,  2005  Chapter  2-66 
All  cell  manipulations  were  performed  in  a  laminar  flow  cabinet  using  aseptic 
technique.  The  collection  tubing  was  flushed  with  20mis  of  TC  medium  pnd  the 
cells  were  collected  into  a  50ml  sterile  conical  tube  (Greiner  Bio-One,  Longwood, 
Florida,  USA).  After  gentle  mixing  by  inversion,  the  cell  suspension  was  carefully 
layered  on  top  of  3mls  of  Histopaque®-1077  (Sigma)  in  15ml  test  tubes  (Greiner), 
and  spun  at  1700rpm  for  20mins  (density  gradient  separation).  The  serum  was  the 
pipetted  off  mononuclear  cell  layer  leaving  0.5cm  above  the  interface,  which  wad 
then  carefully  removed  and  placed  in  a  fresh  15ml  tube.  The  cells  were  washed 
three  times  in  fresh  TC  medium,  the  first  spin  was  at  1000rpm  for  1  Omins  to  alsq 
remove  any  excess  Histopaque  and  the  next  two  spins  were  at  800  rpm  for 
10mins  to  leave  platelets  suspended  in  the  supernatant.  The  supernatant  was 
removed  by  careful  pipetting  and  the  cells  were  resuspended  by  gentle  flicking  of 
the  tube  at  5x106ml  TC  medium  and  cultured  overnight  to  rest,  at  37°C,  in  75cm2 
tissue  culture  flasks,  in  preparation  for  cell  sorting. 
2.2.5  Red  cell  Lysis 
Red  blood  cells  in  peripheral  blood  mononuclear  cell  (PBMC)  preparations  were 
lysed  with  ammonium  chloride  solution  (0.083%,  Sigma)  at  37°C  for  ten  minutes 
and  repeated  if  required.  Cells  were  washed  in  PBS  and  recovered  by 
centrifugation  at  1000rpm  for  10mins  and  resuspended  in  medium  or  PBS  as 
required. 
Red  blood  cells  in  whole  blood  (WB)  preparations  were  lysed  with  sterile, 
deionised  water  for  15secs  (at  a  ratio  of  1:  10  WB  to  H20),  the  cells  were 
immediately  washed  in  PBS/Alba  (1:  4,  water  to  PBS)  and  the  whole  procedure 
repeated  once.  Cells  were  then  suspended  in  PBS/Alba  or  appropriate  tissue 
culture  medium  as  required. Dr  Simon  J  Harrison,  2005 
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Clinical  full  blood  counts  were  performed  on  a  Coulter  Gen-S  analyser  (Beckmann 
Coulter,  Fullerton,  CA,  USA)  in  Glasgow  Royal  Infirmary  and  Sysmex  SF9500 
analyser  (Sysmex,  Kobe,  Japan)  at  the  Western  Infirmary,  Glasgow.  Both 
analysers  use  a  sample  size  between  200  and  250pl  to  produce  a  full  blood  court 
and  5  part  differential.  Both  laboratories  participate  in  the  United  Kingdom  National 
External  Quality  Assessment  Service  (NEQUAS)  surveillance  scheme  fpr  quality 
assurance. 
All  other  cell  counts  were  performed  manually  with  a  haemocytometer  and  viability 
was  assessed  by  Trypan  Blue  (Sigma)  exclusion.  Briefly,  90pl  of  1:  10  Trypan  Blie 
was  added  to  10pl  of  cell  suspension  and  10pl  was  then  transferred  to  a 
haemocytometer  (i.  e.  cells  were  diluted  1:  10)  Blue  stained  cells  were  counted  as 
non-viable,  and  the  mean  number  of  unstained  cells  counted  in  5  large  squares, 
multiplied  by  10  (the  dilution  factor),  was  taken  as  the  viable  cell  count  X104/ml. 
2.2.7  Cryopreservation  of  cells 
All  cells  that  required  cryopreservation  were  washed  once  in  cold  Alba  and 
resuspended  at  a  concentration  of  not  more  than  2x107/ml  in  DMSO/Alba  on  ice.  A 
1  ml  aliquot  of  cell  suspension  was  then  transferred  into  1.5ml  Nunc  Cryotubes 
(Nunc  A/S,  Roskilde,  Denmark)  and  the  cells  were  placed  in  a  polystyrene  box 
surrounded  by  polystyrene  packing  beads.  The  box  was  then  cooled  at  -20°C  for  1 
hour  and  -80°C  overnight  before  the  cryotubes  were  transferred  to  liquid  nitrogen 
(LN)  for  storage. Dr  Simon  J  Harrison,  2005 
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Extreme  care  was  taken  to  ensure  good  cell  recovery,  especially  when  thawing 
un-sorted  PBMC  from  apheresis  collections,  which  contain  high  numbers  of 
granulocytes.  On  removal  from  LN,  cryotubes  were  immediately  placed  in  a  37°Q 
water  bath  until  all  ice  crystals  had  melted.  The  cell  suspension  was  the  gently 
transferred  into  a  15ml  test  tube  and  DMP  thawing  solution  was  added  slowly, 
drop  by  drop  initially,  with  constant  gentle  agitation  on  ice  until  14mis  of  DMP  had 
been  added.  The  tube  was  then  placed  in  a  37°C  water  bath  for  10mins  to  facilitpte 
the  action  of  the  enzyme.  Cells  were  then  spun  at  1000rpm  for  10mins,  the 
supernatant  removed  by  pipetting,  resuspended  in  DMP  and  incubated  at  37°C  for 
a  further  5mins.  Cells  were  then  washed  twice  in  TC  medium,  counted  and 
checked  for  viability. 
2.2.9  Preparation  of  Ag 
2.2.9.  lTumour  Lysate 
Tumour  cell  lysates  were  prepared  by  harvesting  cells  from  culture,  and  placing 
them  in  15m1  test  tubes.  The  cells  were  recovered  by  centrifugation  at  1200rpm  for 
10mins,  the  supernatant  discarded  and  the  cells  resuspended  in  1ml  of  TC 
medium.  The  cells  were  then  counted,  and  the  cell  suspension  snap  frozen  at  - 
80°C  for  15mins.  The  cell  preparation  was  rapidly  thawed  in  a  37°C  water  bath, 
vigorously  vortexed  for  2mins,  and  the  process  of  freezing,  thawing  and  vortexing 
was  repeated  3  times  to  ensure  all  cell  were  disrupted.  TC  medium  was  added  to 
adjust  the  final  cell  concentration  to  1x107/ml  and  the  freeze/  thaw  preparation  was 
then  stored  at  -80°C  for  future  use. Dr  Simon  J  Harrison,  2005  Chapter  2-69 
2.2.9.2lnduction  of  tumour  cell  apoptosis 
Tumour  cell  lines  were  suspended  at  1  x105/ml  in  SFM,  and  placed  in  a  75cm2 
culture  flask  in  15ml  aliquots.  The  cells  were  exposed  to  a  Philips  SLPF15E  ultra 
violet  light  source  for  30mins  and  cultured  overnight  at  37°C  to  allow  them  to  enter 
cell  cycle  and  undergo  apoptosis.  Apoptosis  was  confirmed  using  Annexin-V  and 
7AAD  (Viaprobe)  staining,  and  analysed  by  flow  cytometry  (as  described  in  2.3.7). 
The  rates  of  apoptosis  were  compared  in  cells  that  had  been  irradiated  and 
cultured  overnight  in  SF  medium  and  TC  medium,  with  un-irradiated  cells  cultured 
under  the  same  conditions,  Figure  2-1.  This  confirmed  that  UV  irradiation  and 
overnight  culture  in  SF  medium  (mean  40.5  ±  3.7,  p<0.01)  were  the  optimum 
conditions  to  induce  apoptosis  in  U266  cells,  as  compared  to  serum  free  culture 
(mean  23.7  ±  2.5).  UV  irradiation  alone  (mean  12.8  ±  1.8,  was  not  significantly 
different  from  the  untreated  control  (mean  13.5  ±  1.6). 
A  Control  B  Serum  free 
Yzca.  oo9  ýze6  2 
1.2  9.4  0.6  19.4 
4.6  77  ý  2.8 
1O  IC  _  m1  V'  1Y' 
FEOC  M-  VFITC 
C  UV  30mins 
1.3  7.4 
5.6 
_oU  ö'  02 
Mww  V  FITC 
D  UV  30mins  +  serum  free 
ýma.  on 
3.2  36.0 
57-  ....:,  :  3.1 
2100  10'  i00  Ia  ion  Mn.  nV  Frtc 
Figure  2-1  Apoptosis  in  irradiated  and  un-irradiated  cells  cultured  overnight 
in  SF  medium  and  TC  medium 
The  proportion  of  U266  cells  undergoing  apoptosis  was  compared  in  cells  that  had 
been  irradiated  and  cultured  overnight  in  SF  medium  or  TC  medium,  with  un- 
irradiated  cells  cultured  under  the  same  conditions.  Apoptosis  was  measured 
using  Annexin-V  and  7RAD  (Viaprobe)  staining,  and  analysed  by  flow  cytometry. 
Assays  were  performed  in  triplicate. Dr  Simon  J  Harrison,  2005  Chapter  2-70 
2.2.10  Selection  of  CD14+  monocytes  and  CD3+  T  cells 
To  obtain  monocytes  and  T  cells  with  a  purity  of  >90%,  cells  collected  by 
apheresis  were  sorted  using  the  MACS  system  (Miltenyi  Biotec,  Bergisch 
Gladbach,  Germany).  All  sorts  were  performed  as  per  the  manufacturers 
instructions  using  the  LS  size  column,  allowing  the  selection  of  up  to  1x108 
positively  labelled  cells  from  up  to  a  total  of  1x109  cells.  Cells  were  placed  into  2 
15ml  test  tubes,  washed  once  in  cold  PBS/EDTA/Alba  and  resuspended  in  7Opl  of 
cold  PBS/EDTA/Alba  per  107  cells.  We  labelled  one  tube  with  CD14  microbeads  to 
isolate  monocytes,  and  the  other  with  CD3  microbeads  for  T  cells,  both  at  20pl/107 
cells  and  incubated  at  4°C  for  15mins  under  slow  continuous  mixing.  Cells  were 
washed  in  cold  PBS/EDTA/Alba,  passed  through  a  pre-wetted  30pm  filter  and  LS 
column  in  a  midi-MACS  magnet  (all  Miltenyi  Biotec).  The  column  was  washed 
through  with  3x3ml  of  PBS/EDTA/Alba  and  removed  from  the  magnet.  The 
positively  selected  cells  were  then  eluted  off  the  column  in  5ml  of  PBS/EDTA/Alba 
with  the  supplied  plunger.  The  cells  were  then  counted  and  checked  for  viability 
and  an  aliquot  of  5x105  was  retained  for  flow  cytometry. 
2.2.11  MoDC  production 
Monocytes,  purified  from  PBMC  by  CD14  magnetic  bead  separation,  were 
suspended  in  DC  medium  at  a  density  of  5x106/ml  and  placed  in  75cm2  tissue 
culture  flasks.  The  DC  medium  was  then  supplemented  with  GM-CSF  50ng/ml 
(Stem  Cell  Technologies)  and  either  IL-4  30ng/mI  (Peprotech)  or  IL-13  50ng/ml 
(Peprotech).  Cells  were  cultured  for  4  days  at  37°C  and  5%  C02,  counted,  checked 
for  viability,  and  the  concentration  of  cells  was  adjusted  to  1x106/ml  by  the  addition 
of  DC  medium  supplemented  with  the  appropriate  cytokines.  The  Ag  preparation, 
either  apoptotic  or  freeze-thawed  U266  cells  suspended  at  1x107/ml,  was  added  to Dr  Simon  J  Harrison,  2005  Chapter  2-71 
a  final  ratio  of  1  iDC  to  1  tumour  cell  (equivalent  to  an  approximate  protein 
concentration  of  1  mg/ml)  (Thumann,  et  a/  2003).  To  induce  iDC  Ag  IoaOing  and 
maturation,  either  the  monocyte  conditioned  medium  mimic  (MIMIC)  combination 
of  TNF-a  (10ng/ml)  (Peprotech),  IL-1p  (10ng/ml)  (Peprotech),  IL-6  (10np/ml)  (Stem 
Cell  Technologies)  and  PGE2  (10-7M)  (Sigma)  (Feuerstein,  et  al  2000),  pr  the 
novel  in-house  combination  X4,  TNF-a  (10ng/ml),  PGE2  (10"7M),  Poly  (l;  C) 
(1  Ong/ml)  (Sigma)  and  CD40L  (250ng/ml)  (Peprotech),  and  the  Ag  preparation 
were  added  at  the  same  time  (Thumann,  et  al  2003),  The  cells  were  cultured 
overnight  at  37°C  with  tissue  culture  flasks  standing  up-right  to  facilitate  cell 
contact  and  Ag  phagocytosis.  The  antigen-loaded  matDC  were  harvested  the 
following  morning,  washed  in  warm  TC  medium  and  resuspended  in  1  ml  of  TC 
medium.  The  mat  DC  were  counted,  assessed  for  viability,  and  resuspended  at  p 
concentration  of  1x106/ml.  An  aliquot  of  1x106  matDC  was  cryopreserved  for  use 
in  the  second  DC  stimulation  step  of  cytotoxic  T  cell  production. 
2.2.12  T  cell  pre-stimulation  with  T  cell  activation  beads 
T  cell  activation  beads  (a  kind  gift,  Dr  John  Campbell,  Miltenyi  Biotec),  are  3.5pm 
inert,  magnetic  beads  (2x10$/ml)  conjugated  to  anti-biotin  monoclonal  antibody. 
This  facilitates  the  beads  being  loaded  with  biotinylated  molecules,  in  our  case 
anti-CD2  (1  OOpg/mI),  anti-CD3  (1  OOpg/mI)  and  anti-CD28  (100pg/mI).  This  was 
done  in  accordance  with  the  manufacturer's  protocol.  Briefly,  500pl  of  beads, 
100NI  of  biotin-anti-CD2,100NI  of  biotin-anti-CD3,100NI  of  biotin-anti-CD28,  and 
200pl  PBS/EDTA/Alba  were  placed  in  a  1.5ml  Eppendorf  tube.  This  mixture  was 
then  mixed  thoroughly  by  vortexing  and  incubated  for  2hrs,  at  4°C,  under  constant 
slow  rotation  (50-100rpm).  This  mixture  is  stable  for  4wks  at  4°C.  Prior  to  use,  the 
required  number  of  beads  was  removed,  placed  in  x10  volume  of  T  cell  culture 
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the  excess  antibody.  The  beads  were  recovered  by  pipetting  off  the  supernatant 
and  resuspended  in  200p1  of  TC  media  ready  for  use. 
The  manufacturer  suggests  that  when  using  beads  alone  to  activate  T  cells,  they 
should  be  used  in  the  range  of  1:  1  to  1:  2,  beads  to  T  cells,  in  order  to  avoid 
activation  induce  cell  death.  As  the  beads  were  used  in  conjunction  with  cytokine, 
they  were  added  to  the  T  cells  (1-5x106/ml)  at  a  ratio  of  1:  4,  in  6  well  tissue  culture 
plates.  The  T  cell/bead  mixture  was  supplemented  with  IL-2  (201U/ml)  (MM  and 
ND  cells)  or  IL-15  (15ng/ml)  (MM  cells  only)  and  incubated  at  37°C  for  3days. 
T  cell  activation  beads  were  removed  from  the  T  cells  as  per  the  manufacturers 
instructions.  Briefly,  the  T  cell/bead  culture  mix  was  placed  in  a  15ml  tube  and 
washed  in  15mis  of  cold  PBS/EDTA/Alba,  recovering  the  cells  by  centrifugation  at 
1200rpm  for  5  mins.  The  supernatant  was  then  completely  removed,  the  cells 
suspended  at  a  maximum  concentration  of  2x107/ml  and  placed  in  the  field  of  a 
Dynal  magnet  (Dynal  AS,  Oslo,  Norway)  for  2mins.  The  supernatant,  which 
contains  the  cells,  was  then  removed  and  placed  in  a  fresh  tube  with  the  original 
tube  still  in  the  magnetic  field  to  retain  the  beads  against  the  sidewall  of  the  tube. 
The  original  tube  was  then  removed  from  the  magnet,  the  2ml  of  buffer  was  added 
to  it,  vortexed  and  the  bead  removal  procedure  was  repeated  to  optimise  cell 
recovery.  The  cells  were  then  washed  in  TC  medium,  counted,  checked  for 
viability,  and  resuspended  at  1x106/ml  in  TC  medium  ready  for  use  in  cytotoxicT 
cell  generation  experiments.  Cell  for  use  in  T  cell  proliferation  assays  were 
cultured  overnight  in  6  well  tissue  culture  plates  to  rest. 
2.2.13-Cytotoxic  T  cell  generation 
Dendritic  cells  and  either  un-stimulated  or  pre-stimulated  T  cells  were  co-cultured 
for  3  days  in  TC  medium  at  a  ratio  of  1  DC  (1x105/mI)  to  10  TC  (1x106/mi)  in  24 Dr  Simon  J  Harrison,  2005  Chapter  2-73 
in  24  well  tissue  culture  plates,  with  an  aliquot  of  DC  cryopreserved  for  use  later  in 
the  experiment.  After  3  days  50%  of  the  media  was  removed  and  replaced  with  an 
equal  volume  of  TC  media  supplemented  with  IL-2  (401U/ml).  After  7  days,  the 
cells  were  transferred  into  12  or  6  well  plates,  the  aliquot  of  cryopreserved  Ag 
loaded  matDC  was  thawed,  washed,  and  added  to  the  T  cell/DC  co-cultures  in  an 
equal  volume  of  TC  medium.  The  cultures  were  fed  IL-2  supplemented  TC 
medium,  final  concentration  of  201U/ml,  every  3-4  days  until  sufficient  numbers  of 
T  cells  were  present  to  perform  a  cytotoxicity  assay,  between  3  and  6  weeks. 
2.3  Flow  cytometry  techniques 
2.3.1  Antibody  labelling 
All  fluorescently  labelled  antibodies  were  purchased  from  BD/Pharmingen  (BD 
Biosciences,  San  Jose,  CA,  USA),  with  the  exception  of  CD11  C-FITC 
(DakoCytomation  Norden  A/S,  Glostrup,  Denmark).  All  antibodies  were  titrated  to 
determine  the  optimal  concentration  for  staining,  and  pre-loaded  in  to  the  75mm 
Falcon  tubes  (BD  Biosciences).  Cells  were  suspended  in  PBS/EDTA/Alba  at  a 
concentration  of  5x105  -1x106/ml  and  1  00NI  was  added  to  each  tube.  T  cells  were 
incubated  at  4°C  for  30mins  in  the  dark.  DC  and  monocytes  were  incubated  in  the 
dark  at  room  temperature  (RD  for  15mins  to  avoid  temperature  related  down 
regulation  of  chemokine  receptors.  Cells  were  then  washed  twice  in 
PBS/EDTA/Alba,  the  cells  recovered  by  spinning  at  1000rpm  for  1Omins  and 
resuspended  in  200pl  of  PBS/EDTA/Alba  for  analysis.  All  samples  were  analysed 
within  an  hour  of  antibody  staining  or  fixed  with  500pl  of  FACS-Fix  solution,  stored 
in  the  dark  at  4°C,  and  analysed  within  3days. Dr  Simon  J  Harrison,  2005 
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Tumour  cells  to  be  used  as  targets  for  phagocytosis  and  cytotoxicity  assays  were 
labelled  with  the  PKH26  (red)  and  PKH67  (green)  fluorescent  membrane  dyes 
(Sigma)  as  per  the  manufacturers  instructions.  Cells  were  washed  twice  in  un- 
supplemented  RPMI  1640  to  remove  any  serum,  1x107  cells  were  suspended  in 
Iml  of  diluent  C  and  2pls  of  dye  was  diluted  in  1ml  of  diluent  C in  a  15ml  test  tube. 
The  cell  suspension  was  added  to  the  dye  and  incubated  at  RT  for  5mins.  Excess 
dye  was  bound  by  adding  2mis  of  neat  AB  serum,  incubating  for  2mins  at  room 
temp  and  then  adding  11  mIs  TC  medium.  Cells  were  then  washed  twice  in  TC 
medium  and  resuspended  in  TC  medium  at  the  concentration  required  for  the 
assay. 
2.3.3  Flow  cytometric  analysis 
All  flow  cytometric  analysis  was  performed  on  a  FACScaliber  analyser  using  Cell 
Quest  Pro  software  (both  Becton  Dickinson).  The  cell  populations  to  be  analysed 
were  initially  gated  on  using  their  forward  scatter  (size)  and  side  scatter 
(granularity)  characteristics  with  the  detectors  set  on  a  linear  scale.  The 
fluorescence  detectors  (FLI-4)  were  set  with  a  Log  scale.  To  ensure  the  accuracy 
and  reproducibility  of  the  flow  data,  great  care  was  taken  to  optimise  the  cytometer 
for  each  experiment.  The  level  of  background  auto-fluorescence,  non-specific 
staining  and  day-to-day  drift  in  laser  intensity  and  alignment  was  compensated  for 
on  each  experiment.  An  aliquot  of  cells  was  stained  with  an  isotype  control 
antibody  for  each  of  the  fluorochrome  colours  to  be  used  and  the  detector 
sensitivity  was  adjusted  so  that  the  level  of  fluorescence  fell  within  the  first  decade. 
Cells  were  deemed  positive  if  their  fluorescence  level  was  greater  than  101.  The 
spectral  overlap  of  fluorochromes  was  compensated  for  by  staining  an  aliquot  of Dr  Simon  J  Harrison,  2005  Chapter  2-75 
cells  with  a  single  positive  antibody  for  the  fluorochrome  to  be  measured  in  FLI, 
FL2,  FL3  or  FL4  and  with  the  isotype  control  antibodies  for  the  other  colours  to  be 
used  in  the  experiment.  The  level  of  the  compensation  control  was  set  to  ensure 
that  cells  stained  with  an  antibody  measured  in  each  channel,  e.  g.  FL1,  only 
appeared  in  the  positive  region  of  the  analysis  for  that  channel,  FL1,  and  no  othopr. 
This  procedure  was  repeated  for  each  colour  of  fluorochrome  used  in  the 
experiment. 
Data  was  analysed  using  Cell  Quest  Pro  or  FlowJo  (Tree  Star  Inc,  Ashland, 
Oregon,  USA)  software. 
2.3.4-  Mean  fluoresence  intensity  (MFI) 
The  MFI  of  a  population  of  cells  was  calculated  by  subtracting  the  mean  fluoresce 
of  the  negative  control  from  the  mean  fluoresce  of  the  target  population. 
When  a  blocking  was  added  to  an  assay,  as  in  6.1.3,  the  effect  of  this  was 
quantified  using  the  equation  below. 
(Positive  control  MFI  -  Blocked  MFI)  X  100=  %  MFI  Blocking 
Positive  control  MFI 
Equation  2-1  Percentage  blocking  of  MFI 
2.3.5  Chemokine  uptake  assays 
This  methodology  is  based  on  that  previously  optimised  by  collaborators  I. 
Comerford  and  Dr  R.  J.  B.  Nibbs  (Glasgow  University).  Biotinylated  chemokines 
were  synthesised  by  Albachem  (Gladsmuir,  East  Lothian),  with  each  molecule 
carrying  an  N-terminal  biotinylated  lysine  residue.  Other  than  this  residue,  Bio- Dr  Simon  J  Harrison,  2005  Chapter  2-76 
CCL19  was  identical  to  human  CCL19  provided  by  other  commercial  suppliers. 
The  Bio-CCL3  was  based  on  a  mutated  version  of  mouse  CCL3  that  does  not 
aggregate  beyond  a  dimer,  and  is  described  elsewhere  (Weber,  et  a!  2004).  Cells 
were  harvested,  resuspended  at  5x1051ml  and  allowed  to  warm  to  37°C.  For  eich 
sample  to  be  tested,  10pl  of  the  following  mix  was  prepared  in  Falcon  tubes  and 
incubated  in  the  dark  at  RT  for  30-45  minutes:  For  CCL3  receptors,  2.5pl  of 
0.05mg/ml  Biotin  CCL3,3u1  streptavidin  PE  (strep-PE)  (Invitrogen,  Paisley,  UK) 
and  4.5pl  PBS.  For  CCL19  receptors,  5pl  of  0.05mg/ml  Biotin  CCL19,3u1  strep-FE 
and  2p1  PBS.  Control  mix,  3u1  strep-PE  and  7u1  PBS.  Aliquots  of  cells  (2-500p1) 
were  added  to  the  biotinylated  chemokine/Streptavidin-PE  mix  or  strep-PE  only 
control,  and  incubated  at  37°C  for  2  hrs  with  regular  gentle  agitation.  Cells  were 
then  washed  with  ice-cold  flow  cytometry  buffer,  to  stop  the  reaction.  The  cells 
were  retrieved  by  centrifugation  (1200  rpm,  5  min,  4°C),  resuspended  in  400  pi 
PBS/EDTA/Alba,  and  analysed  immediately  by  flow  cytometry. 
2.3.6  CCL1  surface  staining 
The  CCL1  (1-309)  Fluorokine  kit,  (R  and  D  systems,  Minneapolis,  MN,  USA.  )  was 
used  to  examine  the  expression  of  CCR8  on  monocytes  and  DC.  Cells  were 
suspended  in  cold  PBS  at  1x106/ml.  An  aliquot  of  cells  (100pl)  was  added  to  2 
Falcon  tubes  and  20pl  of  biotinylated  CCL1  (2.5ug/ml)  or  negative  control  was 
added.  The  samples  were  incubated  for  1  hour  at  4°C  and  then  20NI  of  avidin- 
FITC  was  added  and  incubated  for  a  further  30mins  in  the  dark  at  4°C.  Samples 
were  then  washed  twice  in  1x  RDF1  buffer  and  analysed  by  flow  cytometry. 
To  test  the  specificity  of  the  staining,  20p1  of  Bio-CCL1  was  incubated  with  40p1  of 
anti-human  CCL1  blocking  antibody,  prior  to  the  addition  of  the  cells.  The  assay 
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by  pre-blocking  I00pl  of  test  cells  with  20pl  of  25ug/ml  non-biotinylated  CCL1 
(Peprotech)  for  1  hour.  The  assay  was  then  completed  as  normal. 
2.3.7  Cytotoxicity  assays 
Target  cells,  U266  MM  cell  line,  were  prepared  the  day  before  setting  up  the 
assay.  Debris  and  dead  cells  were  removed  by  density  gradient  centrifugation. 
The  cells  were  then  stained  with  PKH  26  and  cultured  overnight  in  fresh  TC 
medium.  The  target  cells  were  then  washed  in  fresh  warm  medium  and  suspended 
at  1x106/ml.  The  T  cells  were  washed  in  warm  TC  medium,  counted  and  set  up  at 
8x106/ml  and  10  doubling  dilutions  were  set  up  in  Falcon  tubes,  final  volume 
200pl.  An  equal  volume  of  target  cells  was  then  added  to  produce  the 
effector:  target  cell  ratios  8:  1,4:  1,2:  1,1:  1  etc.  Assays  were  performed  in  duplicate. 
Target  cells  alone  and  TC  alone  were  set  up  to  act  as  negative  and  gating 
controls.  The  tubes  were  then  capped  and  cultured  over  night  at  37°C.  Culturing 
PKH-26  stained  target  cells  in  serum  free  media  after  exposure  to  UV  light  for 
30mins  provided  positive  controls  for  Annexin-V  and  7RAD  staining. 
The  following  morning,  the  tubes  were  centrifuged  at  I000rpm  for  10  minutes,  the 
supernatants  were  removed,  and  cells  resuspended  by  gentle  agitation.  We  then 
added  5pI  of  Annexin-V-FITC  (Pharmingen),  10pl  of  7RAD  (Pharmingen),  and 
100pl  of  Annexin-V  binding  buffer  to  each  tube  and  incubated  for  15mins  at  RT. 
The  reaction  was  stopped  by  adding  400p1  of  Annexin-V  binding  buffer  to  each 
tube  and  the  assays  were  read  by  flow  cytometry  within  I  hour.  A  total  of  20,000 
target  cell  events  were  collected  per  tube  and  the  results  for  each  dilution  were 
expressed  as  the  mean  number  of  dead  test  cells  minus  the  number  of  dead  cells 
in  the  Target  alone  control. Dr  Simon  J  Harrison,  2005 
2.4  T  cell  proliferation  assays 
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All  proliferation  assays  were  set  up  in  96  well  tissue  culture  plates,  with  100pi  of  T 
cells  (1x106/ml)  added  to  quadruplicate  (quad)  sets  of  wells.  100pl  of  TC  medium 
supplemented  with  IL-2  (401U/ml)  was  then  added  to  each  test  well.  Negative 
controls  were  set  up  by  adding  I00pl  of  TC  medium  to  a  quad  set  of  T  cells.  The 
plates  were  incubated  at  37°C  for  3  days,  10  pL  of  TC  media  containing  a  dose  of 
0.25  NCi  3H-thymidine  (Amersham  Biosciences,  Chalfont  St.  Giles,  UK)  was  added 
per  well  for  the  final  18  hours.  The  plates  were  harvested  using  a  96  well cell 
harvester  (Micromate  196,  Packard,  Pangboume,  UK)  onto  a  fittermat,  which  was 
dried  and  read  on  a  beta  counter  (Matrix  96  Direct  Beta  Counter,  Packard)  for  5 
minutes.  The  results  were  expressed  as  the  mean  number  of  counts  of  each  test 
quad  minus  the  mean  of  the  control  quad. 
T  celVmatDC  proliferation  assays  were  performed  by  setting  up  two  test  quads 
containing  1  00NI  of  T  cells  (1x106/ml)  and  1  00NI  of  matDC  (1x105/ml).  One  test  set 
was  supplemented  with  IL-2,  final  concentration  201U/ml.  Negative  controls  of 
matDC  and  T  cells  were  performed  along  with  a  positive  control  of  T  cells  plus 
201U/ml  IL-2  on  each  occasion.  All  reactions  were  performed  in  200p1.  The  assays 
were  then  completed  as  above,  and  the  results  were  expressed  as  the  mean  of 
each  test  quad  minus  the  mean  of  T  cell  only  and  DC  only  quads. 
2.5  Luminex  assays 
A  multiplex  kit  was  used  to  measure  GM-CSF,  IFN-a,  IL-2,  IL-4,  IL-6,  IL-7,  IL-10, 
IL-12p70,  IL-15,  TNF-  a,  and  VGEF  (Biosource  International  Inc,  Camarillo  CA, 
USA.  ).  The  assay  was  performed  as  per  the  manufacturers  instructions  and  read 
on  a  Luminex  I  OOTIA  instrument.  The  working  concentrations  of  all  reagents  were 
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15mis  of  x20  wash  solution  concentrate  in  285ml  of  deionised  water.  The  assay 
diluent  was  diluted  in  an  equal  volume  of  TC  medium  (AD).  The  11  detgctor 
antibody  x10  concentrates  were  combined  and  diluted  in  the  biotin  diluent,  final 
volume  2.5ml.  The  Strep-PE  x10  concentrate  was  diluted  in  9  parts  of  Strep-PE 
diluent,  total  volume  1Oml,  for  use  within  15mins  of  reconstitution.  The  capture 
bead  x10  concentrates  were  combined  and  diluted  in  the  volume  workirpg  wash 
solution,  total  volume  10mis. 
A  96  well  filter  plate  (Millipore,  Billerica,  MA,  USA.  )  was  pre-wet  with  200pl  of 
WWS  for  30secs  and  then  aspirated  with  the  vacuum  manifold  (VM)  (Millipore)  at 
5psi.  All  work  was  then  performed  with  the  plate  on  the  VM,  having  first  released 
the  pressure.  The  bead  solution  was  vortexed  and  25pl  was  added  to  each  well. 
The  plate  was  shaded  from  light  from  this  point  onward  to  prevent  bleaching  of  the 
fluorochromes.  The  beads  were  washed  twice  with  200pl  of  WWS  (the  residual 
liquid  on  the  underside  of  the  plate  was  removed  after  every  wash  step  by  blotting 
with  clean  paper  towels)  and  50pl  of  incubation  buffer  was  added  to  each  well.  The 
standard  curve  was  set  up  by  reconstituting  the  standard  in  150p  of  AD,  serially 
diluting  this  in  300pi  of  AD  (1:  3),  and  adding  100pl  of  each  standard  dilution  in 
duplicate  to  the  appropriate  wells.  Sample  (50pl)  and  AD  (50pl)  were  then  added 
to  each  sample  well  in  duplicate.  The  plate  was  then  incubated  for  2hours  at  RT 
on  an  orbital  shaker  (500-600  rpm).  The  assay  liquid  was  aspirated  with  the  VM, 
the  plate  was  washed  twice  with  WWS.  Biotinylated  detector  antibody  (100pl)  was 
added  to  each  well and  incubated  for  1  hr  at  RT  on  an  orbital  shaker.  The  assay 
liquid  was  aspirated  with  the  VM,  the  plate  was  washed  twice  with  WWS. 
Streptavidin-PE  (100pl)  was  added  to  each  well  and  incubated  for  Ihr  at  RT  on  an 
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times  with  WWS.  Working  wash  solution  (100pl)  was  added  to  each  well,  placed 
on  the  orbital  shaker  for  2mins  and  read  on  a  Luminex  I  OO  instrument.  The 
concentrations  of  the  standard  curve  samples  were  determined  using  the  curve 
fitting  software,  with  a  four-parameter  algorithm  and  multiplied  by  2  to  correct  for 
the  1:  2  dilutions.  The  software  then  calculated  the  concentrations  of  each  analyte 
in  each  well 
2.6  Molecular  techniques 
2.6.1  RT-PCR 
Cells  stored  at  -80°C  as  a  concentrated  cell  pellet  (5x105)  were  thawed,  and  1  ml 
of  TRIzol®  added.  Following  incubation  at  RT  for  5mins,  200pl  of  chloroform 
(Sigma)  was  added,  shaken  vigorously  for  15secs  and  incubated  at  RT  for  3mins. 
The  samples  were  microfuged  at  12000g  and  4°C  for  5mins  and  the  supernatant 
transferred  carefully  into  a  fresh  Eppendorf  tube.  The  RNA  was  precipitated  by 
adding  0.5ml  of  isopropyl  alcohol  per  Iml  original  volume  of  TRlzol®,  mixing  and 
incubating  at  RT  for  10mins,  and  centrifuging  at  12,000g  for  10mins  at  4°C.  The 
supernatant  was  discarded  and  the  RNA  pelleted,  washed  in  70%  alcohol  (to  an 
equal  volume  to  the  original  volume  of  TRlzol®,  and  dried.  The  dried  RNA  was  re- 
dissolved  in  100pl  of  RNAse  free  water  (Sigma).  The  samples  were  then  treated 
with  DNAsel  (DNA  free,  Ambion,  Huntington,  UK)  according  to  the  manufacturers 
instructions.  The  quantity  of  nucleic  acids  was  analysed  spectrophotometrically 
using  an  Eppendorf  Biophotometer  according  to  the  manufacturer's  instructions 
and  the  sample  was  diluted  in  RNAse  free  water  to  a  final  concentration  of 
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The  Superscript  III  First-Strand  Synthesis  System  for  RT-PCR  (Invitrogen)  was 
used  to  synthesise  cDNA  according  to  the  manufacturer's  instructions,  using  1  NI  of 
RNA  template  in  a  20pl  reaction. 
Aliquots  of  cDNA  (2pl)  were  subjected  to  PCR  using  Reddy  Mix  PCR  tubes 
(Abgene,  Epsom,  UK),  which  contain  all  PCR  components,  except  primers  and 
Template.  The  following  primer  pairs  were  added  to  a  final  concentration  of  1Ong/ 
pl.  Forward  and  reverse  primers  for  CCR5  (AGATATTTCCTGCTCCCCAGT  and 
TGGCCTGAATAATTGCAGTA,  )  CCR7  (AACTTGACGCCGATGAAG  and 
TACCTTGTCATCATCCGCA)  and  D6  (CTGGAGTGCGTAGTCTAGATCC  and 
CTCTCATGCTCAGCCCTAC,  all  MWG  Biotec,  Ebersberg,  Germany)  were  added 
to  each  reaction  for  each  sample.  Samples  were  incubated  at  92°C  for  2mins  to 
denature  template,  then  a  repeating  cycle  for  40  cycles  of  92°C  for  30  secs,  54°c 
for  30secs,  and  70°C  for  3mins.  The  final  cycle  was  70°C  for  10  mins,  after  which 
reactions  were  chilled  at  4°C. 
The  products  of  the  PCR  reaction  were  analysed  by  conventional  gel 
electrophoresis,  using  a1%  agarose,  1x  TAE  (40mMol  Tris-acetate,  1  mMol 
EDTA),  1  pg/ml  Ethidium  Bromide  gel,  to  allow  UV  visualisation  of  DNA.  The  gel 
was  placed  in  1x  TAE  buffer,  and  the  samples  were  electropharesed  at  1  00mA  for 
2  hours. 
2.7  Statistical  analysis 
All  statistical  tests  were  two  sided.  Comparisons  between  paired  groups  of 
normally  distributed  continuous  variables  were  performed  using  the  paired  student 
T-test.  Unpaired  groups  of  normally  distributed  continuous  variables  were 
compared  using  the  student  T-test.  The  Mann-Whitney  rank  sum  test  was  used  to 
compare  groups  of  non-parametric  continuous  variables.  Comparisons  of  two Dr  Simon  J  Harrison,  2005  Chapter  2-82 
groups  of  repeated  measure  data  (i.  e.  cytotoxicity  experiments)  were  performed 
using  a  two  way  repeated  measures  analysis  of  variance  (2  way  ANOVA). 
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3.  Results  1 
3.1  Enumeration  of  blood  dendritic  cells  in  multiple 
myeloma  patients  at  presentation  and  through 
therapy 
3.1.1  Introduction 
Although  DC  play  a  central  role  in  the  adaptive  and,  as  is  becoming  clear,  the 
innate  immune  system,  they  are  difficult  to  quantify  in-vivo.  This  is because  iDC 
reside  in  the  peripheral  tissues  where  they  constantly  sample  the  environment. 
When  iDC  encounter  antigen  and  a  second  maturation  signal,  they  then  traffic  to 
the  secondary  lymphoid  tissues  under  the  influence  of  chemokines  such  as  ELC 
and  SLC  in  order  to  present  antigen  to  other  immune  cells  such  as  T  lymphocytes. 
It  has  been  known  for  some  time  that  there  is  a  small  number  of  DC  present  in  the 
peripheral  blood  and  they  represent  a  precursor  population  of  conventional 
myeloid  and  plasmacytoid  DC  (Reid,  et  al  1990).  Precursors  of  the  two  main  DC 
populations  that  have  been  identified  in  the  peripheral  blood  are  becoming  known 
as  the  pre-myeloid  blood  DC  (blood  mDC)  and  pre-plasmacytoid  blood  DC  (blood 
pDC),  although  an  increasing  amount  of  plasticity  in  the  DC  system  has  been 
described  recently  (Zuniga,  et  a/  2004).  Blood  DC  are  classically  identified  in  the 
peripheral  blood  by  a  complex  flow  cytometry  analysis  that  involve  the  lineage 
exclusion  of  the  common  blood  cell  types  (myeloid,  lymphoid,  stem  cells  and  NK 
cells)  and  the  positive  identification  of  blood  mDC  using  CD11c,  with  blood  pDC 
expressing  CD123  in  the  absence  of  CD11c.  These  experiments  are  complex  and 
time  consuming  to  optimise  because  they  involve  analysis  of  forward  scatter/side 
scatter  characteristics  combined  with  a  large  number  of  antibodies  (CD3,19,20, 
33,34,14,16  and  56),  as  well  as  being  relatively  expensive.  A  number  of  new 
antibody  staining  strategies  have  been  proposed  to  simplify  the  identification  of 
blood  DC.  The  CMRF-44  antibody  was  derived  by  Hart's  group  (Hock,  et  a!  1994), Dr  Simon  J  Harrison,  2005  Chapter  3-84 
but  DC  require  overnight  incubation  before  they  express  the  relevant  antigen.  This 
strategy  may  be  flawed  for  a  number  of  reasons;  firstly  it  does  not  directly  identify 
blood  mDC,  rather  an  intermediate  stage  between  blood  mDC  and  iDC  that  is 
dependant  upon  maturation  in  culture.  Secondly,  in  diseases  such  as  MM,  DC 
have  problems  developing  in  the  normal  fashion,  thus  they  may  fail  to  up-regulate 
surface  markers  that  are  dependant  upon  DC  maturation  for  their  expression. 
Finally,  the  CMRF-44  antigen  is  not  expressed  by  blood  pDC.  More  recently, 
Dzionek  described  novel  antigens  that  are  present  on  blood  DC  subsets  (Dzionek, 
eta12000).  BDCA-2  and  BDCA-4  are  expressed  only  on  CD11c%CD123+  blood 
pDC.  BDCA-3  is  expressed  at  high  levels  on  a  small  population  of  CD11c+ICD123" 
blood  mDC  (Blood  MDC2),  but  at  low  levels  on  blood  pDC,  blood  mDC, 
monocytes  and  granulocytes.  CD1c  (BDCA-1)  is  expressed  on  blood  mDC  as  well 
as  on  CD19+  B  lymphocytes.  This  degree  of  co-expression  requires  the 
granulocytes,  monocytes  and  B  lymphocytes  to  be  gated  out  of  the  analysis. 
As  mentioned  earlier,  the  MM  clone  is known  to  affect  blood  mDC  was  discussed 
earlier.  There  is  still  some  debate  as  to  whether  blood  mDC  in  MM  patients  are 
present  in  normal  numbers  (Brown,  et  a12001)  or  are  reduced  in  number  (Ratta,  et 
a/  2002).  Some  of  these  discrepancies  may  be  explained  by  the  fact  that  these 
studies  have  used  different  antibodies  to  identify  the  blood  mDC  populations.  The 
study  by  Brown  et  al  used  the  CMRF-44  antibody  to  identify  blood  mDC,  while 
Ratta  employed  the  more  traditional  lineage  exclusion  method.  However,  there  is 
agreement  that  blood  mDC  in  MM  patients  do  not  function  normally.  In  contrast, 
little  has  been  published  on  what  happens  to  circulating  blood  pDC  in  MM. 
Plasmacytoid  DC  are  the  main  natural  IFN-a  producing  cells  and  they  are  involved 
in  regulating  both  the  adaptive  and  innate  immune  responses  (McKenna,  et  al 
2005),  with  both  immunogenic  and  tolerogenic  effects.  Mature  pDC  seem  to 
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DC  maturation  and  polarising  the  T  cell  response  to  a  Th1  phenotype  through  the 
secretion  of  IFN-a  and  OX40L  expression.  Plasmacytoid  DC  also  interact  with  the 
innate  immune  system  by  recruiting  and  activating  NK  cells,  thus  playing  a  vital 
role  in  anti-viral  immunity.  There  has  been  increasing  interest  in  the  part  these 
cells  play  in  the  immune  response  to  malignancies  (Mohty,  et  al  2005,  Salio,  et  al 
2003).  The  only  study  which  has  reported  blood  pDC  numbers  in  MM,  suggested 
that  they  were  reduced  (Ratta,  et  a!  2002).  It  is known  that  in  diseases  such  as 
HIV/AIDS,  the  number  of  both  blood  blood  mDC  and  blood  pDC  are  reduced 
(Pacanowski,  eta!  2001),  whilst  in  infections  such  as  Dengue,  a  rise  in  blood  pDC 
seems  to  modify  the  severity  of  the  disease  (Pichyangkul,  et  a/  2003).  The 
mechanisms  by  which  pDC  induce  tolerance  are  poorly  understood,  and  they  are 
not  just  dependant  upon  the  state  of  pDC  maturation.  Thus  by  preventing  pDC 
development  and  maturation,  tumours  such  as  MM  could  have  a  negative  impact 
on  both  the  adaptive  and  innate  immune  systems. 
The  initial  aim  of  our  study  was  to  examine  the  numbers  of  circulating  blood 
myeloid  and  plasmacytoid  DC  subsets  in  patients  with  MM  as  compared  to  normal 
individuals.  In  addition,  we  wanted  to  look  at  how  the  DC  numbers  and  proportions 
may  change  in  response  to  conventional  anti-MM  chemotherapy,  following 
autologous  and  allogeneic  HSCT,  and  whether  the  immunomodulatory  drug, 
thalidomide  induced  any  significant  changes  in  the  blood  DC  compartment.  Our 
secondary  aims  were  to  determine  whether  we  could  reliably  measure  a  third, 
recently  identified  and  poorly  studied  blood  DC  subset,  blood  mDC2,  in  both 
normal  subjects  and  MM  patients,  and  if  we  could  use  this  assay  to  simultaneously 
measure  the  CD19  positive  B  lymphocytes. Dr  Simon  J  Harrison,  2005  Chapter  3-86 
3.1.2  Measurement  of  circulating  blood  DC  by  flow-cytometry 
using  the  BDCA  1,2  and  3  antibodies  in  normal  individuals 
The  normal  control  population  was  selected  from  normal  individuals  to  reflect  thT 
mean  age  of  patients  with  MM  in  trials  (controls  50.2yrs,  MM  55-65yrs)  and  M=F 
(controls  10:  11).  The  BDCA  antibody  kit  (Miltenyi  Biotec)  allows  the  rapid 
identification  of  circulating  blood  DC  directly  from  fresh  whole  blood  collected  into 
a  standard  EDTA  tube,  as  used  for  full  blood  counts  in  routine  clinical  practice. 
The  assays  were  performed  on  WB,  anti-coagulated  with  EDTA,  within  24hrs  of 
sampling  and  stored  at  4°C  if  required.  The  antibody  staining  was  performed  on 
two  150ul  aliquots  of  WB  in  12x75  mm  Falcon  tubes.  The  test  sample  was  stained 
with  10ul  of  BDCA  antibody  cocktail  and  the  control  sample  with  1  Oul  of  control 
cocktail.  Each  sample  had  5ul  of  dead  cell  discriminator  added.  Both  samples 
were  mixed  gently  but  thoroughly  and  then  incubated  for  10  minutes,  in  a 
horizontal  position  on  ice,  under  a  60w  white  light  bulb  in  order  to  activate  the 
dead  cell  discriminator  staining.  Red  cells  were  lysed  twice  with  sterile  water,  the 
sample  was  resuspended  in  300ul  of  buffer  and  then  analysed  by  flow  cytometry, 
after  having  run  the  appropriate  negative  and  positive  compensation  controls  for 
channels  FL1-4.  If  the  samples  could  not  be  analysed  immediately,  2.5ul  of 
discriminator  stop  solution  (Deoxyribonucleic  acid  in  10  mM  NaCI,  1  mM  EDTA, 
pH  8)  and  150  ul  of  FACSfix  solution  was  added and  the  samples  analysed  within 
12  hours. 
The  control  antibody  cocktail  contains  mouse  IgGl-FITC,  IgG2a-PE  and  IgGI- 
APC  monoclonal  antibodies  and  CD14-PE-CY5  (mouse  IgG2a)  CD-19-PE-CY5 
(mouse  IgG1).  This  allows  the  neutrophils,  B-lymphocytes  and  monocytes  to  be 
gated  out  of  the  target  population  on  an  FL3  vs.  side  scatter  plot  (Figure  3-1).  The 
control  cocktail  is  also  used  to  set  the  background  level  of  non-specific  staining  in Dr  Simon  J  Harrison,  2005  Chapter  3-87 
the  channels  used  for  measurement  of  blood  pDC  (FL1),  blood  mDC1  (FL2)  and 
blood  mDC2  (FL4).  The  test  antibody  cocktail  contains  the  same  CD14  and  CD19 
exclusion  antibodies,  along  with  the  antibodies  to  identify  blood  mDC1,  blood  pDC 
and  blood  mDC2,  CD1c-PE  (BDCA-1)(mouse  IgG2a),  BDCA-2-FITC  (mouse 
IgGI)  and  BDCA-3-APC  (mouse  IgGI)  respectively.  Dead  cells  are  excluded  from 
the  analysis  by  the  addition  of  a  fluorescent  photolytic  dye  to  both  the  control  and 
test  samples. 
Gate  Region(s)  Cell  Type 
G1  R1  All  live  Cells 
G2  R2  Non  B  cell,  Non  monocyte,  Non  neutrophils 
G3  R1+R2  All  Cells,  not  B  cell,  monocyte,  neutrophil 
G4  R1+R2+R3  blood  mDC1 
G5  R1+R2+R4  blood  pDC 
G6  R1+R2+R5  blood  mDC2 
G7  R1+R6  B  lymphocytes 
Table  3-1  Logic  gates  for  Blood  DC  analysis Dr  Simon  J  Harrison,  2005 
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Figure  3-1  Flow-cytometry  plots  required  for  the  measurement  of  circulating 
blood  DC  subsets  in  a  normal  individual. 
In  plot  A,  all  cellular  events  are  gated  (R1)  in  a  forward  side  (linear)  versus  scatter 
(linear)  plot  composed  of  all  acquired  events.  Plot  B  shows  CD19  positive  B 
lymphocytes,  CD14  positive  monocytes  dead  cells  and  neutrophils  being  excluded 
on  an  FL3  (log)  vs.  side  scatter  plot  of  all  events.  Plots  C-F  show  only  events  in  R1 
and  R2.  Plot  C  shows  the  isotype  controls  for  FL2  (log)  (blood  mDC1)  and  FL1 
(log)  (blood  pDC).  Plot  D  shows  CD1c  PE  positive  blood  mDC1  in  R3  and  BDCA2 
FITC  positive  blood  pDC  in  R4.  Plot  E  shows  the  negative  control  for  blood  mDC2 
on  an  FL4  (log)  versus  FL2.  Plot  F  shows  blood  mDC2  (R5),  which  are  high 
expressers  of  BDCA3  (FL4)  versus  blood  pDC  (FL1,  BDCA2)  which  are 
intermediate  expressers  of  BDCA. 
Absolute  number  of 
DC's  of  each  DC  = 
(%  Gated  sample  -%  Gated  control)  x  WCC 
subset  per  ml  of  blood  100 
Equation  3-1  Determination  of  the  number  of  monocytes  and  blood  DC 
subsets  per  ml  of  peripheral  blood. Dr  Simon  J  Harrison,  2005 
12 
10 
E 
fÖ 
0 
X 
C 
8 
=6 
t 
34 
O 
2 
0 
WCC  B  cell 
5E 
wi 
0 
4X 
E 
3m 
c 
8 
zm 
Chapter  3-89 
Figure  3-2  Total  WCC  and  circulating  B  lymphocyte  numbers  in  normal 
subjects  n=21. 
The  white  blood  cell  count  for  normal  subjects  was  measured  using  a  Coulter  Gen- 
S  or  Sysmex  SE9500  haematology  laboratory  analyser,  on  the  same  sample  on 
the  same  day  as  the  blood  DC  assay  was  performed.  The  B  cell  population  was 
estimated  using  the  BDCA  kit,  gating  on  the  CD19  positive  cells  (G7  =  R1  +  R2 
+R6)  and  then  the  absolute  number  was  calculated  using  Equation  3-1. 
Figure  3-2  shows  the  results  of  the  white  blood  cell  counts  (WBCC)  and  B  cell 
numbers  for  normal  subjects  (n=21).  The  WBCC  were  performed  on  the  same 
sample,  on  the  same  day  as  the  blood  DC  assay  was  performed.  The  mean  value 
was  6.75  ±  1.67  x106/mI,  well  within  the  reference  range  for  both  laboratories  (4-11 
x106/ml).  The  B  cell  population  was  estimated  using  the  BDCA  kit,  gating  on  the 
CD19  positive  cells  (G7  =  R1  +  R2  +R6)  and  then  the  absolute  number  was 
calculated  using  Equation  3-1,  mean  3.35  ±  1.32  x105/ml,  again,  well  within 
quoted  normal  ranges  (0.6-6.6  x105/mI,  HMDS,  Leeds.  2.0-6.0  x105/mI,  GRI, 
Glasgow.  ),  validating  the  use  of  this  method  to  accurately  reflect  the  number  of  ß 
cells  in  the  peripheral  blood. 
The  number  of  each  blood  DC  subset  detected  in  normal  individuals  is  shown  in 
Figure  3-3.  The  proportion  of  each  blood  DC  subset  out  of  the  total  cell  population Dr  Simon  J  Harrison,  2005  Chapter  3-90 
was  measured  using  the  BDCA  antibody  kit  and  the  gating  strategy  outlined  in 
Table  3-1.  The  absolute  number  of  each  blood  DC  subset  was  calculated  using 
Equation  3-1.  The  mean  number  of  blood  mDC1  was  2.35  ±  1.37  x104/ml,  blood 
pDC  1.65  ±  0.74  x104/ml  and  blood  mDC2  1.21  x103/ml  +0.86  x103/ml.  These 
results  are  comparable  with  the  manufacturers  reference  range  (blood  mDC1 
1.56-3.28  x104/ml,  blood  pDCO.  45-2.04  x104/mI  and  blood  mDC2  0-2.16  x103/mI). 
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Figure  3-3  Number  of  DC  per  ml  in  the  blood  of  normal  subjects  n=21 
Each  blood  DC  subset  was  analysed  by  flow  cytometry  using  the  BDCA  antibody 
kit.  Blood  mDC1  were  measured  in  G4  (R1+R2+R3),  blood  pDC  in  G5 
(R1+R2+R4)  and  blood  mDC2  in  G6  (R1+R2+R4),  estimating  each  population  as 
a  percentage  of  the  total  cells  present.  The  absolute  number  of  each  blood  DC 
subset  was  calculated  using  Equation  3-1. 
3.1.3  Measurement  of  circulating  blood  DC  by  flow-cytometry 
using  the  BDCA  1,2  and  3  antibodies  in  patients  with 
multiple  myeloma 
Ethical  approval  for  this  study  was  obtained  from  the  North  Glasgow  University 
Trust  Hospital  (East)  ethics  committee  and  all  samples  were  taken  with  the 
patients  having  given  prior  written  informed  consent.  Samples  were  obtained  from Dr  Simon  J  Harrison,  2005  Chapter  3-91 
patients  with  MM  attending  the  MM  clinics  at  the  Western  Infirmary,  Glasgow  and 
Glasgow  Royal  Infirmary.  Samples  were  stored  and  analysed  as  previously 
described.  Samples  were  obtained  at  the  time  of  diagnosis  prior  to  the  start  of 
chemotherapy  (n=7).  As  a  second  control  group,  samples  were  also  obtained  from 
patients  with  a  plasmacytoma  and  a  detectable  paraprotein  following  radiotherapy 
or  patients  with  monoclonal  gammopathy  of  uncertain  significance  (MGUS)  (n=12). 
These  diseases  are  also  characterised  by  the  presence  of  a  paraprotein  in  the 
peripheral  blood,  and  MGUS  is  regarded  as  pre-maligant  condition  which  occurs  in 
1%  of  the  over  50s  and  3%  of  the  over  70's  (Kyle  and  Rajkumar  2003).  In  contrast 
to  MM,  there  is  much  less  immunosuppression  associated  with  these  disorders 
such  as  an  increase  incidence  of  infection,  reduction  in  the  normal  levels  of 
immunoglobulins  (immune  paresis)  or  cellular  immune  defects,  but  around  1%  of 
patients  with  MGUS  progress  to  MM  each  year.  Representative  flow  cytometry 
plots  are  shown  in  Figure  3-4.  The  number  of  circulating  B  lymphocytes  in  normal 
subjects  vs  MM  patients  at  diagnosis  and  MGUS/Plasmacytoma  patients  was 
quantified  using  the  BDCA  antibody  kit,  Figure  3-5. 
B  lymphocytes  were  measured  in  G7,  and  the  number  of  cells  per  ml  of  blood  was 
calculated  using  Equation  3-1.  The  number  of  circulating  B  lymphocytes  in  MM 
patients  at  diagnosis  (mean  0.9  ±  0.3  x105  /ml,  n=7)  was  significantly  lower 
(p<0.001)  than  in  the  blood  of  normal  subjects  (mean  5.2  ±  0.4  x105  /ml,  n=21). 
The  number  of  circulating  B  lymphocytes  in  MGUS  and  plasmacytoma  patients 
was  also  significantly  lower  (p<O.  005)  than  normal  subjects.  The  clone  used  for 
marking  B  cells  is  the  LT1  9  (Mason,  et  al  2002)  which  is  a  commonly  used  for 
phenotyping  normal  and  malignant  B  lymphocytes  and  is  not  positive  on  normal  or 
MM  plasma  cells. Dr  Simon  J  Harrison,  2005 
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Figure  3-4  Flow  cytometry  plots  from  a  patient  with  MM  at  diagnosis 
Blood  DC  subsets  can  be  readily  identified  in  MM  patient  samples  using  BDCA 
antibodies.  Plot  D  shows  blood  mDC  in  R3,  blood  pDC  in  R4.  In  plot  F,  blood 
mDC2  present  in  R5  are  identified  by  their  high  expression  of  BDCA  2.  Of 
particular  note  is  the  marked  reduction  in  circulating  CD19  +ve  B  lymphocytes 
seen  in  plot  B. 
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Figure  3-5  Circulating  B  cell  numbers  in  normal  subjects  vs  MM  patients  at 
diagnosis  and  MGUS/Plasmacytoma  patients 
Circulating  B  lymphocytes  were  quantified  using  flow  cytometry  and  the  BDCA 
antibody  kit.  B  lymphocytes  were  measured  in  G7,  and  the  absolute  number  of 
cells  per  ml  of  blood  was  calculated  using  Equation  3-1. 
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Blood  DC  subsets  were  quantified  in  samples  from  normal  subjects,  MM  patients 
at  diagnosis  and  patients  with  MGUS  or  plasmacytomas  using  flow  cytometry  and 
the  BDCA  antibody  kit,  Figure  3-6.  The  number  of  blood  mDC1  (mean  1.065  ± 
0.35  x104/ml)  and  blood  pDC  (mean  0.454  ±  0.10  x104/ml)  detected  in  the  blood  of 
MM  patients  at  diagnosis  was  significantly  lower  than  that  seen  in  normal  subjects 
(p<0.03  and  p<0.001  respectively).  The  number  of  blood  mDC2  in  MM  patients 
(mean  0.5  ±  0.016  x103/mI)  and  the  number  of  all  DC  subsets  observed  in  the 
blood  of  patients  with  MGUS/plasmacytoma,  blood  mDC1  (mean  1.9650  ±  0.74 
x104/ml),  blood  pDC  (mean  1.1533±  0.32  x104/ml)  and  blood  mDC2  (mean  1.04  ± 
0.3  x103/mI),  was  not  significantly  different  from  normal  subjects. 
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Figure  3-6  Circulating  DC  subsets  in  MM  patients  at  diagnosis  and 
MGUS/plasmacytoma  vs.  normal  subjects 
The  numbers  of  blood  mDC1,  blood  pDC  and  mDC2  were  quantified  in  samples 
from  normal  subjects,  MM  patients  at  diagnosis  and  patients  with  MGUS  or 
plasmacytomas  using  flow  cytometry  and  the  BDCA  antibody  kit.  Blood  mDC1 
were  measured  in  G4  (R1+R2+R3),  blood  pDC  in  G5  (R1+R2+R4)  and  blood 
mDC2  in  G6  (R1+R2+R4).  The  absolute  number  of  each  blood  DC  subset  was 
calculated  using  Equation  3-1. Dr  Simon  J  Harrison,  2005  Chapter  3-94 
3.1.4  Analysis  of  blood  DC  subsets  in  MM  patients  throughout  the 
course  of  the  disease. 
We  have  shown  above  that  at  diagnosis  the  number  of  blood  DC  in  MM  patients  is 
reduced.  During  the  treatment  of  their  disease,  MM  patients  receive 
chemotherapy,  usually  on  a  monthly  basis,  until  their  paraprotein  levels  stabilise, 
i.  e.  plateau  phase.  Further  conventional  therapy  at  this  stage  has  no  additional 
benefit  to  the  patient  in  terms  of  length  of  plateau  phase  or  survival.  In  qrder  to 
ascertain  whether  there  was  any  recovery  in  the  numbers  of  blood  DC  during 
plateau  phase,  samples  were  obtained  from  patients  who  were  in  stable  plateau 
phase  following  induction  chemotherapy  (n=21).  These  results  were  compared 
with  those  results  obtained  at  the  time  of  diagnosis  (n=7).  Samples  were  also 
analysed  from  patients  who  had  relapsed  (n=12),  prior  to  commencing  rescue 
therapy.  When  malignant  diseases  such  as  MM  relapse,  the  malignant  clone  will 
often  gain  further  mutated  genes,  which  provide  it  with  a  further  survival 
advantage.  These  additional  genetic  abnormalities  may  render  the  clone  more 
resistant  to  chemotherapeutic  agents  by  a  number  of  mechanisms.  These 
protective  mutations  include  the  up  regulation  of  genes  that  protect  the  cell  from 
apoptosis,  i.  e.  BCL-2,  or  proteins  that  actively  pump  drugs  out  of  cells,  such  as 
MDR1.  The  tumour  burden  at  the  time  of  relapse  is  also  rapidly  increasing.  This 
may  suppress  normal  cell  production  by  simple  marrow  infiltration,  or,  as  may  be 
more  important  in  MM,  by  increased  production  of  suppressive  cytokines  such  as 
IL-6,  IL-10,  TGF-ß  and  VEGF.  These  analyses  were  performed  to  determine 
whether  any  additional  suppression  of  the  blood  DC  system  was  associated  with 
the  relapse  phase  of  the  disease  and  the  results  are  shown  in  Figure  3-7.  No 
statistically  significant  increase  in  the  number  of  B  cells  or  any  DC  subset  was 
noted  between  the  time  of  diagnosis  (n=7)  and  the  attainment  of  plateau  phase 
following  chemotherapy  (n=21).  At  the  time  of  relapse  there  was  a  further 
significant  fall  in  the  number  of  blood  mDCI  compared  with  diagnosis  (p<  0.05) Dr  Simon  J  Harrison,  2005  Chapter  3-95 
and  plateau  phase  (p<  0.005).  There  was  an  even  more  striking  decrease  in  the 
number  of  blood  pDC  at  the  time  of  relapse  compared  with  diagnosis  (p<  0.05) 
and  plateau  phase  (p<  0.001).  The  number  of  B  cells  did  not  fall  further  at  relapse. 
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Figure  3-7  Circulating  DC  subsets  in  MM  patients  at  strategic  points  in  the 
disease  course 
The  number  of  B  cells,  blood  mDC1,  blood  pDC  and  mDC2  were  quantified  in 
samples  from  MM  patients  at  diagnosis  (n=7),  in  plateau  phase  following 
chemotherapy  (n=21)  and  at  the  time  of  relapse,  using  flow  cytometry  and  the 
BDCA  antibody  kit.  The  results  were  compared  with  those  obtained  from  ND. Dr  Simon  J  Harrison,  2005  Chapter  3-96 
3.1.5  Blood  DC  subsets  in  MM  patients  following  aptologpus  and 
allogeneic  HSCT. 
Stem  cell  mobilisation  and  autologous  HSCT  as  consolidation  therapy  fpr  MM 
patients  who  are  in  plateau  following  chemotherapy  has  become  the  st9ndard  of 
care  for  patients  below  the  age  of  70  years  who  are  otherwise  fit  enough  to 
tolerate  the  therapy.  This  therapy  is  associated  with  an  over  all  improvement  in 
response  rate,  EFS  and  OS  as  compared  to  conventional  therapy  alone.  Patients 
who  have  a  further  significant  reduction  in  their  disease  burden,  i.  e.  reduction  in 
the  level  of  the  paraprotein,  have  significant  improvements  in  time  to  progression, 
EFS  and  OS  (Child,  et  al  2003,  Harousseau  and  Attal  2002,  Harousseau,  et  al 
1995). 
These  studies  were  designed  to  assess  two  important  aspects  of  the  immune 
response  to  this  therapy.  Firstly,  is  this  treatment  associated  with  an  improvement 
in  the  number  of  circulating  DC  subsets  as  compared  with  diagnosis  or  following 
conventional  chemotherapy?  Secondly,  how  rapidly  do  the  DC  subsets  recover 
following  autologous  HSCT? 
A  small  number  of  patients  are  suitable  to  undergo  alto  HSCT,  because  of  their 
age  (i.  e.  <55years)  and  the  availability  of  a  suitable  donor  (HLA  matched  sibling  or 
volunteer  unrelated  donor).  This  treatment  represents  the  only  chance  of  cure  in 
patients  with  MM  via  the  GVM  effect,  but  it  is  associated  with  significant  risks,  as 
discussed  in  chapter  1.  By  examining  blood  DC  subsets  in  individuals  who  have 
undergone  alto  HSCT,  we  hoped  to  see  whether  this  therapy  was  associated  with 
any  significant  differences  in  blood  DC  levels  as  compared  with  auto  HSCT,  which 
could  be  attributed  to  the  immune  nature  of  the  therapy.  This  picture  may  be 
complicated  by  the  fact  that  the  treatment  protocols  for  alto  HSCT  may  contain 
antibodies  such  as  Campathl-H  as  part  of  the  conditioning  regimen  for  non- Dr  Simon  J  Harrison,  2005  Chapter  3-97 
myeloablative  (NM)  and  VUD  alto  HSCT,  and  immunosuppressive  drugs,  such  as 
cyclosporin  as  prophylaxis  or  treatment  for  GVHD  after  myeloablative  a`lo  HSCT. 
Samples  were  obtained  pre  and  post  auto  and  alto  HSCT  from  in-patients  in  the 
bone  marrow  transplant  unit  in  Glasgow  Royal  Infirmary  and  the  haematology 
ward  in  Gartnavel  General  Hospital,  Glasgow.  Samples  were  analysed  from 
patients  undergoing  auto  HSCT  (n=11)  pre-transplant,  at  the  time  of  engraftment, 
D100  and  1year  post  transplant.  Samples  from  MM  patients  undergoing  alto  HSQT 
(n=3  NM)  were  analysed  at  D100.  This  time  point  was  chosen  because  by  this 
time,  the  majority  of  DC  will  be  of  donor  origin.  There  is  some  evidence  that 
autologous  DC  are  present  for  some  time  following  alto  HSCT,  and  may  contribute 
to  the  development  of  GVHD  (Cowing  and  Gilmore  1992,  Duffner,  eta!  2004). 
There  is  no  data  as  to  whether  blood  DC  are  of  donor  or  host  origin  at  the  time  of 
engraftment,  but  there  is  one  report  that  blood  DC  are  >99%  donor  at  day  60 
(Mohty,  et  al  2002a).  This  report  also  observed  that  the  blood  DC  subsets  in 
patients  undergoing  NM  HSCT  peaked  at  day  60  with  a  significant  decline  noted  at 
day  90  post  HSCT  in  seven  patients. 
The  data  illustrated  in  Figure  3-8  shows  that  following  autologous  HSCT,  blood 
mDC1  show  a  rise  back  into  the  normal  range  (mean  1.52  ±  0.28  x104  /ml) 
(p>0.05),  which  is  maintained  at  D100  (mean  1.55  ±  0.24  x104  /ml),  but  by  one 
year  the  numbers  (mean  0.98  ±  0.36  x104  /ml)  are  back  to  levels  seen  at  diagnosis 
(mean  1.07  ±  0.35  x104  /ml).  The  numbers  of  blood  pDC  show  a  rise  at  the  time  of 
engraftment,  although  not  back  into  the  normal  range,  but  then  decline  at  D100 
and  one  year.  The  numbers  of  blood  mDC2  show  a  similar  trend  to  blood  mDC1. 
At  D100  following  NM  alto  HSCT,  the  numbers  of  blood  mDC1  (0.4600  ±  0.04  XI  04 
/ml),  blood  pDC  (0.31  ±  0.11  x104  /ml)  and  blood  mDC2  (0.350  ±  0.07  x103  /ml) Dr  Simon  J  Harrison,  2005  Chapter  3-98 
were  reduced  as  compared  to  normal,  MM  at  diagnosis  and  post  treatment,  but 
due  to  the  small  sample  size  these  data  are  difficult  to  interpret. 
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Figure  3-8  Circulating  blood  DC  subsets  in  MM  patients  following  auto  and 
NM  alto  HSCT 
Using  flow  cytometry  and  the  BDCA  antibody  kit,  we  quantified  the  number  of 
blood  mDC1,  blood  pDC  and  mDC2  were  in  samples  from  MM  patients 
undergoing  autologous  HSCT  (n=1  1)  and  NM  alto  HSCT  (n=3).  The  auto  group 
were  analysed  pre-conditioning,  at  the  time  of  engraftment  and  at  D100  following 
stem  cell  re-infusion.  Samples  from  the  NM  alto  HSCT  group  were  analysed  at 
D100  to  ensure  that  DC  were  of  donor  origin.  The  results  were  compared  with 
those  obtained  from  at  MM  patients  at  diagnosis  (n=7),  following  chemotherapy 
(n=21),  at  the  time  of  relapse  (n=12),  and  ND  (n=21). Dr  Simon  J  Harrison,  2005  Chapter  3-99 
3.1.6  Blood  DC  subsets  in  MM  patients  following  therapy  for 
relapse  with  thalidomide  and  bortezomib. 
At  the  time  of  relapse,  a  number  of  treatment  options  are  available.  Thalidomide  is 
increasingly  one  the  first  line  drugs  to  be  used  to  treat  relapsed  MM  patients, 
either  alone  or  in  combination  with  steroids  and  conventional  chemotherapeutic 
agents  such  as  cyclophosphamide.  The  mode  of  action  of  thalidomide  is  complgx 
and  is  not  fully  understood.  It's  anti-MM  properties  include  inhibition  of 
angiogenesis,  induction  of  MM  plasma  cell  apoptosis  in  combination  with  steroids, 
prevention  of  adhesion  and  cytokine  signaling  and  enhancement  of  the  TH1 
immune  response.  By  measuring  blood  DC  subsets  in  patients  taking  this  drug  we 
hoped  to  gain  a  further  insight  into  the  immunostimulatory  properties  of 
thalidomide,  and  whether  they  may  be  mediated  in  some  way  by  the  DC  system. 
Samples  were  obtained  from  patients  at  the  time  of  relapse  (n=12)  and  when  they 
were  taking  more  than  100  mg  of  thalidomide  for  1-3  months  (n=12),  the  normal 
starting  dose  being  50mg,  which  is  then  usually  increased  to  100mg  after  2-4 
weeks  if  the  patient  is  able  to  tolerate  the  therapy. 
A  small  number  of  samples  were  obtained  from  patients  with  refractory  MM  who 
were  entered  into  the  bortezomib  (Velcade®)  phase  11113  clinical  study  (n=5). 
Velcade  is  a  proteosome  inhibitor  that  has  been  shown  to  be  active  against  MM  in 
earlier  studies  (Richardson,  et  a/  2003)  and  has  recently  been  granted  a  licence 
for  use  in  MM  patients  at  the  time  of  relapse.  There  is  currently  no  data  that 
bortezomib  has  any  direct  effects  on  the  DC  system,  although  there  is  a  report  that 
bortezomib  mediated  cancer  cell  apoptosis  preferentially  induces  DC  maturation 
(Demaria,  et  a!  2005). 
There  was  a  significant  increase  in  the  number  of  blood  mDC1  (meant 
. 
1247  ± 
0.2122  x104/ml)  in  patients  who  were  taking  more  than  100mg  of  thalidomide  for  1- Dr  Simon  J  Harrison,  2005  Chapter  3-100 
3  months  (n=12)  as  compared  to  patients  at  the  time  of  relapse  (n=12)  (p<0.005), 
Figure  3-9.  There  was  no  significant  change  in  the  number  of  blood  pDG 
(meanO.  3271±  0.0808  x104/mI)  and  blood  mDC2  (0.78  ±  0.16  x103/ml)  in  patients 
taking  thalidomide.  The  patients  in  the  bortezomib  study  (n-5)  showed  no  change 
in  the  number  of  blood  mDC1  (mean  0.5856  ±  0.3490  x104/ml)  and  blood  pDC 
(mean  0.8274  ±  0.7142  x104/ml).  There  was  a  statistical  significant  fall  in  the 
number  of  blood  mDC2  (0.129  ±  0.048  x103/ml)  in  the  bortezomib  group  as 
compared  to  the  relapse  and  thalidomide  patients  (p<0.05). 
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Figure  3-9  Blood  DC  subsets  at  the  time  of  relapse  and  following  therapy 
with  thalidomide  and  bortezomib 
Using  flow  cytometry  and  the  BDCA  antibody  kit,  we  quantified  the  number  of 
blood  mDC1,  blood  pDC  and  mDC2  in  samples  obtained  from  MM  patients  when 
they  had  been  taking  more  than  100  mg  of  thalidomide  for  1-3  months  (n=12),  and 
1  month  after  receiving  bortezomib  (n=5).  These  results  were  compared  to  those 
obtained  in  patients  who  had  relapsed  disease  (n=12). 
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3.1.7  Maturation  of  blood  DC  subsets  from  normal  subjects  and 
MM  patients 
The  DC  system  in  MM  patients  is  functionally  abnormal.  They  fail  to  up-regulate 
costimulatory  molecules  such  as  CD80  and  CD40,  and  they  are  inefficient  at 
priming  naive  T  cells  against  tumour  antigen.  However,  in  the  study  by  Brown  et 
al,  blood  mDC  from  MM  patients  were  identified  using  the  CMRF-44  antibody 
following  overnight  culture  and  30%  of  these  cells  were  already  expressing  CD80 
on  their  surface,  prior  to  maturation.  In  the  Ratta  study  all  blood  DC  were 
examined  for  their  expression  of  maturation  markers  after  72  hours  of  culture  in 
medium  without  any  specific  maturation  stimulus  and  then  enrichment  by 
sequential  density  gradient  centrifugation.  They  showed  a  significant  reduction  in 
the  expression  of  CD40  CD80  and  CD86  in  MM  blood  DC  compared  to  time  0,  Lut 
no  data  was  collected  on  the  state  of  maturation  of  each  DC  subset  and  the  data 
represents  three  repeat  experiments  on  cells  from  the  same  patient. 
These  types  of  experiments  are  difficult  to  perform.  They  require  a  large  number  of 
very  rare  cell  populations,  which  do  not  express  exclusive  surface  markers,  thus 
they  are  obtained  by  a  number  of  negative  and  positive  selection  steps.  In  order  to 
simplify  this  process,  we  examined  whether  we  could  combine  blood  DC  subset 
identification  using  the  BDCA  antibodies  with  an  assay  which  would  show  the  DC's 
ability  to  up-regulate  the  surface  expression  of  co-stimulatory  molecules  such  as 
CD40,  CD80,  CD86  along  with  expression  of  phenotypic  markers  CD1a  and 
CD123.  Mononuclear  cells  were  isolated  by  density  gradient  centrifugation  and 
placed  in  DC  culture  medium.  A  sample  of  cells  was  analysed  for  co-expression  of 
BDCA,  co-stimulatory  and  phenotypic  markers  at  time  zero.  The  remainder  of  the 
cells  were  divided  into  two  aliquots.  One  was  cultured  in  medium  alone,  while  the 
other  had  a  maturation  stimulus  added  in  the  form  of  TNF-a  (20ng/ml)  and  PgE2 Dr  Simon  J  Harrison,  2005  Chapter  3-102 
(10-7M).  Cells  from  each  culture  condition  were  analysed  after  4  hours  and 
overnight  culture. 
Cells  were  analysed  by  flow  cytometry  using  the  BDCA  kit  having  run  the 
appropriate  negative  and  compensation  controls.  As  well  as  analysing  the  contr9l 
and  test  samples,  5  additional  tubes  were  stained  with  the  BDCA  test  antibody 
cocktail,  with  the  addition  of  an  extra  FL4  antibody  to  measure  the  surface 
expression  of  CD1a,  CD40,  CD83,  CD86  and  CD123.  These  experiments  were 
repeated  on  three  occasions  on  samples  from  normal  subjects. 
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Figure  3-10  BDCA2  and  CD123  double  staining  of  blood  pDC  control  and 
after  4  hours  culture 
At  time  zero,  blood  pDC  were  positive  for  the  additional  FL4  CD123,  as  expected, 
and  this  antibody  was  included  in  the  panel  to  act  as  a  positive  control.  None  of 
the  other  additional  antibody  stains  were  positive  prior  to  culture.  After  4  hours  of 
culture  in  medium  the  level  of  CD123  staining  is  reduced  on  the  blood  pDC  (100% 
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Figure  3-11  Blood  DC  expression  of  CD83  and  CD86  after  4  hours  culture  in 
medium  supplemented  with  TNF-a  and  PgE2. 
After  4  hours  culture  in  DC  medium  alone  and  DC  medium  supplemented  with 
TNF-a  and  PgE2,  the  control  (plot  A)  and  Test  (plot  B)  are  still  able  to  identify  the 
blood  mDC  and  blood  pDC  populations.  Plot  C  and  D  shows  blood  pDC 
expression  of  CD  83  and  86  respectively.  Plots  E  and  F  show  blood  mDC 
expression  of  CD  83  and  86.  At  4  hours  the  number  of  cells  expressing  these 
markers  of  DC  maturity  has  increased  from  0%  pre-culture,  to  between  3%  and 
7%  of  each  of  the  DC  subset  population. 
At  4hrs  we  were  able  to  show  that  there  is  a  small  but  detectable  increase  in  the 
levels  of  CD83  and  CD86  surface  staining  on  both  blood  mDC  and  blood  pDC9, 
Figure  3-11  and  Table  3-2.  There  was  no  increase  in  the  level  of  CD1  a  or  CD40 
at  4  hours.  The  surface  expression  of  CD123  on  blood  pDC  was  almost 
completely  down  regulated  (-84.64  ±  5.2)  after  4  hours  of  culture  in  both 
supplemented  and  plain  DC  medium.  However,  following  overnight  culture  in Dr  Simon  J  Harrison,  2005  Chapter  3-104 
medium  alone  or  supplemented  with  TNF-a  and  PgE2,  the  numbers  of  cells  that 
remained  in  the  blood  mDC  and  blood  pDC  gates  were  so  low  that  no  meaningful 
estimate  of  surface  expression  of  other  markers  could  be  made. 
CD83  CD  86  CD123 
blood  7.34+0.8  10.03+0.7 
mDC1 
blood  5.52+0.6  8.52+0.5  -84.64+5.2 
pDC 
Table  3-2  Change  in  the  mean  fluorescence  intensity  of  maturation  markers 
in  blood  mDC  and  blood  pDC  following  4  hours  culture  in  TNF-a 
and  PgE2  supplemented  DC  medium 
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Figure  3-12  BDCA  1  and  2  surface  expression  after  overnight  incubation  in 
medium  supplemented  TNF-a  and  PgE2 
Plot  A  and  B  show  BDCA  1  and  2  surface  expression  following  overnight  culture  in 
DC  medium  (A)  or  DC  medium  supplemented  with  TNF-a  (20ng/ml)  and  PgE2 
(10-7M)  (B). 
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The  presence  of  DC  subsets  in  the  blood  gives  a  unique  window  into  the  DC 
system  in  both  normal  subjects  and  those  patients  with  malignant  disease,  such  as 
MM.  Using  the  BDCA  kit  we  were  able  to  reliably  measure  the  number  9f  blood 
mDC,  blood  pDC  and  blood  mDC2  in  the  peripheral  blood  of  normal  subjects,  with 
our  results  being  comparable  with  the  manufacturers  reference  range.  We  also 
validated  the  use  of  the  kit  to  reliably  measure  the  number  of  B  lymphocytes  in  tie 
blood  of  normal  subjects  and  our  results  are  within  a  number  of  published 
reference  values  (HMDS,  Leeds)  (Glassman  and  Bennett  1977,  Reichert,  et  al 
1991).  Having  validated  its  use,  we  went  on  to  use  the  BDCA  antibody  kit  to 
analyse  samples  from  patients  with  MM  at  a  number  of  time  points  during  the 
disease  course. 
Using  this  assay,  we  found  that  the  number  of  B  lymphocytes  in  the  blood  of  MM 
patients  (mean  0.9386  ±  0.2750  x105  /ml)  was  significantly  lower  than  in  normal 
subjects  (p<0.001).  There  is  some  debate  in  the  published  literature  as  to  whether 
B  lymphocyte  numbers  are  suppressed  in  MM,  with  various  groups  reporting 
normal,  low  and  heterogeneous  numbers  of  B  lymphocyte  in  the  blood  of  MM 
patients  (Kay,  et  a11997,  Pilarski,  et  a11984,  Rasmussen,  et  a/2000,  Schutt,  et  al 
2005).  Why  should  B  lymphocyte  numbers  be  reduced  in  MM?  MM  is  a  clonal 
disorder  of  the  B  cell  compartment,  and  as  with  other  clonal  disorders,  this  may 
represent  a  simple  replacement  of  the  normal  cells  by  the  malignant  clone. 
Another  possibility  is  that  the  immunosuppressive  cytokines,  such  as  IL-6,  IL-10, 
TGF-ß  and  VEGF  secreted  by  the  (pre-)  malignant  MM  plasma  cell  are  actively 
suppressing  the  development  of  normal  B  lymphocytes.  A  third  possibility  is  that 
epitopes  expressed  in  the  CD19  molecule  are  altered  in  MM  and  MGUS  patients 
by  the  cytokines  secreted  by  the  malignant  clone,  preventing  some  antibodies 
such  as  Leu-12,  FMC-63  and  B4  from  detecting  CD19  molecules.  This  may  go Dr  Simon  J  Harrison,  2005  Chapter  3-106 
some  way  to  explain  the  differences  in  B  cell  numbers  reported  in  MM  patients  in 
the  literature.  The  antibody  used  in  our  analysis  is  produced  by  the  LT19  clone, 
which  is  commonly  used  for  phenotyping  CD19+  cells  and  there  are  no  reported 
discrepancies  between  normal  and  MM  B  cell  staining.  We  also  found  that  the 
number  of  B  cells  in  the  blood  of  patients  with  MGUS  and  plasmacytoma  (1.5883  ± 
0.3405  x105  /ml)  was  also  lower  than  in  normal  subjects  (p<O.  005).  This  last 
finding  was  unexpected,  as  there  are  no  previous  reports  of  cellular  immune 
defects  in  MGUS.  However,  there  are  a  number  of  reports  of  clonal  B  cell 
populations  in  the  blood  of  MGUS  patients  (Pilarski,  et  al  1996).  There  is 
speculation  as  to  whether  this  represents  a  pre-malignant  clone  that  is  awaiting  p 
further  genetic  mutation  (2"d  hit)  to  become  truly  malignant,  or  a  malignant  clone, 
that  is  being  held  in  check  by  the  immune  system  which  is  allowed  to  progress 
when  the  immune  system  is  down  regulated  by  mechanisms  we  have  discussed 
previously.  We  feel  that  these  observations  warrant  further  investigation,  as  they 
may  reveal  further  mechanisms  by  which  the  MM  clone  evolves  and  induces  an 
immunosuppressive  state  in  its  host. 
The  number  of  blood  mDC1  and  blood  pDC  detected  in  the  blood  of  MM  patients 
with  the  BDCA  antibodies  was  significantly  lower  than  in  the  control  group.  This 
effect  was  even  more  pronounced  at  the  time  of  relapse.  The  number  of  blood 
pDC  seemed  to  be  particularly  affected,  especially  at  the  time  of  relapse.  Standard 
induction  chemotherapy  made  no  significant  improvement  in  the  number  of  blood 
mDC1  or  blood  pDC  seen  in  the  blood  of  MM  patients.  The  number  of  blood 
mDC2  seen  throughout  the  course  of  the  disease  was  not  significantly  different 
from  the  normal  population.  The  number  of  DC  improve  in  the  short  term  after  auto 
HSCT,  with  the  numbers  of  blood  mDC1  returning  to  within  the  normal  range  at 
the  time  of  engraftment  (mean  1.52  ±  0.28  x104  /ml)  (p>0.05)  and  subsequently 
maintained  up  to  D100,  but  then  fall  back  again  at  one  year  post  auto  HSCT.  The Dr  Simon  J  Harrison,  2005  Chapter  3-107 
improvement  in  blood  pDC  and  blood  mDC2  after  HSCT  is less  impressive  and 
again  the  levels  were  low  at  one  year  post  auto  HSCT.  These  findings  qre 
encouraging,  as  they  reflect  the  improved  survival  data  that  suggest  auto  HSCT 
has  an  important  role  in  further  reducing  the  tumour  burden  in  MM  patients  as 
compared  to  conventional  therapy  alone.  In  the  future,  these  kinds  of  data  may  be 
important  in  deciding  upon  the  timing  of  immune  based  therapies,  which  should 
have  the  best  chance  of  inducing  significant  benefits  when  the  disease  burden, 
and  hence  it's  immunosuppressive  potential,  is  at  it's  lowest.  Our  data  on  the 
recovery  of  blood  DC  following  NM  alto  HSCT  was  limited  due  to  the  very  small 
numbers  of  patients  that  are  eligible  for  this  treatment  option.  We  found  that  the 
level  of  all  blood  DC  subsets  were  low  at  D100,  which  appears  to  be  at  odds  with 
data  generated  within  our  group  from  patients  undergoing  NM  alto  HSCT  for  the 
treatment  of  CML,  which  showed  that  at  D100  blood  mDC1  numbers  were  27-fold 
higher  than  ND,  and  the  other  blood  DC  subsets  were  relatively  normal  (Harrison, 
et  a/  2003).  Both  of  these  findings  offer  only  snap  shots  of  complex,  dynamic  and 
rapidly  evolving  interactions  between  the  prolonged  effects  of  conditioning  therapy 
(i.  e.  Campath  1  H),  the  process  of  immune  reconstitution,  response  to  infections 
and  the  underlying  malignant  disease.  The  true  picture  seems  to  be  one  where  the 
numbers  of  blood  DC  subsets  vary  dramatically  throughout  the  first  year  following 
alto  HSCT  in  a  series  of  peaks  and  troughs  (Hart,  personal  communication).  The 
process  of  blood  DC  recovery  following  HSCT  will  only  become  better  understood 
by  studying  these  aspects  of  immune  reconstitution  in  a  formal,  longitudinal  study. 
Thalidomide  is  playing  an  increasingly  important  role  in  the  management  of 
patients  with  MM.  In  the  MRC  UK  myeloma  IX  study,  it  is  being  used  in  both  the 
induction  regime  for  new  patients  and  as  single  agent  maintenance  therapy 
following  autologous  HSCT.  Of  the  many  putative  modes  of  action  of  thalidomide, 
its  immuno-stimulatory  properties  are  some  of  the  most  interesting.  Our  finding Dr  Simon  J  Harrison,  2005  Chapter  3-108 
that  the  number  of  blood  mDC1  in  patients  taking  thalidomide  was  significantly 
higher  than  patients  at  relapse  suggests  that  thalidomide  is  able  to  either  stimulate 
the  DC  system  or  allow  it  to  recover  somewhat  from  the  added  insult  of  disease 
relapse.  There  are  no  published  data  on  the  clinical  effect  of  thalidomide  on  bloqd 
DC,  but  our  data  are  in  keeping  with  the  in  vitro  data  which  suggests  that 
thalidomide  is  able  to  improve  the  ability  of  MoDC  to  induce  TH1  type  responses 
(Mohty,  et  a!  2002b).  The  number  patients  in  the  bortezomib  study  were  small  and 
they  had  been  heavily  pre-treated,  making  the  data  difficult  to  interpret.  Even  so,  it 
was  interesting  to  note  that  the  blood  mDC1  and  pDC  numbers  were  similar  to  the 
relapse  group,  while  the  blood  mDC2  numbers  were  significantly  lower  that  at 
relapse  and  following  thalidomide  treatment.  As  this  drug  becomes  more  widely 
used  it  will  be  important  to  assess  the  impact  that  it  has  on  the  immune  system  in 
MM  and  other  malignant  diseases. 
In  the  final  set  of  experiments  we  attempted  to  use  the  BDCA  antibodies  to 
monitor  the  blood  DC  response  to  a  maturation  signal  in  a  mononuclear  cell 
population.  We  were  able  to  show  early  up  regulation  of  surface  expression  of  the 
costimulatory  molecules  CD83  and  CD86  on  blood  mDC  and  blood  pDC  and  down 
regulation  of  CD123  on  blood  pDC  at  4  hours.  Following  overnight  culture  we  were 
not  able  to  reliably  identify  the  blood  DC  subsets  due  to  down  regulation  of  CD1  c 
and  BDCA2.  These  experiments  were  able  to  give  some  insight  into  the  timing  of 
changes  in  the  surface  phenotype  of  blood  DC. In  order  to  take  these  experiments 
further,  formal  isolation  of  the  DC  subsets  by  either  FAGS  or  magnetic  bead 
sorting  would  need  to  be  performed  prior  to  culture.  These  experiments  require  a 
large  number  of  starting  cells  because  of  the  small  target  populations  and  the 
magnitude  of  cell  loss  encountered  at  each  step. Dr  Simon  J  Harrison,  2005  Chapter  3-109 
In  summary,  The  BDCA  antibodies  allowed  us  to  reliably  measure  the  DC  subsets 
and  B  cell  in  the  blood  of  normal  subjects  and  patients  with  MM  throughout  the 
disease  course.  The  numbers  of  blood  mDC  and  blood  pDC  are  low  thrpughout 
the  course  of  the  disease,  and  only  improve  for  a  short  period  of  time  following 
autologous  HSCT.  Thalidomide  is  able  to  increase  blood  mDC1  and  blood  pDC 
numbers  in  patients  with  relapsed  disease. Dr  Simon  J  Harrison,  2005 
4.  Results  2 
4.1  MoDC  Generation  in  NDs  and  MM-patients 
4.1.1  Introduction 
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Multiple  myeloma  is  not  curable  in  the  majority  of  patients,  however  the  immune 
system  is  able  to  affect  the  cure  of  a  small  number  of  young  patients  via  the  GVM 
effect  seen  in  alto  BMT,  but  at  the  cost  of  increased  toxicity.  The  introduction  of 
non-myeloablative  alto  BMT  has  attempted  to  reduce  the  toxicity  of  alto  BMT  and 
thus  make  it  a  more  viable  treatment  option  in  older  patients  (Shaw,  et  a!  2003). 
However,  this  may  also  reduce  the  effectiveness  of  the  immune  component  of  the 
therapy  against  the  disease,  especially  in  groups  with  advanced  and  heavily  pre- 
treated  disease  (Crawley,  et  a!  2005a).  Many  groups  around  the  world  are 
therefore  attempting  to  use  the  autologous  immune  system  to  eradicate  residual 
MM  following  standard  and  high  dose  conventional  chemotherapy.  Dendritic  cells 
are  seen  as  one  of  the  most  promising  tools  that  we  can  manipulate  in  order  to 
increase  a  patient's  immunity  against  their  residual  tumour  cells.  In  the  previous 
chapter  it  was  shown  that  circulating  BDC  in  MM  patients  are  quantitatively 
abnormal.  As  previously  discussed,  these  cells  are  also  qualitatively  abnormal  in 
MM  patients,  thus  it  is  difficult  to  justify  using  BDC  from  MM  patients  in  the 
treatment  of  their  disease.  It  is  possible  to  produce  iDC  from  steady  state  or 
mobilised  monocytes  from  ND  and  patients  with  malignant  disease  (Morse,  et  al 
1999b,  Syme,  et  a!  2001).  Alternatively,  monocytes  can  be  separated  by  plastic 
adherence  or  CD14  selection  (Motta,  et  al  2003,  Suen,  et  a!  2001)  and  they  are 
then  cultured  in  medium  supplemented  with  cytokines  such  as  GM-CSF, IL-4,  IL- 
13  and  lFN-a  (Della  Bella,  et  a/  2004,  Gabriele,  et  a!  2004,  Motta,  et  a!  2003).  To 
date,  there  are  few  comparative  studies  to  show  if  these  methods  are  equally Dr  Simon  J  Harrison,  2005  Chapter  4-111 
effective  and  there  are  almost  none  to  show  whether  they  are  equivalent  when 
using  monocytes  from  patients  with  diseases  such  as  MM  (Syme,  et  a/  2001, 
Tarte,  et  al  1998).  In  addition,  we  are  only  just  beginning  to  explore  how 
therapeutic  interventions  and  the  level  of  residual  disease  may  influence  our  ability 
to  produce  immune  therapies  in  the  context  of  malignant  disease  states.  For 
example,  Schutt  has  shown  that  if  MM  patients  are  taking  thalidomide,  dendritic 
cells  produced  by  in  vitro  culture  from  monocytes  have  a  reduced  expression  of 
DC  surface  markers  such  as  CD1  a,  CD40,  CD83,  and  HLA-DR  (Schutt,  et  al 
2005).  The  question  on  how  to  mature  OC  is  also  confused.  There  are  many 
published  cytokine  combinations  containing  TNFa,  PGE2,  IL-1  P,  IL-6,  CD40L, 
Poly(I;  C),  IFNs  (Luft,  et  al  2002b)  etc.  in  numerous  combinations  and  doses  that 
can  be  used  to  produce  matDC  from  Ag-loaded  iDC,  but  there  are  few 
comparative  studies  in  MM  (Curti,  et  al  2004). 
lt  is  therefore  conceivable  that  in  view  of  the  hostile  environment  induced  by  the 
MM  tumour  cell,  with  high  levels  of  TGFß  etc,  monocytes  from  MM  patients  may 
produce  overall  less  efficient  MoDC.  Thus,  culture  conditions  may  be  even  more 
critical  for  the  production  of  DC  for  clinical  use,  which  may  eventually  translate  into 
more  effective  immunotherapy  for  use  in  clinical  trials,  when  these  cells  are 
injected  back  into  the  patient  and  a  hostile  cytokine  environment. 
The  aim  of  the  experiments  described  in  this  chapter  was  to  examine  whether  the 
method  of  iDC  production  from  monocytes  influenced  the  quality  and  function  of 
immature  MoDC  produced  from  MM  patients  vs.  ND.  We  also  examined  whether 
different  maturation  cytokine  combinations  were  able  to  overcome  any  blockade  of 
maturation  in  MM  patient  derived  DC  as  compared  to  cells  from  ND. Dr  Simon  J  Harrison,  2005  Chapter  4-112 
4.1.2  A  comparison  of  iDC  generation  using  GM-CSF  and  IL-4  or 
IL-13  from  mobilised  monocytes  collected  from  ND$  and  h  IM 
patients 
In  order  to  examine  whether  monocytes  from  NDs  and  MM  patients  could  equally 
be  used  to  produce  iDC  using  the  cytokine  combinations  GM-CSF  and  IL-4  or  GM- 
CSF  and  IL-13,  monocytes  were  obtained  from  subjects  who  gave  informed 
consent  and  were  undergoing  stem  cell  collection  at  the  Apheresis  Unit,  GRI.  NQs 
were  conditioned  with  growth  factor  (G-CSF)  alone,  while  most  MM  patients  were 
mobilised  with  growth  factor  (G-CSF)  following  myelosuppressive  chemotherapy. 
Excess  cells  that  remained  in  the  apheresis  harness  were  harvested  immediately 
following  the  procedure.  The  PBMC  were  obtained  by  density  gradient 
centrifugation  and  then  cultured  overnight  in  DC  medium  to  allow  the  cells  to  rest 
following  the  mobilisation  and  apheresis  procedures.  The  following  morning, 
monocytes  were  purified  from  PBMC  by  CD14  magnetic  bead  separation  (Miltenyi 
Biotech).  An  aliquot  of  monocytes  (2x106)  was  retained  for  flow  cytometric  analysis 
of  surface  phenotype  (Figure  4-1),  while  the  remainder  were  suspended  in  DC 
medium  at  a  density  of  5x106/ml  and  placed  into  75cm2  tissue  culture  flasks 
(Coming  Life  Sciences).  The  DC  medium  was  then  supplemented  with  GM-CSF 
50ng/ml  (Stem  Cell  Technologies,  Vancouver,  Canada)  and  either  IL-4  30ng/ml 
(Peprotech)  or  IL-13  50ng/ml  (Peprotech).  Cells  were  cultured  for  4  days  at  37°C 
and  5%  C02,  and  then  assessed  by  flow  cytometry  for  surface  expression  of 
markers  of  DC  phenotype  (Figure  4-2). Dr  Simon  J  Harrison,  2005 
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Figure  4-1  ND  and  MM  monocyte  surface  phenotype  prior  to  DC  induction 
Monocytes  from  NDs  (n=10)  and  MM  patients  (n=10)  were  collected  during  stem 
cell  mobilisation  and  purified  by  density  gradient  centrifugation  and  CD14 
magnetic  bead  separation.  Cells  were  cultured  overnight  in  DC  medium  and  the 
surface  phenotype  was  analysed  by  flow  cytometry  prior  to  culture  in  DC  medium 
supplemented  with  GM-CSF  and  IL-4  or  IL-13.  The  results  are  expressed  as  the 
percentage  of  total  cells  that  were  positive  for  the  marker. 
The  purity  achieved  by  CD14  magnetic  bead  separation  was  similar  in  both  the  ND 
and  MM  patient  samples  (mean  93.8  ±  1.8%  vs.  89.9  ±  3.2%).  The  proportion  of 
cells  that  expressed  CD86  (mean  74.4  ±  6.2%  vs.  44.7  ±  10.2%,  p<0.03),  HLA-DR 
(mean  83.6  ±  5.2%  vs.  55.8  ±  8.8%,  p<0.05)  and  CCR5  (mean  45.1  ±  6.5%  vs. 
21.6  +  10.0%,  p<0.05)  on  their  surface  was  significantly  higher  in  the  ND 
monocytes  as  compared  to  MM  cells.  There  was  also  a  small,  but  significant 
increase  in  the  surface  expression  of  CD40  on  MM  monocytes  compared  to  ND 
cells  (mean  7.0  ±  1.9%  vs.  3.1  ±  0.7%,  p<0.05). 
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Figure  4-2  ND  and  MM  iDC  surface  phenotype  on  D+4  DC  induction 
An  aliquot  of  ND  (n=20)  or  MM  (n=17)  iDC  (1-2xl  06)  was  removed  after  4  days  in 
culture  with  GM-CSF  (50ng/ml)  and  either  IL-4  (30ng/mi)  or  IL-13  (50ng/mI).  The 
number  of  cells  expressing  DC  markers  were  analysed  by  flow  cytometry. 
Following  4  days  culture  in  DC  medium  supplemented  with  GM/IL-4  or  GM/IL-13, 
all  iDC  down  regulated  CD14,  with  no  significant  difference  between  ND  and  MM 
0 
cells.  There  was  an  up  regulation  of  the  surface  expression  of  CD86,  HLA-DR, 
CCR5,  CD1  a,  and  CD1  c  on  both  ND  and  MM  iDC  as  compared  to  monocytes.  The Dr  Simon  J  Harrison,  2005  Chapter  4-115 
proportion  of  ND  iDC  that  expressed  CDIc  (mean  63.4  ±  4.6%  vs.  36.0  ±  6.5%, 
p<O.  003),  CD86  (mean  87.2  ±  3.0%  vs.  70.9  ±  3.4%,  p<O.  001),  and  CCý5  (mean 
49.1  ±  5.6%  vs.  34.2  ±  6.3%,  p<0.05)  was  significantly  higher  as  compared  to  MM 
iDC.  The  MFI  of  HLA-DR  (mean  223.0  ±  40.7  vs.  126.3  ±  20.2,  p<0.05)'and  CD1a 
(mean  34.3  ±  7.2  vs.  11.3  ±  2.0,  p<O.  001)  surface  expression  was  also 
significantly  higher  on  ND  iDC  as  compared  to  MM  iDC  (Figure  4-2). 
There  were  no  significant  differences  in  the  surface  expression  of  CDla,  CD40, 
CD86,  HLA-DR  and  HLA-class  I  between  iDC  from  ND  and  MM  patients 
generated  with  GM-CSF  and  IL-4,  as  compared  with  cells  generated  with  GM-CPF 
and  IL-13.  These  findings  are  summarised  in  Table  4-1. 
ND  IL-4  ND  IL-13  MM  IL-4  MM  1113 
CDIa 
CDIc 
42.8+7.0% 
37.2+10.6 
68.6+5.6% 
20.1+3.4 
37.6+8.5% 
30.8+9.9 
29.9+7.5% 
10.7+3.2 
35.6+9.0% 
37.2+10.63 
CD40 
CD86 
CCR5 
HLA-DR 
HLA-class  I 
57.2+7.5% 
12.9+2.8 
34.0+8.1% 
6.2+1.7 
51.0+9.0%  40.5+  10.4%  44.6+8.5% 
19.1+7.3  15.9+8.3  10.5+2.9 
85.7+4.8% 
64.0+16.0 
89.1+3.4% 
51.4+12.8 
72.1+4.0% 
48.4+23.0 
46.9+8.2% 
9.6+3.8 
94.7+2.1% 
197+47.2 
89.4+2.7% 
73.4+18.3 
58.6+9.0% 
12.9+4.3 
94.8+2.7% 
255+71.5 
90.3+3.2% 
93.4+31.9 
27.0+7.8% 
4.8+2.1 
88.8+4.8% 
124+24.8 
81.5+4.0% 
42.2+6.7 
38.4+11.1% 
12.8+7.2 
49.7+10.4% 
11.7+3.6 
69.5+6.0% 
70.4+44.9 
43.9+9.61% 
6.3+2.2 
91.8+3.2% 
129+35.0 
83.7+6.0% 
60.0+13.3 
Table  4-1  Surface  phenotype  of  iDC  from  ND  and  MM  patients  generated  with 
GMIIL-4  or  GMIIL-13 
The  surface  phenotype  of  OC  from  ND  and  MM  patients  generated  with  GMIIL-4 
(n=1  1  and  9)  or  GM/IL-13  (n=9  and  8)  was  expressed  as  the  mean  percentage  of 
positive  cells  +  SEM  (top  line)  and  mean  MFI  +  SEM  (bottom  line). Dr  Simon  J  Harrison,  2005  Chapter  4-116 
ND  iDC  generated  with  GM-CSF  and  IL-4  expressed  significantly  higher  levels  of 
CD1c  (68.6+5.6%,  MFI  20.1+3.4)  as  compared  with  iDC  generated  with  GM-CSF 
and  IL-13  (57.2±7.5%,  MFI 12.9±2.8)  (p<O.  03  and  p<O.  005).  Immature  QC 
i 
generated  from  MM  patients  had  significantly  higher  expression  of  CD4p  when 
generated  with  GM-CSF  and  IL-4  (MFI  10.5±2.9)  compared  with  those  generated 
with  GM-CSF  and  IL-13  (MFI  11.7±3.6,  p<O.  01).  In  contrast,  MM  iDC  cultured  with 
GM-CSF  and  IL-13  had  a  higher  proportion  of  CCR5  positive  cells  (43.9±9.61  %) 
compared  with  those  produce  with  GM-CSF  and  IL-4  (27.0+7.8%,  p<0.03).  Thus 
DC  from  patients  with  MM  were  consistently  of  poorer  quality  than  cells  from  NQ 
irrespective  of  the  cytokines  used  to  generate  them. 
4.1.3  Phagocytosis  of  Ag  by  ND  and  MM  patient  iDC  generated 
using  GM-CSF  and  IL-4  or  IL-13 
One  of  the  main  functions  of  DC  is  to  continuously  monitor  the  in-vivo 
environment  for  Ag.  Immature  DC  encounter  Ag  in  the  peripheral  tissues  in  many 
forms,  such  as  apoptotic  bodies,  cell  debris  following  necrosis,  bacteria,  food  and 
purified  proteins  following  vaccination.  The  main  way  in  which  iDC  take  up  Ag  is  by 
simple  phagocytosis.  Immature  DC  may  also  employ  a  number  of  more  specific 
mechanisms  that  enhance  the  efficiency  of  Ag  loading  such  as  CD68  mediated 
uptake  of  antibody  coated  particles,  HSP  uptake  via  CD91  and  the  uptake  of 
apoptotic  bodies  via  various  receptors,  including  the  phosphotidylserine  receptor, 
vitronectin  receptor  and  CD36.  In  order  to  assess  whether  iDC  from  ND  and  MM 
patients  generated  with  GM/IL-4  and  GM/IL-13  were  equally  efficient  at 
phagocytosing  particulate  Ag,  we  performed  phagocytosis  assays  using  1  or  2pm 
latex  beads  that  were  coated  with  PE  (Sigma). Dr  Simon  J  Harrison,  2005  Chapter  4-117 
Dendritic  cells  were  suspended  in  DC  medium  at  a  concentration  of  1x106/mI,  and 
100pl  was  added  to  a  Falcon  tube.  Latex-PE  beads  (1  mg/ml)  were  diluted  1:  100, 
and  1  Opi  was  added  to  each  sample.  The  assay  was  then  incubated  at  37°C  for  1 
hour.  The  cells  were  counter  stained  with  CD11c-FITC,  which  was  added  to  the 
assays  for  the  final  10mins  of  the  incubation.  Excess  antibody  and  non 
phagocytosed  beads  were  removed  by  washing  the  cells  in  5mls  of  cold  PBS.  Toe 
cells  were  recovered  by  centrifugation  at  800  rpm  for  10  minutes,  before 
completely  removing  the  supernatant.  This  was  repeated  and  the  cells  were 
suspended  in  300pl  of  PBS  prior  to  analysis  by  flow  cytometry,  having  first  run  the 
appropriate  compensation  controls  (i.  e.  unstained  cells,  Isotype  control  PE  and 
FITC  cells,  CD11c-FITC  positive  cells,  PE  bead  positive  cells)  (Figure  4-3). 
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Figure  4-3  iDC  bead  phagocytosis  assays 
ND  OC  generated  with  GM-CSF  and  either  IL-4  or  IL-13,  were  incubated  with  PE 
labelled  1  or  2  um  latex  beads  and  incubated  for  one  hour.  Immature  DC  were 
counter  stained  with  CD1  1cFITC,  washed  twice  in  PBS  and  analysed  by  flow 
cytometry.  Cells  may  phagocytose  more  than  one  bead,  and  this  produces  an 
incremental  increase  in  the  fluorescence  of  the  cell  per  bead,  as  illustrated  by  the 
arrows  and  the  characteristic  'stripes'  within  the  plots. Dr  Simon  J  Harrison,  2005  Chapter  4-118 
immature  DC  generated  from  ND  (mean  59.4  +  3.9%)  were  significantly  better  at 
phagocytosing  fluorescent  latex  beads  compared  to  those  generated  from  MM 
patients  (mean  20.1  +  2.1  %,  p<0.001).  The  cytokines  used  to  generate  the  iDC 
made  no  significant  difference  to  the  ability  of  ND  (IL-4  mean  57.2  +  6.6%,  IL-13 
mean  61.6  +  4.6%)  or  MM  iDC  (IL-4  mean  19.5  +  0.6%,  IL-1  3  mean  20.8+  2.3%) 
to  phagocytose  fluorescent  beads. 
100 
(1) 
a) U 
a) 
N 
O 
Q 
w  O 
a) a) 
C 
u) U 
a) 
a- 
80 
P<0.001 
60 
40 
o  ND  IL-4  iDC 
ND  IL-13  iDC 
MM  IL-4  iDC 
MM  IL-13  iDC 
20 
Figure  4-4  ND  and  MM  iDC  latex  bead  phagocytosis  assays 
ND  (n=7)  and  MM  OC  (n=4)  were  generated  with  GMAL-4  and  GMAL-13. 
Fluorescent  latex  bead  phagocytosis  assays  were  performed  on  D4  of  culture. 
Live  DC  were  gated  on  by  forward  and  side  scatter  and  CD1  1c  expression,  and 
the  percentage  of  cells  that  have  phagocytosed  at  least  one  bead  are  expressed 
as  the  mean  +  SEM. 
In  order  to  assess  the  ability  of  DC  to  phagocytose  tumour  Ag  we  modified  the 
phagocytosis  assay  by  using  MM  turnour  cells,  labelled  with  fluorescent  dye,  in 
place  of  PE  labelled  latex  beads.  The  U266  myeloma  tumour  cells  (HLA-A2)  were 
labelled  with  the  PKH-67  green  fluorescent  dye,  which  is  detected  in  FL1  and 
washed  three  times  in  DC  medium.  Labelled  tumour  cells  were  added  to  the  DC 
at  a  ratio  of  5:  1  to  ensure  that  the  number  of  available  tumour  cells  did  not  limit  the 
rate  of  DC  phagocytosis,  and  the  cells  were  incubated  for  1  hour  at  370C. Dr  Simon  J  Harrison,  2005  Chapter  4-119 
Dendritic  cells  were  counter  stained  with  CD1  1c-PE.  The  cells  were  washed  in 
PBS  and  the  results  were  analysed  immediately  by  flow  cytometry  (Figure  4-5). 
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Figure  4-5  Fluorescent  tumour  cell  phagocytosis  assay 
ND  DC  generated  with  GM-CSF  and  either  IL-4  or  IL-13,  were  incubated  with 
PKH-67  labelled  U266  tumour  cells  and  incubated  for  one  hour.  Immature  DC 
were  counter  stained  with  CID1  1c-PE,  washed  twice  in  PBS  and  analysed  by  flow 
cytometry. 
The  results  from  the  fluorescent  tumour  cell  assay  were  in  keeping  with  the  bead 
phagocytosis  assay,  although  iDC  were  better  able  to  take  up  turnour-derived 
material  as  compared  to  the  latex  beads.  ND  derived  DC  were  more  efficient  at 
phagocytosing  tumour  cell  Ag  (mean  70.2  +  3.9%)  as  compared  to  OC  generated 
from  MM  patients  (mean  34.2  +  6.9%,  p<0.001).  Once  again,  the  cytokine 
combination  that  was  used  to  generate  the  iDC  had  no  significant  impact  on  the 
ability  of  ND  (IL-4  mean  69.8  +  4.2%,  IL-13  mean  70.7  +  5.3%)  or  MM  DC  (IL-4 
mean  32.5  +  10.3%,  1  L-1  3  mean  36.0  +  10.7%)  to  phagocytose  turnour  cell 
derived  Ag  (Figure  4-6). Dr  Simon  J  Harrison,  2005 
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Figure  4-6  ND  and  MM  patient  iDC  fluorescent  tumour  cell  phagocytosis 
assay 
ND  (n=7)  and  MM  DC  (n=4)  were  generated  with  GM/IL-4  and  GM/IL-13. 
Fluorescent  tumour  cell  phagocytosis  assays  were  performed  on  D4  of  culture. 
Live  DC  were  gated  on  by  forward  and  side  scatter  and  CID  11  c  expression,  and 
the  percentage  of  cells  that  have  phagocytosed  tumour  derived  Ag  are  expressqd 
and  the  mean  +  SEM. 
4.1.4  Maturing  iDC  from  ND  and  MM  patient  iDC  using  thq  MIMIp 
and  X4  cytokine  combinations 
It  has  been  known  for  some  time  that  iDC  do  not  induce  potent  anti-tumour 
responses,  and  may  even  induce  tolerance  when  administered  to  patients  as 
immune  therapy.  Thus  it  is  crucial  to  any  immunotherapeutic  strategy  that  DC 
achieve  a  state  of  full  maturity,  i.  e.  up  regulate  co-stimulatory  molecules  such  as 
CD40,  CD80,  CD83,  CD86  and  HLA  class  I  and  11  prior  to  being  given  to  patien% 
(Nieda,  et  al  2003).  The  process  of  maturation  also  alters  the  chemokine  receptor 
profile,  i.  e.  down  regulation  of  CCR5  and  up  regulation  of  CCR7,  which  facilitates 
the  migration  of  matDC  from  peripheral  tissues  to  lymph  nodes  where  they  are 
brought  into  close  proximity  to  na"fve  T  cells  for  Ag  presentation  to  occur.  As 
previously  discussed  BDC  from  MM  patients  do  not  up  regulate  co-stimulatory Dr  Simon  J  Harrison,  2005  Chapter  4-121 
molecules  in  response  to  maturation  signals  such  as  TNF-a  and  PGE2as 
compared  to  cells  from  normal  subjects.  There  is  some  debate  as  to  whether 
MoDC  from  MM  patients  mature  normally  in  response  to  standard  matufation 
stimuli  (Ratta,  et  al  2000).  A  number  of  strategies  have  been  shown  to  ipduce  DC 
maturation.  One  of  the  first  methods  that  was  shown  to  induce  effective  DC 
maturation  was  the  use  of  monocyte  conditioned  medium  (Bender,  et  al  1996), 
however  these  media  are  time  consuming  to  produce  and  are  subject  to  marked 
inter  batch  variation  in  responses.  Cytokines  such  as  TNF-a  can  be  used  alone  to 
induce  DC  maturation,  but  may  be  used  more  effectively  in  combination  with 
PGE2,  which  seems  particularly  important  in  the  up  regulation  of  CCR7  (Scandeýla, 
et  al  2002).  The  interaction  between  CD40  and  CD40L  is  particularly  important  ip 
the  induction  of  DC  maturity  in-vivo,  and  it  has  been  shown  that  it  can  be  used 
alone  or  in  combination  with  other  cytokines  such  as  ILAP  and  IFN-a  to  induce  a 
potent  maturation  of  iDC  in-vivo  (Caux,  et  al  1994,  Luft,  et  al  2002a,  Luft,  et  al 
2002b). 
The  aim  of  the  next  set  of  experiments  was  to  compare  the  ability  of  two  cytokine 
combinations  to  induce  the  maturation  of  iDC  from  ND  and  MM  patients  generated 
with  GM/IL-4  and  GM/IL-13.  We  compared  the  monocyte  conditioned  medium 
mimic  (MIMIC)  combination  of  TNF-a  (10ng/mI)  (Peprotech),  ILAP  (10ng/ml) 
(Peprotech),  IL-6  (10ng/ml)  (Stem  Cell  Technologies)  and  PGE2  00-7M)  (Sigma) 
(Feuerstein,  et  al  2000)  with  the  novel  in-house  combination  X4,  TN  F-a  (1  Ong/ml), 
PGE2  00-7M),  Poly  (I;  C)  (10ng/mI)  (Sigma)  and  CD40L  (250ng/ml)  (Peprotech). 
The  X4  combination  was  rationally  designed  to  maximise  the  stimulus  to  the  MM 
iDC.  In  particular,  by  incorporating  the  signalling  of  CD40L  via  CD40  with  the  more 
traditional  TNF-a  signalling  via  CD120,  PGE2  via  the  eicosanoid  receptors  2  and  4 
(EP2  and  4),  and  finally  polyriboinosinic  polyribocytidylic  acid  (poly  I:  C),  which  is  a 
member  of  the  path  ogen-associated  molecular  patterns  (PAMP)  group  of Dr  Simon  J  Harrison,  2005  Chapter  4-122 
molecules  and  signals  through  Toll-like  receptor  3,  X4  may  overcome  the  relatively 
poor  expression  of  co-stimulatory  molecules  on  MM  DC  and  the  impairment  of 
i 
their  up  regulation  seen  in  MM  BDC,  as  discussed  in  the  previous  chapjer. 
Immature  DC  were  prepared  from  CD14  selected  monocytes  from  MM  patients 
and  ND  cultured  for  4  days  in  DC  medium  supplemented  with  GM/lL-4  or  GM/IL, 
13.  The  DC  were  then  counted  and  fresh  DC  media,  supplemented  with  the 
appropriate  cytokines,  was  added  so  that  DC  were  at  a  final  concentration  of 
1  x1  06/ml  and  placed  in  two  25CM2  tissue  culture  flasks.  The  Ag  preparations, 
either  apoptotic  or  freeze-thawed  U266  cells  suspended  at  1  x1  07/ml,  were  addeo 
to  a  final  ratio  of  1  iDC  to  1  tumour  cell  (equivalent  to  an  approximate  protein 
concentration  of  1  mg/ml)  (Thumann,  et  al  2003).  The  X4  or  MIMIC  maturation 
cytokine  combinations  were  added  immediately  and  the  cells  were  cultured 
overnight  at  37"C  (Thumann,  et  a/  2003),  with  tissue  culture  flasks  standing  up- 
right  to  improve  cell  contact  and  phagocytosis.  The  following  morning  2A  06 
matDC  generated  with  the  X4  and  MIMIC  cytokine  combinations  were  removed  for 
flow  cytometric  analysis  of  their  surface  phenotype  (Figure  4-7a  and  b). 
The  results  of  the  phenotypic  analyses  of  matDC  from  ND  and  MM  patients  are 
surnmarised  in  Table  4-2.  In  ND,  both  X4  (n=15)  and  MIMIC  (n=14)  induced  up 
regulation  of  the  costimulatory  molecules  CD40,  CD80,  CD83,  CD86,  HLA-DR  and 
HLA-Class  1,  with  X4  producing  significantly  higher  expression  of  CD80  (mean 
17.1  +  1.8)  compared  to  MIMIC  (mean  9.7  +  1.5,  pýý0.02).  The  expression  of 
CCR7  in  both  groups  was  disappointing,  but  the  proportion  of  positive  cells  and 
the  level  of  expression  were  higher  in  the  X4  treated  matDC  (mean  12.1  +  2.3%. 
mean  3.3  +  0.9)  as  compared  to  the  MIMIC  treated  group  mean  (mean  9.4  +  1.8% 
p<O.  05,  mean  1.8  ±  0.6  p<O.  05). Dr  Simon  J  Harrison,  2005 
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Figure  4-7  Surface  phenotype  of  ND  matDC  matured  overnight  with  the  X4 
(A)  and  MIMIC  (B)  cytokine  combinations 
DC  were  gated  on  using  forward  and  side  scatter,  and  expression  of  CD1  1c. 
The  MM  matDC  had  broadly  similar  expression  of  costimulatory  molecules  and 
CCR7.  The  only  exception  was  that  the  X4  group  had  significantly  higher 
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proportion  of  CD83  positive  cells  than  the  MIMIC  treated  matDC  (mean  65.5 
5.6%  vs.  46.3  +  8.3%,  p:  SO.  05).  The  level  of  CD83  expression  was  also  hg  er  in 
the  X4  matDC,  but  this  failed  to  reach  statistical  significance. 
All 
Normal  Donor 
X4  mimic  All 
MM  Patient 
X4  mimic 
76  6+3  9%  79.7  +  4.6%  73.3  +6.4%  65.6+5.2%  70.8  +  5.3%  56.0  +  11.0%  CD40  .  .  43.0±6.1  42.7  ±  6.7  43.3  ±10.8  24.8+3.3  27.8+3.8  19.1+6.7 
6+4.6%  59  67.2+6.4%  51.4+6.2%  64.3+5.4%  70.0+6.0%  53.4+10.6%  CDBO  .  13.6  ±1.3  17.1  ±1.8  9.7  ±1.5  11  15.9+1.8  17.6+2.0  12.8+3.7 
4%  72  1+4  77.1+5.5%  66.8  +  6.7%  58.9  +  4.9%  65.5+5.6%  46.3+8.3%  CD83  .  .  30.7  ±4.0  36.4  ±6.6  24.6  ±3.7  15.8+2.3  17.5+6.7  12.5+2.7 
9+3  1%  91  94.1+3.3%  89.6+5.6%  87.7+1.9%  +2.3%  88.8  85.7+3.5%  CD86  .  .  366  ±  57.0  332  ±  77.4  403  ±  85.6  157+32.1  -  158+41.9  143+50.9 
8+1  4%  10  12  1+2.3%  9.4+1.8%  6.5+1.7%  8.3+2.5%  3.1+0.6%  CCR7  .  .  2.6  ±0.6 
.  3.3  ±0.9  1.870.6  4.573.3  1.4+0.4  1.4+0.9 
HLA-  95.6+1.5%  95.1+1.8%  96.1+2.5% 
- 
97.7+4.1%  95.2+1.0%  95.2+12.1% 
DR  394  48.9  371765.1  419  75.5  213731.4  262+41.4  121+30.2 
HLA-  96.4+1.0%  96.3+1.7%  96.5+1.2%  87.2+2.6%  89.3+2.9%  83.2+5.0% 
Class  1  169+18.4  181+24.3  155+28.3  123+22.5  145+30.0  83.5+30.5 
Table  4-2  Phenotype  of  ND  and  MM  matDC  generated  with  X4  and  MIMIC 
cytokine  combinations 
Immature  DC  from  ND  (n=1  1)  and  MM  (n=9)  patients  were  loaded  with  Ag  and 
simultaneously  matured  by  overnight  culture  with  the  X4  (ND  s=1  5,  MM  s=1  9)  or 
MIMIC  cytokine  combination  (ND  s=14,  MM  s=7).  The  results  are  shown  as  the 
mean  percentage  expression  +  SEM  (top  line)  and  the  mean  MFI  +  SEM  (bottom 
line). 
The  results  of  the  surface  phenotype  of  MM  matDC  were  compared  to  those  from 
ND. It  was  found  that  the  levels  of  CD40  (mean  24.8  +  3.3  vs.  43.3  +  6.1, 
p:  SO.  002),  CD83  (mean  58.9  +  4.9%  vs.  72.1  +  4.4%,  p:!  jO.  05  and  15.8  +  2.3  vs. 
30.7  +  4.0,  p:  SO.  002),  CD86  (mean  156.9  +  32.1  vs.  366.3  +  57.0,  p:  SO.  002),  HLA- 
DR  (mean  213.0  +  31.4  vs.  mean  394.0  +  48.9,  p:!  iO.  005)  and  HLA-Class  I  (mean Dr  Simon  J  Harrison,  2005  Chapter  4-125 
87.2  +  2.6%  vs.  96.4  +  1.0%,  p<0.002)  expression  were  significantly  reduced 
(Figure  4-8).  The  level  of  CD80  and  CCR7  expression  was  similar  in  the  both 
groups. 
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Figure  4-8  Co-stimulatory  markers  on  ND  and  MM  matDC 
Mature  DC  were  generated  from  ND  and  MM  patient  DC  by  loading  with  Ag  and 
overnight  incubation  with  the  X4  or  MIMIC  combination  of  cytokines.  Samples 
were  analysed  for  surface  expression  of  co-stimulatory  molecules  by  flow 
cytometry. Dr  Simon  J  Hardson,  2005  Chapter  4-126 
Although  the  expression  of  the  co-stimulatory  molecules  on  both  ND  and  matDC 
following  either  the  X4  or  MIMIC  cytokine  combination  was  satisfactory,  the  level 
of  CCR7  up  regulation  was  poor.  Therefore,  the  expression  of  CCR7  on  ND 
matDC  was  examined  after  an  additional  24hrs  incubation  in  X4  maturation 
medium  (n=4)  or  after  24  hours  interacting  with  autologous  T  cells  (n=6)  isolated 
from  the  apheresis  sample  by  anti-CD3  magnetic  bead  isolation  and  cryo- 
preserved  in  LN2  until  the  day  of  the  assay.  The  cells  were  placed  in  24  well  plates 
(Corning)  at  a  ratio  of  1  DC  (JX105/ml)  to  10  T  cells  (1  X1  06/M  1)  in  TC  medium.  The 
surface  expression  of  CCR5  and  7  was  analysed  by  flow  cytometry  (Figure  4-9) 
with  live  matDC  gated  by  forward  and  side  scatter  in  both  analyses,  as  there  was  a 
clear  separation  between  matDC  and  T  cells  in  the  co-culture  experiments. 
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Figure  4-9  CCR5  and  7  expression  on  ND  matDC  after  an  extra  24  hrs  culture 
in  X4  supplemented  media  or  co-culture  with  autologous  T  cells 
Immature  DC  were  cultured  in  X4  supplemented  DC  medium  for  overnight.  Cells 
were  divided  into  two  aliquots.  The  first  was  cultured  in  X4  supplemented  medium 
for  a  further  24  hrs  (left),  while  the  second  aliquot  was  cultured  with  autologous  T 
cells  at  a  ratio  of  1  DC  to  10  T  cells  for  24hrs  (right).  The  surface  phenotype  of  the 
cells  was  then  analysed  by  flow  cytometry. 
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There  was  a  highly  statistically  significant  up  regulation  of  CCR7  expreýsion  in  ND 
mat  DC  culture  for  42  hours  in  X4  (32.4  +  15.7%  and  13.4  +  6.3)  as  compared  with 
overnight  culture  (10.8  +  1.4%  and  2.6  +  0.6,  p<0.001).  Extended  culture  in 
maturation  media,  or  24hrs  co-culture  with  autologous  T  cells  produced  no 
significant  differences  in  the  level  of  CCR7  expression  (13.4  +  6.3  vs.  1  ?.  7  +  2.4) 
or  the  proportion  of  positive  cells  (32.4  +  15.7%  vs.  28.69  +  7.6%),  as  shown  in 
Figure  4-10.  There  was  no  significant  increase  in  the  level  of  expression  of  the 
other  co-stimulatory  molecules  in  either  the  extended  X4  or  T  cell  matDC.  Thesq 
findings  indicate  that  DC  rapidly  up  regulate  surface  expression  of  co-stimulatory 
markers  during  maturation.  However,  the  level  of  CCR7  expression  continues  to 
increase  with  prolonged  exposure  to  a  maturation  stimulus,  such  as  cytokine  or  T 
cells. 
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Figure  4-10  CCR7  expression  on  ND  mat  DC  after  overnight  maturation 
compared  with  an  additional  24hrs  maturation  or  24  hrs  co-culture  with 
autologous  T  cells 
ND  DC  were  incubated  with  X4  overnight  to  induce  maturation.  The  surface 
expression  of  CCR7  was  measure  by  surface  antibody staining  and  flow  cytometry 
(A).  Two  aliquots  of  cells  were  culture  for  a  further  24hrs  in  either  X4  or  in  co- 
culture  with  auto  T  cells,  isolated  by  CD3  magnetic  bead  isolation,  at  a  ratio  of  10 
T  cell  to  1  DC  and  the  CCR7  expression  measured  by  flow  cytometry  (B). 
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4.1.5  Discussion 
Chapter  4-128 
Dendritic  cell  based  immune  therapy  of  MM  has  thus  far  failed  to  produce 
significant  benefits  to  patients  in  terms  of  time  to  progression  and  OS.  If  we  are  to 
generate  meaningful  clinical  responses,  we  must  learn  how  to  induce  autologous 
matDC  from  MM  patients  that  are  able  to  migrate  efficiently  to  lymph  nodes  using 
chemokine  receptors.  Once  there,  anti-MM  matDC  should  prime  an  immunogenic 
response  to  the  turnour  Ags  by  the  interaction  of  matDC  and  T  cell  via  the  HLA-Ag 
complex  and  T  cell  receptor,  and  driven  by  the  matDC  co-stimulatory  molecule 
expression  profile.  During  this  process,  the  therapeutic  DC  should  be  resistant  to 
the  hostile  in-vivo  cytokine  environment  generated  by  the  MM  tumour  plasma  cell. 
These  experiments  shown  that,  as  with  the  circulating  BDC,  monocytes  from  MM 
patients  are  already  different  from  ND  monocytes.  They  have  reduced  expression 
of  CD86,  HLA-DR  and  CCR5,  thus  the  building  blocks  of  the  cellular  therapy  would 
seem  to  be  abnormal.  These  changes  are  almost  certainly  induced  by  cytokines, 
such  as  IL-6  and  TGF-P,  produced  by  the  MM  plasma  cells.  The  reduction  of 
CCR5  is  interesting  in  that  it's  ligand,  MIP-l  a,  is  present  in  increased  amounts  in 
MM  patients  and  it  correlates  with  the  extent  of  MM  bone  disease  and  survival 
(Terpos,  eta/  2003).  The  increased  MIP-1  a  levels  may  directly  lead  to  a 
homeostatic  down  regulation  of  CCR5  expression  on  MM  monocytes,  interfering 
with  their  ability  to  respond  to  pro-inflammatory  chemokines. 
Using  CD14  positively  selected  monocytes  collected  during  stem  cell  mobilisation, 
iDC  were  produced  using  either  GM-CSF/IL-4  or  GM-CSF/IL-13  from  both  ND  and 
MM  patients.  Within  the  two  subject  groups,  the  cytokines  used  to  generate  the 
DC  made  little  impact  on  the  quality  of  the  cells  that  were  produced  in  terms  of 
their  phenotype  and  phagocytic  function.  However,  when  MM  iDC  were  compared Dr  Simon  J  Harrison,  2005  Chapter  4-129 
with  ND  iDC  they  were  found  to  be  of  infefior  quality.  The  surface  expression  of 
CD1  a,  CD1c,  CD86,  HLA-DR  and  CCR5  was  significantly  reduced  on  MM  iDC, 
and  their  ability  to  phagocytose  Ag  was  also  significantly  impaired,  as  measured 
by  the  fluorescent  latex  bead  and  tumour  cell  assays.  It  was  not  possible  to 
overcome  these  deficiencies  in  the  MM  iDC  using  either  of  the  cytokine 
combinations  chosen  to  generate  iDC.  The  question  that  was  addressed  next  wps 
whether  the  X4  or  MIMIC  maturation  cytokine  combinations  were  able  to  produce 
improved  maturation  of  the  MM  iDC. 
The  maturity  of  the  DC  used  in  immunotherapy  is  crucial.  Immature  DC  will  tend  to 
induce  a  toleragenic  rather  than  immunogenic  T  cell  response.  It  was  hoped  that 
by  maximising  the  maturation  stimulus  it  might  be  possible  to  overcome  the 
inhibition  of  MM  DC  maturation  previously  reported.  The  X4  and  MIMIC  cytokine 
combinations  were  given  to  the  iDC  from  ND  and  MM  patients  in  overnight  culture 
at  the  same  time  as  the  Ag  preparations  for  two  reasons;  firstly  to  speed  up  the 
process  of  DC  production,  and  secondly  to  give  the  Ag  in  the  context  of  a  pro- 
inflammatory  environment,  in  a  bid  to  increase  the  chances  of  generating  an 
immunogenic  rather  than  a  toleragenic  response  to  the  chosen  Ag.  ND  matDC 
generated  with  X4  had  an  increase  in  the  expression  of  CD80  and  CCR7 
compared  to  MIMIC  matured  matDC,  while  the  MM  X4  matDC  had  an  increase  in 
CD83  expression.  Unfortunately,  MM  matDC  had  significantly  reduced  CD40, 
CD83,  CD86,  HLA-DR  and  Class  I  expression  compared  to  ND  matDC 
irrespective  of  the  maturation  cytokine  combination  used.  The  level  of  CCR7 
expression  was  disappointing  in  both  ND  and  MM  patient  cells.  We  went  on  to 
show  that  this  continues  to  up  regulate  for  24hrs  when  ND  DC  are  cultured  with 
cytokines  or  autologous  T  cells,  thus  increasing  the  time  in  the  cytokine 
combination  media  seems  to  have  no  benefit  over  placing  the  mat  DC  in  culture 
with  T  cells  in-vitro.  However  in-vivo,  DC  need  to  migrate  to  lymph  nodes  in  order Dr  Simon  J  Harfison,  2005  Chapter  4-130 
to  encounter  naive  T  cells  to  interact  with.  Thus  when  producing  matDC  for  use  in 
patients,  extending  the  time  spent  in  maturation  media  is  likely  to  be  of  benefit,  as 
the  DC  need  to  be  administered  in  a  state  that  enables  them  to  migrate 
immediately  to  lymph  nodes. 
Overall  these  results  show  that  MoDC  from  MM  patients  are  phenotypically  and 
functionally  abnormal  at  all  stages  of  the  production  process,  including  the  freshly 
isolated  monocytes.  It  was  not  possible  to  completely  overcome  these  defects 
using  the  various  combinations  of  cytokines,  however,  cells  generated  with  IL-4  or 
11-13,  and  matured  with  X4,  produced  the  best  quality  matDC.  In  order  to  further 
improve  the  quality  of  DC  obtained  from  MM  patients  a  number  of  strategies  could 
be  investigated.  Monocytes  were  obtained  from  MM  patients  that  had  been 
harvested  following  chemotherapy  and  G-CSF,  rather  than  G-CSF  alone,  as  in  the 
ND  group.  In  order  to  examine  the  impact  of  the  mobilisation  regimen  on  DC 
production  on  cells  from  MM  patients'  further,  chemo-mobilised  cells  from  could  be 
compared  with  monocytes  obtained  with  G-CSF  alone  or  collected  in  a  steady 
state.  It  is  not  ethical  to  mobilise  cells  from  ND  using  chemotherapy.  To  examine 
the  impact  of  MM  on  the  quality  of  DC  produced  using  chemo-mobilised  cells,  it 
may  be  better  to  compare  MM  cells  to  those  collected  from  patients  with  malignant 
diseases  such  as  Non-Hodgkin's  Lymphoma  (NHL),  as  these  conditions  are  not 
thought  to  have  a  significant  negative  impact  on  the  host  immune  system. 
The  experiments  described  in  this  chapter,  cells  were  collected  at  an  unspecified 
level  of  residual  disease.  Therefore  it  is  not  possible  to  say  whether  cells  collected 
from  patients  with  a  higher  level  of  residual  disease  produced  DC  that  were  of 
poorer  quality  than  those  from  patients  with  undetectable  disease.  This  is  an 
obvious  comparison  to  perform  in  future  studies.  Finally,  there  are  other 
compounds  such,  as  IFN-a,  that  have  been  used  for  MoDC  production,  and  the Dr  Simon  J  Harrison,  2005  Chapter  4-131 
use  of  more  novel  cytokine  combinations  for  DC  production  could  be  examined  in 
mm. 
In  conclusion,  matDC  were  produced  from  MM  patients  and  ND  using  monocytes 
mobilised  at  the  time  of  stem  cell  collection.  The  matDC  produced  from  MM 
patients  were  of  poorer  quality  as  compared  to  those  from  ND,  despite  using 
combinations  of  GM/IL-4,  GM/IL-13,  X4  and  MIMIC  in  the  production  prpcess.  Te 
combinations  that  contained  the  X4  maturation  cocktail  produced  the  best  quali 
matDC.  In  the  next  chapter  the  functional  interaction  of  MM  matDC  with 
autologous  MM  T  cells  will  be  discussed. Dr  Simon  J  Harrison,  2005  Chapter  5-132 
5.  Results  3 
5.1  Optimisation  of  autologous  anti-MM  cytotoxic  T  cell 
production  using  matDC  and  T  cell  pre-stimulation 
5.1.1  Introduction 
Dendritic  cells  are  crucial  to  the  initiation  and  co-ordination of  the  immune 
response.  However,  one  of  the  most  important,  complex,  and  perhaps  least 
understood  parts  of  this  process,  is  the  interaction  of  DC  with  immune  effector 
cells  such  as  T,  NK  and  NKT  cells.  These  interactions  require  close  cell-to-cell 
contact  and  the  interface  between  DC  and  T  cells  via  receptors  and  cytokines  has 
become  known  as  the  immunological  synapse  (Creusot,  et  al  2002).  In  this 
chapter  we  will  concentrate  on  the  interaction  between  DC  and  T  cells,  one  of  the 
main  effector  cells  of  the  adaptive  immune  system.  Na*fve  T  cells  can  be  primed  by 
DC  to  differentiate  into  antigen  specific  cytotoxic  T  cells,  and  this  is  the  main  goal 
when  using  DC  as  an  anti-tumour  immune  therapy,  where  the  antigen  is  an  tumour 
specific  one.  Unfortunately,  this  is  not  the  only  possible  outcome  of  this  interaction. 
Depending  on  the  state  of  DC  maturation  (Benvenuti,  et  al  2004),  the  affinity  of  the 
T  cell  receptor  for  the  antigen  being  presented,  the  availability  of  T  cell 
help/regulation  and  the  cytokine  environment,  DC  may  induce  abortive  T  cell 
proliferation,  T  regs  (Fiore,  et  a/  2005)  or  even  clonal  deletion.  T  cells  are  also 
susceptible  to  the  immunosuppressive  effects  of  the  MM  turnour  cells  induced  by 
cytokines  such  as  IL-6,  IL-10,  TGF-P  and  VEGF. 
Previously,  our  group  has  described  a  defect  in  MM  T  cells,  induced  by  TGF-P, 
which  prevented  normal  T  cell  proliferation  in  response  to  IL-2  (Cook,  et  a/  1999). 
It  was  also  reported  that  pre-stimulation  with  anti-CD3  antibody  and  IL-1  5 
reinstates  the  MM  T  cell  proliferative  response  to  IL-2.  It  is  not  known  whether  this Dr  Simon  J  Harrison,  2005  Chapter  5-133 
method  of  reinstating  the  T  cell  response  to  IL-2  can  be  transferred  to  the  DC:  T 
cell  interaction,  thus  improving  the  proliferative  capacity  of  T  cells  in  response  to 
DC  stimulation  alone,  or  combined  with  IL-2.  It  is  also  not  known  whether  this  can, 
in  turn,  increase  the  ability  of  antigen  primed  MM  T  cells  to  kill  MM  turnour  cells. 
The  aims  of  the  expedments  described  in  this  chapter  are  to  answer  the  following 
questions. 
1.  Can  MM  T  cell  pre-stimulation  improve  the  proliferative  response  to  DC 
alone  and  in  combination  with  IL-2? 
2.  Do  MM  matDC  produced  with  the  MIMIC  or  X4  cytokine  combinations 
have  the  same  ability  to  induce  MM  T  cell  proliferation? 
3.  Does  the  cytokine  profile  produced  during  the  DC:  T  cell  interaction  vary 
with  T  cell  pre-stimulation? 
4.  Are  pre-stimulated,  DC  primed  MM  T  cells  better  able  to  kill  MM  tumour 
cells  compared  to  un-stimulated  and  ND  T  cells? 
5.1.2  AID  and  MM  T  cell  proliferation  in  response  to  IL-2  with  and 
without  T  cell  pre-stimulation. 
In  the  published  experiments  that  showed  pre-stimulation  of  MM  T  cells  with  anti- 
CD3  antibody  and  IL-15  improved  the  proliferative  response  of  MM  T  cells  to  IL-2, 
we  used  tissue  culture  plates  pre-coated  with  anti-CD3  antibody.  This  is  a 
relatively  inefficient  method  to  stimulate  T  cells,  as  the  antibody  is  only  available  in 
one  plane  of  the  T  cell  at  a  time.  Physiologically,  T  cells  are  stimulated  in  3- 
dimensions,  and  grow  best  when  allowed  to  form  cell  balls  or  clusters.  To  improve 
the  efficiency  of  our  pre-stimulation  system  we  substituted  the  pre-coated plates Dr  Simon  J  Harrison,  2005  Chapter  5-134 
with  T  cell  activation  beads  (a  kind  gift,  Dr  John  Campbell,  Miltenyi  Biotec),  which 
are  inert,  magnetic  particles  conjugated  to  anti-biotin  monoclonal  antibody.  This 
facilitates  the  beads  being  loaded  with  biotinylated  molecules,  in  our  carpe  anti- 
CD2,  anti-CD3  and  anti-CD28. 
T  cells  were  collected  from  ND  and  MM  patients  at  the  time  of  stem  cell  harvest 
and  prepared  by  density  gradient  separation  and  anti-CD3  magnetic  bead 
isolation.  Sixty  percent  of  the  T  cells  were  cryo-preserved,  while  40%  were  pre- 
stimulated  With  beads  and  either  IL-2  or  IL-15  (MM  cells  only).  Prior  to  re- 
stimulation  with  IL-2,  the  beads  were  removed  from  the  T  cells,  resuspended  at 
5x1  06/ml  in  T  cell  medium  and  cultured  overnight  in  6  well  tissue  culture  plates  tp 
rest.  The  cryo-preserved  T  cells  were  recovered,  washed  and  cultured  overnight  in 
T  cell  medium,  in  a6  well  plate  at  a  density  of  5x1  06/ml.  Both  cryopreserved  and 
Pre-stimulated  T  cells  were  then  used  in  T  cell  proliferation  and  DC  co-culture 
expe(iments. 
The  following  morning,  the  rested  T  cells  were  harvested  into  15ml  tubes, 
centrifuged  at  1200rpm  for  5mins  and  resuspended  in  fresh  warm  T  cell  medium  at 
5A  05/ml.  The  proliferation  assays  were  then  set  up  with  2  quad  sets  of  200pl 
samples  for  each  test  condition.  Interleukin-2  was  added  to  one  set  of  samples, 
final  concentration  20p/ml,  while  the  other  set  of  samples  acted  as  an  un- 
stimulated  control.  The  results  were  analysed  using  the  mean  values  of  the  total 
counts  for  each  sample  quad  minus  the  mean  of  the  background  rate  of 
proliferation  in  the  un-stimulated  control  quad  (Figure  5-1). 
There  was  no  statistical  difference  between  the  un-stimulated  ND  (mean 
13329+2569)  and  MM  (mean  10573+2228)  T  cell  proliferative  response  to  11-2. 
The  IL-2  proliferative  response  of  either  ND  (mean  22643+3403)  or  MM  (mean Dr  Simon  J  Harrison,  2005  Chapter  5-135 
24772+  5250)  T  cells  pre-stimulated  with  beads  and  IL-2  was  significantly 
enhanced  as  compared  to  un-stimulated  cells  (p<0.05  and  p<0.01  respectively). 
The  response  of  the  IL-15  and  bead  pre-stimulated  MM  T  cells  (mean 
12525+3130)  was  not  improved. 
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Figure  5-1  ND  and  MM  T  cell  proliferation  in  response  to  IL-2  with  and 
without  pre-stimulation 
T  cells  from  ND  and  MM  patients  were  isolated  using  anti-CD3  magnetic  beads  at 
the  time  of  stem  cell  harvest.  An  aliquot  of  cells  was  pre-stimulated  with  T  cell 
activation  beads  and  either  IL-2  or  IL-15  (MM  patients  only)  for  3  days.  The 
remaining  cells  were  cryopreserved  and  recovered  on  day  3.  Both  the  activated 
and  cryopreserved  cells  were  rested  over  night  and  then  set  up  at  1  X1  06/M  I  in  aT 
cell  proliferation  assay  with  and  without  IL-2  (201U/ml)  and  read  on  day  3  having 
been  exposed  to  3H-thymidine  for  the  final  18hrs. 
These  findings  would  appear  to  be  at  odds  with  our  previously  published  results. 
However,  our  previous  results  were  obtained  using  cells  from  MM  patients  at  the 
time  of  diagnosis.  The  cells  used  in  these  experiments  were  obtained  at  a  time 
when  the  patients  have  had  a  significant  amount  of  therapy,  and  the  disease Dr  Simon  J  Harrison,  2005  Chapter  5-136 
burden  is  likely  to  be  at  a  much  lower  level.  Consequently,  any  suppressive  effects 
of  tumour  cell  defived  TGFP  may  be  less  pronounced  or  absent. 
5.1.3  The  proliferative  response  of  ND  and'MM  cryopreserved  and 
pre-stimulated  T  cells  to  autologous  matDC  in  the  presence 
and  absence  of  IL-2 
In  our  next  set  of  experiments  we  examined  the  T  cell  proliferative  response,  with 
and  without  pre-stimulation,  to  autologous  matDC  from  ND  and  MM  patients  in  the 
presence  and  absence  of  exogenous  IL-2.  T  cells  and  monocytes  were  obtained  at 
the  time  of  stem  cell  harvest,  and  purified  by  density  gradient  centrifugation  and 
magnetic  bead  isolation.  Mature  dendritic  cells  were  generated  with  GM/lL-4  or 
GM/IL-13  and  simultaneously  loaded  with  antigen  (U266  apoptotic  cells  or  lysate 
preparation)  and  matured  with  the  X4  or  MIMIC  cytokine  combination.  T  cells  were 
pre-stimulated  with  T  cell  activation  beads,  and  either  I  L-2  or  I  L-1  5  for  4days,  then 
rested  overnight.  An  aliquot  of  T  cells  was  cryopreserved  to  act  as  an  un- 
stimulated  control. 
A  proliferation  assay  was  set  up  With  a  DC:  TC  ratio  of  1:  10  in  the  presence  and 
absence  of  IL-2  (201U/ml),  with  matDC  alone  and  T  cells  +  IL-2  as  controls.  The 
cultures  were  analysed  after  3  days  incubation  at  370C  and  the  results  are 
expressed  as  the  mean  number  for  DC:  TC  or  DC:  TC:  IL-2  quads  minus  the  means 
of  the  DC  and  T  cell  quads  alone,  as  shown  in  Figure  5-2. 
The  most  striking  observation  was  that  pre-stimulation  of  T  cells  blocks  the  ability 
of  ND  (mean  3815  +  1632)  and  MM  (mean  2492  +  874)  T  cells  to  proliferate  in 
response  to  matDC  as  compared  to  un-stimulated  T  cells  (ND  mean  12794  +  1455 
and  MM  10890  +  2542).  The  proliferative  response  of  un-stimulated  ND  and  MM  T Dr  Simon  J  Harrison,  2005  Chapter  5-137 
cells  to  matDC  alone  was  similar  (mean  12794  +  1455  vs.  mean  10890  +  2542)  as 
was  the  result  obtained  using  pre-stimulated  T  cells  and  matDC  in  the  presence  of 
IL-2  (ND  mean  31501  +  3362  vs.  MM  30583  +  2397). 
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Figure  5-2  ND  (A)  and  MM  (B)  patient  un/pre-stimulated  T  cell  proliferative 
response  to  autologous  matDC  in  the  presence  and  absence  of 
IL-2 
ND  and  MM  T  cells  and  monocytes  were  isolated  at  the  time  of  stem  cell  harvest. 
An  aliquot  of  T  cells  was  cryopreserved  to  act  as  controls;  the  remainder  were 
stimulated  for  4  days  with  T  cell  activation  beads  and  either  IL-2  or  11-15  and  the 
rested  overnight.  Monocytes  were  cultured  with  GM/IL-4  or  GM/IL-1  3  for  4  days, 
and  then  simultaneously  loaded  with  antigen  and  matured  with  the  X4  or  MIMIC 
cytokine  combinations.  The  Proliferation  assays  were  set  up  in  quadruplicate  at  a 
DC:  TC  ratio  of  1:  10  +  IL-2  (201U/ml)  with  stimulated  and  un-stimulated  T  cells.  T 
cells  +  IL-2  and  DC  alone  were  used  as  positive  and  negative  controls.  The  results 
represent  the  mean  of  each  test  quad  minus  the  means  of  the  T  cells  and  DC 
alone  quads. 
There  was  a  trend  for  the  ND  T  cell  +DC  +  IL-2  proliferation  (mean  31259  +  3838) 
to  be  higher  than  that  seen  in  the  MM  patients  (mean  24246  +  4381),  but  this  did 
not  achieve  statistical  significance.  The  pre-stimulated  MM  T  cells  proliferated 
better  in  response  to  matDC  and  IL-2  (mean  30583  +  2397),  as  compared  to  the 
un-stimulated  MM  T  cells  (mean  24246  +  4381),  but  this  again  failed  to  achieve 
statistical  significance. Dr  Simon  J  Harrison,  2005  Chapter  5-138 
We  went  on  to  examine  whether  the  DC  maturation  cytokine  combination  or  the 
cytokine  used  for  the  T  cell  stimulation  had  an  impact  on  the  proliferative  response 
of  the  T  cells  to  DC  in  the  presence  and  absence  of  IL-2  (Figure  5-3). 
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Figure  5-3  ND  and  MM  patient  un-stimulated  and  pre-stimulated  T  cell 
proliferative  response  to  autologous  X4  and  MIMIC  matDC 
ND  and  MM  T  cells  and  monocytes  were  isolated  at  the  time  of  stem  cell  harvest. 
An  aliquot  of  T  cells  was  cryopreserved  to  act  as  controls;  the  remainder  were 
stimulated  for  4  days  with  T  cell  activation  beads  and  IL-2  or  11-15  and  the  rested 
overnight.  Monocytes  were  cultured  with  GM/IL-4  or  GM/IL-1  3  for  4  days,  and  then 
simultaneously  loaded  with  antigen and  matured  with  the  X4  or  MIMIC  cytokine 
combinations.  The  Proliferation  assays  were  set  up  in  quadruplicate  at  a  DC:  TC 
ratio  of  1:  10  +  IL-2  (201U/ml)  with  stimulated  and  un-stimulated  T  cells.  T  cells  +  IL- 
2  and  DC  alone  were  used  as  positive  and  negative  controls.  The  results 
represent  the  mean  of  each  quad,  minus  the  means  of  the  T  cells  and  DC  alone 
quads. Dr  Simon  J  Harrison,  2005  Chapter  5-139 
Although  the  proliferation  of  un-stimulated  T  cells  was  greater  with  MIMIC  than  X4 
matDC  in  both  the  ND  and  MM  patients,  there  were  no  significant  differences  in 
the  ability  of  ND  or  MM  patient  matDC  generated  with  X4  or  MIMIC  to  induce 
control  or  pre-stimulated  T  cell  proliferation  and  the  results  are  summarised  in 
Table  5-1. 
DC  TC  DC  TC  IL-2  Pre  Stim  Pre  Stim 
DC  TC  DC  TC  IL-2 
ND  X4 
10108  27150  2245  30365 
+1755  +5279  +1363  +4865 
ND  MIMIC 
14344  33640  5032  31595 
+2258  +4325  +2780  +4484 
10468  22378  2502  30582  MM  X4 
+3326  +5045  +1115  +3046 
mm  mimic  11624  27107  2476  30585 
+2972  +5981  +1462  +4104 
Table  5-1  ND  and  MM  patient  mean  and  SEM  of  control  and  pre-stimulated  T 
cell  proliferation  in  response  to  X4  and  MIMIC  matDC 
We  found  that  there  was  a  trend  for  the  proliferation  of  MM  T  cells  pre-stimulated 
with  beads  and  IL-2  in  response  to  matDC,  in  the  presence  of  IL-2  (mean  33626 
2936)  to  be  greater  than  MM  T  cells  stimulated  with  beads  and  IL-1  5  (mean  23737 
7458),  but  this  just  failed  to  achieve  statistical  significance  (p=0.055),  Figure 
5-4. 
In  summary,  we  found  that  T  cells  collected  at  the  time  of  stem  cell  harvest  are 
able  to  proliferate  relatively  normally  in  response  to  IL-2.  Pre-stimulation  of  ND  and 
MM  patient  T  cells  with  anti-CD2,  anti-CD3  and  anti-CD28  coated  beads,  and  IL-2, 
significantly  increases  their  proliferative  response  to  IL-2,  but  pre-stimulation  of 
MM  T  cells  with  beads  and  IL-1  5  had  no  significant  effect. Chapter  5-140 
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Figure  5-4  The  proliferative  response  of  ND  and  MM  patient  T  cells  pre- 
stimulated  with  beads  and  IL-2  or  IL-15  to  matDC  in  the  presence 
of  IL-2 
ND  and  MM  T  cells  and  monocytes  were  isolated  at  the  time  of  stem  cell  harvest. 
An  aliquot  of  T  cells  was  cryopreserved  to  act  as  controls;  the  remainder  were 
stimulated  for  4  days  with  T  cell  activation  beads  and  IL-2  or  IL15  and  the  rested 
overnight.  Monocytes  were  cultured  with  GM/IL-4  or  GM/IL-1  3  for  4  days,  and  then 
simultaneously  loaded  with  antigen  and  matured  with  the  X4  or  MIMIC  cytokine 
combinations.  The  Proliferation  assays  were  set  up  in  quadruplicate  at  a  DC:  TC 
ratio  of  1:  10  +  IL-2  (201U/ml)  with  stimulated  and  un-stimulated  T  cells.  T  cells  +  IL- 
2  and  DC  alone  were  used  as  positive  and  negative  controls.  The  results 
represent  the  mean  of  each  quad  minus  the  means  of  the  T  cells  and  DC  alone 
quads. 
Pre-stimulation  blocks  the  proliferative  response  of  ND  and  MM  patient  T  cells  to 
autologous  matDC  alone.  Although  the  proliferation  of  pre-stimulated  T  cells  in  the 
presence  of  IL-2  and  mat  DC  was  higher  than  the  un-stimulated  T  cells,  it  did  not 
achieve  statistical  significance.  The  proliferation  of  MM  T  cells  pre-stimulated  with 
beads  and  IL-2  induced  by  autologous  mat  DC  in  the  presence  of  IL-2  was 
significantly  better  than  that  achieved  by  those  pre-stimulated  with  beads  and  U 
15 Dr  Simon  J  HarTison,  2005  Chapter  5-141 
5.1.4  The  measurement  of  cytokines  secreted  during  the  T  cell 
matDC  interaction  by  Luminex  technology  from  MM  patients 
and  ND 
The  interaction  between  T  cells  and  DC  is  complex,  and  involves  both  contact  and 
cytokine  dependant  processes.  Cytokines,  such  as  IL-2,  may  be  secreted  within 
the  immunological  synapse,  while  others  may  be  secreted  in  a  more  generalised 
manner.  Traditionally  these  cytokines  have  been  detected  using  a  solid  phase  (96 
well  plate)  ELISA  for  each  analyte  to  be  measured,  making  it  difficult  to  measure  a 
number  of  cytokines  because  of  cost,  the  size  of  the  sample  required  and  the  time 
taken  for  each  ELISA.  Luminex  technology  allows  multiple  different  ELISAs  to  be 
performed  concurrently  on  the  same  sample  in  the  same  well  (Carson  and  Vignali 
1999). 
This  has  been  achieved  by  linking  the  capture  antibody  for  each  analyte  to  a 
polystyrene  bead  that  has  a  unique  and  fixed  fluorescence  signature  (Vignali 
2000).  This  signature  is  achieved  by  mixing  two  fluorescent  dyes  in  up  to  100 
different  ratios  to  allow  labelling  of  100  different  analytes  simultaneously.  The 
detection  antibody  is biotinylated,  and  the  binding  of  a  streptavidin-PE  conjugate 
to  the  detection  antibody  allows  the  system  to  identify  beads  that  have  bound  to 
their  specific  analyte.  The  detection  system  is  based  around  two  lasers  and  a  flow 
cell  similar  to  that  of  a  flow  cytometer.  The  sample  is  passed  through  the  beams  of 
each  laser  sequentially  in  a  stream  that  allows  one  bead  to  be  interrogated  by  the 
laser  at  a  time.  The  first  laser  determines  the  identity  of  the  bead  (i.  e.  which 
analyte  is being  detected),  and  the  second  laser  determines  whether  there  is 
analyte  bound  to  the  bead,  i.  e.  is  there  Strep-PE  bound  to  the  bead?  The  machipe 
aspirates  a  fixed  volume  of  sample  and  the  concentration  of  beads  is  fixed, Dr  Simon  J  Hanison,  2005  Chapter  5-142 
allowing  the  analysis  software  to  calculate  the  concentration  of  each  analyte  to  be 
measured. 
The  DC  and  T  cells  used  in  these  experiments  were  prepared  as  described  above 
in  5.1.3,  washed  once  in  fresh  T  cell  medium  and  co-cultured  at  a  ratio  of  1  DC 
(1  x1  06/ml)  to  10  T  cells  (1  x1  06/ml)  in  24  well  tissue  culture  plates.  The 
supernatants  were  collected  after  3  days,  snap  frozen  in  1.5ml  Eppendorf  tubes 
and  stored  at  minus  800C.  A  multiplex  kit  was  used  to  measure  GM-CSF,  IFN-a, 
IL-2,  IL-4,  IL-6,  IL-7,  IL-10,  IL-12p7O,  IL-15,  TNF-  a,  and  VEGF.  The  assay  was 
performed  as  per  the  manufacturers  instructions  and  read  on  a  Luminex  1  OOTm 
instrument.  Each  sample  was  analysed  in  duplicate  and  the  results  were 
expressed  as  the  mean  of  the  two  observations.  Data  was  obtained  from  38  DC  T 
cell  supernatants,  from  6  ND  and  4  MM  patients  and  is  shown  in  Figure  5-5.  The  T 
cells  from  2  ND  and  MM  patients  had  been  pre-stimulated  with  beads  and  IL-2, 
and  un-stimulated  T  cells  were  used  from  all  10  subjects. 
The  most  striking  observation  was  that  there  was  almost  no  IL-2  detected  in  the 
supernatant  from  the  reactions  in  which  T  cells  that  had  been  pre-stimulated  With  T 
cell  stimulation  beads  (mean  0.3pg/ml  +  0.1),  as  compared  to  un-stimulated  cells 
(mean  98.2pg/ml  +  33.42),  and  this  was  highly  statistically  significant  (p:  s  0.001). 
The  level  of  I  L-1  0  detected  in  the  un-stimulated  T  cell  group  (mean  62pg/ml  +  32) 
was  significantly  higher  than  the  bead-stimulated  cells  (mean  2pg/ml  +  2,  p:  SO.  01). 
The  amount  of  GM-CSF  (mean  348pg/ml  +  168,  p:  SO.  05)  and  TNF-a  (mean 
991pg/ml  +  470,  p:  ý0.01)  was  also  significantly  higher  in  the  un-stimulated  T  cell 
reaction  (mean  24.8pg/ml  +  14.6,  mean  18.6pg/ml  +  9.4  respectively)  as 
compared  to  the  bead-stimulated  cells. Dr  Simon  J  Harrison,  2005 
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Figure  5-5  IL-2,  IL-10,  GM-CSF  and  TNF-cx  levels  detected  in  the  supernatants 
of  ND  and  MM  DC  and  T  cell  co-cultures  by  LurninexTm 
technology 
To  facilitate  antigen  presentation,  DC  from  ND  (n=6)  and  MM  patients(n=4) 
produced  from  monocytes  collected  at  the  time  of  stem  cell  harvest,  cultured  with 
GM/IL-4  or  GM/IL-1  3,  Ag  primed  with  U266  cell  lysate  and  matured  with  X4  or 
MIMIC  cytokine  combination  were  co-cultured  with  T  cells  pre-stimulated  with 
beads  and  IL-2  (n=4,  MM=2,  ND=2)  or  cryopreserved  un-stimulated  cells  (n=10, 
MM=4,  ND=6).  The  supernatants  were  harvested  after  3  days  and  the  levels  of  IL- 
2,  IL-10,  GM-CSF  and  TNF-cx  were  measured  using  the  Luminex  system. 
There  was  some  concern  that  these  levels  could,  at  least  in  part,  have  been  due  to 
the  cytokines  added  to  the  DC  cultures  during  the  generation  of  maturation  phase. 
However,  all  cells  were  washed  prior  to  the  co-culture  experiments,  and  the  DC 
used  in  each  arm  of  the  experiments  had  had  identical  treatment  and  cytokine 
exposure. 
The  level  of  IL-6  detected  in  the  un-stimulated  T  cell  group  (mean  48.8pg/ml 
22.5)  was  similar  to  the  bead  stimulated  T  cell  group  (mean  31.0pg/ml  ±  4.8) Dr  Simon  J  Harrison,  2005  Chapter  5-144 
Figure  5-6.  However,  a  statistically  higher  amount  of  IL-6  was  detected  in  the 
supernatants  from  DC  matured  with  X4  cocktail  (mean  57.05pg/ml  +  9),  which 
contained  no  IL-6,  as  compared  with  MIMIC  matured  cells  (mean  31.8pg/ml  +  6, 
p<0.005),  which  were  exposed  to  lOng/ml  IL-6. 
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Figure  5-6  IL-6  levels  detected  in  the  supernatants  of  ND  and  MM  DC  and  T 
cell  co-cultures  by  LumineXTM  technology 
To  facilitate  antigen  presentation,  DC  from  ND  and  MM  patients  produced  from 
monocytes  collected  at  the  time  of  stem  cell  harvest,  cultured  with  GM/IL-4  or 
GMAL-13,  Ag  primed  with  U266  cell  lysate  and  matured  with  X4  or  MIMIC  cytokine 
combination  were  co-cultured  with  T  cells  pre-stimulated  with  beads  and  IL-2  or 
cryopreserved  un-stimulated  cells.  The  supernatants  were  harvested  after  3  days 
and  the  levels  of  IL-6  were  measured  using  the  Luminex  system. 
We  did  not  detect  any  significant  levels  of  IL-4,  IL-7,  IL-12p7O,  IL-15,  IFN-a  or 
VEGF.  Interestingly,  no  differences  in  cytokine  levels  were  detected  between  ND 
and  MM  cells,  or  between  the  cytokines  used  to  generate  the  DC. 
In  summary  the  LuminexTm  system  is  a  reliable,  straightforward  method  to  detect 
multiple  cytokines  simultaneously  in  small  volume  samples.  Pre-stimulation  of  T 
cells  with  T  cell  activating  beads  and  IL-2  significantly  reduces  the  amount  of  GM- 
CSF,  IL-2,  IL-10  and  TNF-a  detected  in  the  supernatants  of  T  cell,  DC  co-cultures, 
as  compared  to  those  using  un-stimulated  cells.  The  IL-6  detected  was  higher  in 
the  X4  matured  DC  cells.  No  significant  amounts  of  IL-4,  IL-7,  IL-12p7O,  IL-15, 
IFN-a  or  VEGF  were  found. Dr  Simon  J  Hanison,  2005  Phapter  5-145 
5.1.5  In-vitro  cytotoxicity  of  AID  and  MM  T  cells  following  co- 
culture  with  autologous  matDC  and  the  effect  of  T  cell  pre7 
stimulation  with  T  cell  activation  beads  and  IL-2 
The  anti-tumour  effects  of  DC  based  immune  therapies  are  mainly  mediated  via 
cytotoxic  T  cells,  although  a  number  of  groups  are  investigating  effects  that  may 
be  induced  by  the  interaction  of  DC  with  NK  and  NKT  cells.  In  order  to  quantify  the 
potency  of  the  cytotoxic  T  cells  generateed  from  ND  and  MM  patients,  it  was 
decided  to  use  a  modification  of  the  flow  cytometry  based  assay  in  which 
fluorescently  stained  target  tumour  cells  are  co-incubated  with  un-labelled  effector 
cells.  This  allows  the  target  cells  to  be  easily  gated  and  then  the  number  of  dead 
target  cells  can  be  quantified  by  annexin-V  (a  marker  of  early  apoptosis)  and  either 
I 
PI  or  MAD  (necrotic)  staining  (Derby,  et  al  2001,  Fischer,  et  al  2002).  In  these 
analyses  7AAD  was  used  rather  than  propidium  iodide  because it  has  much  less 
spectral  overlap  and  is  therefore  much  easier  to  compensate. 
The  first  set  of  experiments  investigated  whether  the  pre-stimulation  of  ND  and 
MM  patient  T  cells  with  T  cell  activation  beads  and  IL-2,  and  then  further 
expansion  with  IL-2  alone,  was  sufficient  to  induce  significant  cytotoxicity  using  the 
annexin-V/  MAD  assay.  T  cells  were  stimulated  for  3  or  4  days  with  T  cell 
activating  beads  and  IL-2.  The  beads  were  then  removed  and  the  T  cells  were 
expanded  in  IL-2  supplemented  TC  medium  for  2-4  weeks.  Prior  to  use  in  the 
cytotoxicity  assay  dead  cells  were  removed  by  density  gradient  centrifugation 
Cytotoxicity  assays  were  set  up  in  duplicate  with  effector:  target  cell  ratios  ranging 
from  16:  1  to  1:  16,  cultured  for  18hrs  and  the  assays  were  read  by  flow  cytometry 
within  1  hour  of  annexin-V  and  MAD  staining.  A  total  of  20,000  target  cell  events 
were  collected  per  tube  and  representative  plots  are  shown  in  Figure  5-7. Dr  Simon  J  Harrison,  2005 
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Figure  5-7  Cytotoxicity  assay  gating  for  controls  and  2  dilutions 
The  left-hand  plot  shows  that  only  cellular  events  are  gated  in  R1.  The  middle  plot 
shows  that  T  cells  are  excluded  from  the  analysis  using  R2.  The  right-hand  plot 
shows  that  >95%  are  alive  control  target  cells  in  the  logic  gate  G3  (R1  and  R2), 
less  than  1%  of  T  cells  appear  in  the  analysis,  and  that  the  cytotoxic  effects  of  the 
T  cells  are  dose  dependant. 
Foý"rd  Sc«w 
TC  v.  s.  Target  4:  1 Dr  Simon  J  Harrison,  2005  Chapter  5-147 
The  results  for  each  dilution  were  expressed  as  the  mean  number  of  dead  test 
cells  minus  the  number  of  dead  cells  in  the  Target  alone  control  and  the  results 
are  shown  in  Figure  5-8. 
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Figure  5-8  ND  and  MM  bead  pre-stimulated  T  cell  cytotoxicity  assay 
T  cells  from  ND(n=4)  and  MM  (n=5)  patients  were  collected  at  the  time  of  stem  cell 
harvest,  pre-stimulated  with  T  cell  activating  beads  and  IL-2  and  expanded  with  U 
2  for  2-4  weeks.  They  were  placed  in  culture  with  PKH-26  labelled  U266  MM  cell 
targets  at  effector  target  ratios  between  16:  1  and  1:  16,  incubated  overnight,  and 
the  degree  of  target  cell  kill  was  assessed  using  Annexin-V  and  7AAD  staining  by 
flow  cytometry. 
There  was  a  small  cytotoxic  effect  detected  at  the  highest  effector  target  ratio  8:  1 
using  MM  bead  T  cells,  with  a  mean  of  29.5%  +  8.3  of  targets  killed,  and  at  16:  1 
with  ND  bead  T  cells,  18.4%  +  7.4.  At  the  effector  target  ratio  of  8:  1,  MM  pre- 
stimulated  T  cells  produced  statistically  more  tumour  cell  kill  than  ND  pre- 
stimulated  T  cells  (p<  0.005).  There  was  no  difference  in  the  cytotoxic  activity  of 
pre-stimulated  T  cells  from  ND  or  MM  patients  at  any  other  dilution. Dr  Simon  J  Hardson,  2005  Chapter  5-148 
We  next  compared  the  cytotoxic  activity  of  MM  pre-stimulated  T  cells  with  T  cells 
that  had  also  had  been  primed  with  antigen  loaded  autologous  DC,  and  un- 
stimulated  T  cells  that  had  been  primed  with  antigen  loaded  autologous  DC, 
Figure  5-9. 
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Figure  5-9  Cytotoxicity  of  pre-stimulated  MM  T  cells,  DC  primed  pre- 
stimulated  MM  T  cells  and  DC  primed  un-stimulated  MM  T  cells 
T  cells  from  MM  patients  (n=5)  were  collected  at  the  time  of  stem  cell  harvest.  An 
aliquot  of  cells  was  cryopreserved  and  the  remainder  were  pre-stimulated  with  T 
cell  activating  beads  and  IL-2  for  3-4  days.  An  aliquot  of  pre-stimulated  T  cells  was 
expanded  with  IL-2  for  2-4  weeks  as  an  antigen  negative  control.  The  remainder  of 
the  pre-stimulated  cells,  and  the  cryo-preserved  un-stimulated  T  cells,  were 
primed  with  autologous  antigen  loaded  DC,  expanded  in  IL-2,  re-stimulated  with 
DC  after  7days  and  expanded  in  IL-2  for  3-6  weeks.  T  cells  were  placed  in  culture 
with  PKH-26  labelled  U266  MM  cell  targets  at  effector  target  ratios  between  8:  1 
and  1:  8,  incubated  overnight,  and  the  degree  of  target  cell  kill  was  assessed  using 
Annexin-V  and  7AAD  staining  by  flow  cytometry. 
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Pre-stimulated  MM  T  cells  primed  with  autologous  DC  were  significantly  more 
effective  at  killing  target  cells,  compared  to  un-stimulated,  DC  primed,  MM  T  cells 
with  (p<  0.05).  Pre-stimulated  T  cells  that  had  been  primed  with  autolo  9  ous  DC 
were  significantly  more  effective  at  killing  target  cells  at  all  ET  ratios  compared  to  T 
cells  that  had  only  been  pre-stimulated  with  beads  and  IL-2  (p<  0.05).  Although 
un-stimulated  DC  primed  T  cells  were  more  effective  at  killing  targets  compared  to 
pre-stimulated  only  T  cells,  this  did  not  reach  statistical  significance  at  Iny  effector 
target  ratio. 
The  results  obtained  using  ND  pre-stimulated  T  cells  were  then  compared  with 
those  generated  using  ND  un-stimulated  T  cells,  primed  with  autologous  antigen 
loaded  DC,  Figure  5-10.  Again  no  difference  was  observed  between  the  two 
groups  at  any  effector  target  ratio. 
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Figure  5-10  Cytotoxicity  of  pre-stimulated  ND  T  cells  and  DC  primed  un- 
stimulated  ND  T  cells 
T  cells  from  ND  (n=5)  were  collected  at  the  time  of  stem  cell  harvest.  An  aliquot  of 
cells  was  cryopreserved  and  the  remainder  were  pre-stimulated  with  T  cell 
activating  beads  and  IL-2  for  3-4  days  and  expanded  with  IL-2  for  2-4  weeks  as  an 
antigen  negative  control.  The  cryo-preserved  un-stimulated  T  cells  were  primed 
with  autologous  antigen  loaded  DC,  expanded  in  IL-2,  re-stimulated  with  DC  after 
7days  and  expanded  in  IL-2  for  3-6  weeks.  T  cells  were  placed  in  culture  with 
PKH-26  labelled  U266  MM  cell  targets  at  effector  target  ratios  between  8:  1  and 
1:  8,  incubated  overnight,  and  the  degree  of  target  cell  kill  was  assessed  using 
Annexin-V  and  MAD  staining  by  flow  cytometry. Dr  Simon  J  Harrison,  2005  Chapter  5-150 
In  the  final  analysis  the  effectiveness  of  MM  pre-stimulated  and  un-stimulated  T 
cells  were  compared  with  un-stimulated  ND  T  cells,  which  had  all  been  primed 
with  autologous  antigen  loaded  DC,  Figure  5-11. 
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Figure  5-11  Comparing  the  cytotoxicity  of  DC  primed  pre-stimulated  MM  T 
cells  (n=19)  with  DC  primed  un-stimulated  MM  (n=14)  and  ND  T 
cells  (n=20) 
T  cells  from  ND  (n=5)  and  MM  patients  (n=5)  were  collected  at  the  time  of  stem 
cell  harvest.  T  cells  were  cryopreserved.  An  aliquot  of  MM  T  cells  were  pre- 
stimulated  with  T  cell  activating  beads  and  IL-2  for  3-4  days  and  then  rested 
overnight.  All  T  cells  were  primed  with  autologous  antigen  loaded  DC,  expanded  in 
IL-2,  re-stimulated  with  DC  after  7days  and  expanded  in  IL-2  for  3-6  weeks.  T  cells 
were  placed  in  culture  with  PKH-26  labelled  U266  MM  cell  targets  at  effector  target 
ratios  between  8:  1  and  1:  8,  incubated  overnight,  and  the  degree  of  target  cell  kill 
was  assessed  using  Annexin-V  and  7AAD  staining  by  flow  cytometry. 
Multiple  myeloma  DC  primed,  pre-stimulated  T  cells  were  significantly  better  at 
killing  target  tumour  cells  compared  to  ND  un-stimulated  DC  primed  T  cells Dr  Simon  J  Hanison,  2005  Chapter  5-151 
(p:  S  0.001).  T  cells  from  MM  patients  that  had  only  been  primed  with  DC  were 
significantly  better  at  killing  targets  at  the  highest  two  effector  target  ratios 
(P:  s 
In  summary,  it  was  found  that  the  flow  cytometry  based  cytotoxicity  assay  was  an 
effective  way  of  determining  the  killing  ability  of  T  cell  line  generated  by  pre- 
stimulation  with  T  cell  activating  beads  and/or  antigen  loaded  autologous  DC.  The 
most  effective  cytotoxic  cells  were  MM  patient  T  cells  that  had  been  pre-stimulated 
and  primed  with  DC,  followed  by  MM  patient  T  cells  that  had  only  been  primed 
with  DC.  T  cells  from  ND  primed  with  DC,  MM  patient  and  ND  T  cells  pre- 
stimulated  with  T  cells  activating  beads  and  IL-2  were  relatively  ineffective  at  killing 
target  cells  in  this  assay.  This  observation  may  be  linked  to  the  conditions  under 
which  the  cells  were  originally  collected. 
5.1.6  Discussion 
Immune  based  therapies  are  normally  considered  for  use  in  patients  who  have 
malignant  disease,  such  as  MM.  When  designing  the  methods  for  the  production 
of  these  therapies  we  must  take  into  account  that  the  immune  systems  in  these 
patients  will  almost  certainly  not  be  normal.  This  may  be  due  to  a  number  of 
factors,  such  as  immune  suppression  by  the  malignant  clone,  the  effects  of 
previous  therapy  and  more  general  issues  such  as  nutrition  and  co-morbidities. 
The  cells  used  in  these  experiments  were  collected  at  a  time  when  the  MM 
patients  had  received  at  least  6  courses  of  MM  induction  therapy  and  a  course  of 
intravenous  cyclophosphamide  prior  to  the  start  of  G-CSF  for  the  mobilisation  of 
stem  cells.  In  contrast,  the  previously  published  experiments  (Campbell,  et  al 
2001)  used  cells  from  MM  patients  who  were  at  diagnosis  and  so  the  immune 
systems  were  likely  to  have  been  subject  to  a  greater  disease  burden  at  that  time. Dr  Simon  J  HarTison,  2005  Chapter  5-152 
This  is  likely  to  be  at  least  part  of  the  explanation  for  the  current  finding  that  there 
was  no  difference  between  the  abilities  of  ND  and  MM  patient  T  cells  to  proliferate 
in  response  to  IL-2.  Thus  we  should  aim  to  collect  immune  effector  cells  at  a  time 
when  the  disease  is  either  in  remission,  or  is  at  its  lowest  level  during  the  disea§e 
course.  This  observation  may  be  crucial  in  determining  the  success  of  immune 
therapies  for  MM  patients,  but  also  for  patients  with  other  malignant  diseases  that 
induce  immune  suppression  by  secreting  cytokines  such  as  TGF-P,  IL-10  and  1ý-6. 
Pre-stimulation  of  MM  T  cells  with  T  cell  activation  beads  and  IL-2  significantly  qp- 
regulated  the  T  cell  proliferative  response  to  IL-2,  in  a  similar  manner  to  that  seen 
in  ND  cells.  In  contrast  to  the  previous  experiments,  we  did  not  see  an  improved 
response  when  MM  T  cells  were  pre-stimulated  with  beads  and  I  L-1  5.  This  is 
again  likely  to  be  due  to  the  more  normal  baseline  responses  of  the  MM  T  cells 
that  we  used  in  these  experiments.  How  ever,  the  activation  beads  deliver  a  co- 
stimulatory  signal  via  CD28  as  well  as  cross-linking  T  cell  CD3  in  three 
dimensions.  This  is  a  more  physiological  stimulus  compared  to  plate  bound  anti- 
CD3  alone,  and  this  may  contribute  to  the  improved  level  of  proliferation  of  MM  T 
cells  that  were  pre-stimulated  with  beads  and  IL-2,  compared  to  beads  and  ILA  5. 
It  was  hoped  that  this  would  translate  into  a  better  response  to  autologous  antigen 
loaded  DC. 
There  was  a  normal  proliferative  response  by  MM  un-stimulated  T  cells  to 
autologous  antigen  loaded  DC  in  the  presence  and  absence  of  IL-2.  However,  the 
pre-stimulated  T  cells  completely  failed  to  proliferate  in  response  to  autologous  DC 
alone.  The  same  cells  proliferated  normally  in  response  to  autologous  DC  in  the 
presence  of  IL-2,  suggesting  that  these  cells  had  been  rendered  IL-2  dependant. 
This  is  of  some  concern  if  these  cells  were  to  be  used  as  part  of  an  immune  based 
therapy  in  MM  patients  as  IL-2  would  be  need  to  be  given  in  conjunction  to  ensure Dr  Simon  J  Harrison,  2005  Chapter  5-153 
an  adequate  initial  proliferative  response  to  antigen  presenting  cells.  It  is  likely  that 
this  would  have  to  be  continued  for  a  time  afterward  to  ensure  the  survival  of  any  T 
cell  clones  that  were  produced  by  this  interaction.  We  do  not  currently  know  what 
the  minimum  concentration  of  IL-2  is  which  ensures  this  response,  or  whether  this 
is  safely  achievable  in  patients.  IL-2  has  been  given  to  patients  by  both  IV  infusipn 
and  SC  injection,  however  the  IV  route  is  associated  with  a  number  of  potentially 
fatal  side-effects,  making  the  SC  route  the  only  feasible  option.  These 
observations  were  important  when  interpreting  the  data  obtained  by  the  LumineýTm 
analysis  of  the  cytokine  levels  in  the  supernatants  from  the  DC  T  cell  interactions. 
The  LuminexTIA  system  is  a  convenient  way  to  examine  the  levels  of  multiple 
cytokines  in  small  volume  samples.  This  method  provided  another  way  in  which 
the  DC  T  cell  interactions  could  be  investigated  to  see  how  the  pre-stimulation  of  T 
cells  modifies  the  process.  This  system  was  able  to  measure  levels  of  IL-2,  IL-6, 
IL-10,  GM-CSF  and  TNF-a  in  the  supernatants  obtained  from  DC:  TC  co-cultures. 
With  the  exception  of  IL-6,  the  level  of  these  cytokines  in  the  supernatants 
collected  from  the  interactions  between  DC  and  pre-stimulated  T  cells  were 
significantly  lower  than  that  seen  with  DC  and  un-stimulated  T  cells.  This  suggests 
that  the  pre-stimulation  process  is  interfering  with  the  DC  T  cell  interaction.  It  is 
most  likely  that  both  pre-stimulated  CD4+  and  CD8+  cells  are  unable  to  secrete 
these  cytokines  in  the  absence  of  IL-2. 
The  level  of  IL-6  detected  did  not  vary  in  respect  to  the  T  cell  pre-stimulation; 
rather  it  varied  in  respect  to  the  maturation  stimulus  received  by  the  DC.  DC 
matured  by  X4  produced  significantly  more  IL-6  as  compared  to  MIMIC  mature 
DC.  This  is in  keeping  with  data  from  Fillatreau's  group  in  Berlin,  who  have  shown 
that  DC  actively  secrete  IL-6  in  response  to  microbial  products  or  CD40L,  and  was Dr  Simon  J  Harrison,  2005  Chapter  5-154 
highest  in  cells  that  had  received  both  (www.  drfz.  de/i)df/arO4/aq  fillatreauO4.  pdf  and 
personal  communicabon). 
At  first  glance  this  combination  of  cytokines  may  seem  a  little  confusing,  being  a 
combination  of  TH1  and  TH2  type  responses.  When  the  pattern  is  examined  as  a 
whole  it  becomes  clear  that  the  cells  are  attempting  to  induce  a  pro-inflammatory 
environment  favouring  the  development  of  a  CD8  cytotoxic  T  cell  respopse, 
Figure  5-12.  Pre-stimulation  of  the  T  cell  blocked  the  secretion  of  all  T  cell  derived 
cytokines,  but  had  no  effect  on  matDC  production  of  IL-6.  Currently,  there  is  no 
data  to  determine  whether  supplementation  of  the  matDC:  pre-stimulated  T  cell 
co-cultures  is  able  to  reinstate  the  cytokine  response  of  the  T  cells,  or  whether 
201U/ml  of  IL-2  simply  over-rides  these  mechanisms  and  directly  induces  T  cell 
proliferation,  enhanced  by  the  DC  antigen  and  co-stimulatory  signals.  However,  in 
view  of  the  fact  that  matDC  primed,  pre-stimulated  T  cells  produce  the  best  target 
cell  kill  in  the  cytotoxicity  assay,  it  can  be  speculated  that  when  IL-2  was  added  to 
the  matDC:  T  cell  co-cultures,  at  least  some  of  these  mechanisms  were  re- 
instated. 
The  flow  cytometry  based  cytotoxicity  assay  was  easy  to  handle,  as  compared  to 
the  more  traditional  radioactive  chromium  release  assay,  although  great  care  is 
needed  when  setting  up  the  initial  compensations.  Both  ND  and  MM  patient  pre- 
stimulated  T  cells  produced  some  target  cell  killing  at  the  highest  effector  target 
cell  ratios.  This  is  most  likely  due  to  effects  mediated  by  minor  histocompatibility 
antigen  mismatch,  as  all  effector  cells  were  HLA-class  I  (HLA-A2)  matched  with 
the  U266  cell  line  (Kloosterboer,  et  al  2005).  Interestingly,  pre-stimulated  MM  T 
cells  produced  statistically  better  killing  than  ND  pre-stimulated  T  cells  at  the 
highest  Eff  ratio.  There  are  a  number  of  likely  explanations  for  this  observation. Dr  Simon  J  Harrison,  2005 
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Figure  5-12  Cytokine  interactions  during  co-culture  of  matDC  and  un- 
stimulated  T  cells  to  facilitate  antigen  presentation 
Mature  DC  present  antigen  to  T  cells  in  the  context  of  co-stimulatory  markers.  This 
activates  both  CD4  and  CD8  T  cells  in  an  antigen  dependant  manner.  The  CID4 
cells  produce  iL-2,  IL-10  and  TNIF-a,  which  along  with  IL-6  from  the  matDC, 
preferentially  induce  the  CID8  T  cells  to  proliferate  and  differentiate  into  cytotoxic  T 
cells.  The  CID8  cells  also  secrete  IL-10,  which  recruits  other  CID8  cells  by 
chemotaxis.  In-vivo,  the  GM-CSF  produced  by  activated  CID8  T  cells  and  other 
cells,  such  as  fibroblasts  and  endothelial  cells,  under  the  influence  of  TNF-a, 
induce  monocytes  to  differentiate  into  DC,  completing  the  loop. 
It  is  known  that  MM  patients  have  circulating  T  cells  that  have  anti-MM  activity 
(Beckhove,  et  al  2003,  Yi,  et  al  1995).  Thus  the  pre-stimulation  process  may 
simply  be  un-masking  this  activity.  However,  the  MM  cells  were  collected  after  a 
number  of  courses  of  chemotherapy  and  immediately  after  a  course  of  IV 
cyclophosphamide,  a  very  powerful  T  cell  immunosuppressive  agent  (Winkelstein 
1973).  It  is  possible  that  these  pre-treatments  are  depleting  the  MM  patients  of 
regulatory  cells,  thus  allowing  greater  anti-MM  cytotoxic  activity.  It  may  be  possible Dr  Simon  J  Harrison,  2005  Chapter  5-156 
to  differentiate  between  these  two  possibilities  by  repeating  these  experiments 
using  cells  mobilised  with  a  similar  regime  in  non-MM  patients,  such  as  those  with 
follicular  lymphoma,  who  should  not  be  able  to  mount  an  anti-MM  mempry  T  cell 
response.  These  two  explanations  may  also  help  us  understand  the  re§ults 
obtained  using  ND  and  MM  patient  matDC  primed  T  cells. 
The  cytotoxic  activity  of  ND  matDC  primed  un-stimulated  T  cells  was  significantly 
less  than  that  seen  in  cells  from  MM  patients.  The  ND  T  cells  and  monocytes  were 
I 
collected  after  G-CSF  alone.  This  is  known  to  induce  T  cell  hypo-responsiveness 
(Jun,  et  al  2004)  and  increase  the  number  of  toleragenic  DC  present  in  the  graft 
(Lonial,  et  al  2004),  which  may  go  some  way  to  explain  the  reduced  incidence  of 
acute  GVHD  following  the  use  of  mobilised  stem  cells.  The  cytotoxicity  of  the  MM 
cells  was  further  enhanced  by  the  pre-stimulation  step.  Again  this  could  be 
because  we  are  simply  un-masking  and  enhancing  the  inherent  anti-MM  potentiRl 
of  the  MM  patient  T  cells,  but  there  was  a  substantial  DC  dependant  increase  in 
the  target  cell  killing  ability  of  the  MM  patient  T  cells.  This  would  favour  the 
hypothesis  that  collecting  the  T  cells  following  immunosuppressive  chemotherapy 
has  down  regulated  any  suppressive  effects  induced  by  the  G-CSF  and  the 
disease. 
In  summary,  pre-stimulation  of  MM  T  cells  with  beads  and  IL-2  enhanced  their 
proliferative  response  to  IL-2  and  matDC+IL-2,  but  blocked  proliferation  in 
response  to  matDC  alone.  Pre-stimulation  also  blocked  T  cell  cytokine  secretion  in 
response  to  DC  alone.  Despite  this,  pre-stimulated  matDC  primed  T  cells 
produced  the  best  killing  of  MM  tumour  cell  targets,  followed  by  un-stimulated 
matDC  primed  T  cells,  with  ND  un-stimulated  matDC  pdmed  T  cells  producing 
poor  cytotoxic  effects.  These  results  suggest  that  a  combined  immunotherapy Dr  Simon  J  HarTison,  2005  Chapter  5-157 
approach  using  pre-stimulated  T  cells,  MM  Ag  primed  DC  and  IL-2  may  produce 
better  clinical  responses  in  patients. Dr  Simon  J  Harrison,  2005  Chapter  6-158 
6.  Results  4 
6.1  Chemokine  receptor  expression/activity  on 
monocytes  and  monocyte  derived  dendritic  cells 
assessed  by  fluorescent  labelled  chemokine  up  takq 
6.1.1  Introduction 
The  interaction  between  chemokines  and  their  receptors  is  vital  to  the  function  of 
the  immune  system.  The  homeostatic  migration  of  cells  such,  as  DC  and  T  cells, 
from  the  bone  marrow  to  peripheral  tissues  and  then  lymph  nodes,  is  governed  by 
changes  in  of  chemokine  receptor  gene  expression  during  differentiation  and 
maturation,  and  their  interaction  with  ligands  that  are  constitutively  expressed  by 
tissues.  Inflammatory  processes  up-regulate  inducible  CCL,  inducing  leukocyte 
chernotaxis  towards  pro-inflammatory  CCLs,  such  as  CCL3  (Figure  1-3). 
Professional  antigen  presenting  cells,  such  as  DC,  mature  during  these 
interactions.  This  induces  down  regulation  pro-inflammatory  CCRs,  and  up 
regulation  of  CCRs,  such  as  CCR7,  that  promote  APC  migration  to  lymph  nodes, 
facilitating  Ag  presentation  by  the  co-localisation  of  naive  T  cells,  which  also 
express  CCR7. 
The  chemokine  expression  pattern  of  the  tumour  may  also  have  a  direct  bearing 
on  the  host's  ability  to  mobilise  monocytes,  DC,  T  cells  and  NK  cells  against  the 
tumour.  The  chemokine  balance  within  the  patient  and  the  tumour  may  be  crucial 
in  determining  the  type  of  immune  response  that  is  mounted,  in  that  the  tumour 
may  shift  the  balance  from  an  immunogenic  response  to  a  toleragenic  response  by 
the  expression  of  a  different  chemokine  'signature'. 
The  study  of  the  chemokine  system  is  made  more  difficult  by  the  structural 
constraints  imposed  by  the  GPCR,  which  makes  it  difficult  to  produce  good  quality Dr  Simon  J  Harrison,  2005  Chapter  6-159 
antibodies  for  use  in  experimental  work.  In  addition,  antibody  staining  dpes  not 
give  any  indication  of  functional  receptor  activity.  During  the  experiments  in  the 
previous  chapters,  the  level  of  CCR7  expression  on  matDC,  as  detecteý  by 
surface  antibody  staining,  was  not  as  good  as  expected  in  view  of  the  lqvel  of 
expression  of  the  other  co-stimulatory  markers  such  as  CD40,  CD80,  CP83  and 
CD86.  This  led  us  to  explore  other  ways  in  which  we  could  examine  chomokine 
receptor  expression  and  function  on  normal  and  MM  DC  and  monocyteý. 
Biotinylated  chemokines  (biokines),  such  as  CCL3  (Bio-CCL3)  and  CCL1  9  (Bio- 
CCI-19),  can  be  synthesized  with  an  additional  biotinylated  lysine  residue  on  the  C 
terminus  (Ravkov,  et  al  2003,  Weber,  et  a/  2004).  These  biokines  retain  the  full 
functional  activity  of  the  wild  type  molecules,  and  they  can  be  labelled  with 
streptavidin-linked  fluorochromes.  The  labelled  biokine  retains  it's  ability  to  bind  to 
CCR  on  the  surface  of  the  target  cell  and,  crucially,  to  be  internalised.  This  leads 
to  accumulation  of  fluorochrome  within  the  cell,  which  can  be  detected  by 
fluorescence  microscopy  or  flow  cytometry.  The  main  advantage  of  these 
techniques  is  that  they  allow  analysis  to  be  performed  on  a  cell-by-cell  basis, 
rather  than  on  the  population  as  a  whole,  as  is  the  case  when  using  radio  labelled 
CCL.  These  reagents  have  been  used  to  great  effect  in  the  analysis  of  D6  and 
CXC-CKR  by  local  collaborator  Dr  RAB.  Nibbs  (Weber,  et  al  2004)  and  others 
(Ravkov,  et  al  2003).  This  method  can  be  combined  with  other  fluorescent  surface 
markers,  allowing  further  characterisation  of  cells  taking  up  the  fluorescent  ligand. 
In  view  of  the  recent  evidence,  the  expression  of  CCR8  on  MM  monocytes  and  DC 
compared  to  cells  from  normal  individuals  was  of  considerable  interest  (Qu,  et  a/ 
2004,  Sebastiani,  et  al  2002).  There  were  no  reliable  anti-CCR8  antibodies 
available  at  the  time  these  experiments  were  performed.  Therefore  alternative Dr  Simon  J  Harrison,  2005  Chapter  6-160 
methods  to  detect  the  level  of  CCR8  surface  expression  are  required.  To  address 
these  issues,  the  use  of  biotinylated  chemokines  was  explored 
6.1.2  Optimisation  of  fluorescent  chemokine  uptake  in  CCR 
transfected  cell  lines  and  monocyte  derived  DC 
Firstly,  to  establish  these  approaches  in  the  lab,  HEK293  cells  that  had  been 
stably  transfected  to  express  D6  or  CCR7  were  assessed  for  their  ability  to  take  up 
Bio-CCL3  or  Bio-CCL19  respectively.  These  biolkines  were  mixed  with  PE-coupled 
streptavidin  and  these  complexes  or  Strep-PE  alone  were  fed  to  harvested  cells. 
As  can  be  seen  in  Figure  6-1,  D6  or  CCR7  expressing  cells  became  strongly 
fluorecent  after  incubation  with  Bio-CCL3/PE  or  Bio-CCL1  9/Pecomplexes 
respectively.  Parental  untransfected  HEK293  cells  failed  to  internalise  these 
tagged  chemokines,  (Data  not  shown).  These  assays  act  as  positive  controls  for 
the  subsequent  experiments  on  primary  human  material. 
A  Bio-CCL3  uptake  via  D6  B  Bio-CCL19  uptake  via  CCR7 
6tmp  rt 
Figure  6-1  Fluorescent  chemokine  uptake  in  HEK  cells  stably  transfected 
with  D6  and  CCR7 
HEK  293  cells  transfected  with  D6  (A)  or  CCR7  (B)  were  analysed  for  their  ability 
to  take  up  fluorescently  labelled  biokines,  CCL3  (A)  and  CCL1  9  (B),  as  compared 
to  control  samples  stained  with  strep-PE  alone. 
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For  the  next  experiment,  iDC  were  generated  from  CD14  selected  monocytes,  by 
culture  in  GM-CSF  and  IL-4  for  4  days.  On  day  4  an  aliquot  was  removed  for 
analysis  and  the  remaining  cells  were  fed  with  GM-CSF  and  IL-4  supplemented 
media,  pulsed  with  U266  lysate  as  a  source  of  antigen  and  cultured  over  night.  On 
day  5,  an  aliquot  of  antigen  pulsed  DC  was  removed  for  analysis  and  the 
remaining  cells  were  then  divided  in  half  for  maturation.  The  antigen-loaded  DC 
were  cultured  with  either  the  MIMIC  or  X4  maturation  cocktail  and  incubated 
overnight  prior  to  analysis.  The  biokine  uptake  assays  were  all  performed  in  500ul, 
on  the  same  day  as  the  aliquots  were  removed  from  the  parent  culture.  The 
surface  expression  CD1a,  1c,  14,40,80,83,86,  HLA  class  1,  HLA  DR,  CCR5  and 
CCR7  of  each  sample  was  determined  by  surface  antibody  staining  and  flow 
cytometry.  The  results  of  the  surface  phenotype  and  fluorescent  chemokine 
uptake  are  shown  in  Figures  6-2a-d. 
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Figure  6-2a  Fluorescent  chemokine  uptake  and  surface  phenotype  of  iDC 
Immature  DC,  generated  from  CD14  positive  monocytes  were  analysed  after  4 
days  of  culture  in  GM-CSF  and  IL-4  supplemented  DC  medium.  Live  cells  have 
been  gated  on  forward  and  side  scatter.  The  uptake  of  fluorescent  Bio-CCL3  and 
Bio-CCI-19  is  shown  in  the  upper  histogram  plots  and  the  surface  antibody 
staining  is  shown  in  the  lower  dot  plots. Dr  Simon  J  Harrison,  2005 
0. 
0 
Neg  control 
Bio  CCL3 
I 
S 
V. 
CCL3  PE 
PO  STAGWA2.0105 
62 
CD83  FITC 
ra 
CCL19  PE 
5- 
Figure  6-2b  Fluorescent  chemokine  uptake  and  surface  phenotype  of  iDC 
post  antigen  loading  with  turnour  lysate 
Immature  DC  were  loaded  with  tumour  antigen  by  adding  U266  cell  lysate  to  the 
culture  medium,  incubated  overnight  and  analysed  on  D5  of  culture.  Live  cells 
have  been  gated  on  forward  and  side  scatter.  The  uptake  of  fluorescent  Bio-CCL3 
and  Bio-CCL1  9  is  shown  in  the  upper  histogram  plots  and  the  surface  antibody 
staining  is  shown  in  the  lower  dot  plots. 
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Figure  6-2c  Fluorescent  chemokine  uptake  and  surface  phenotype  of  MIMIC 
matured  DC 
Antigen  loaded  DC  were  give  the  MIMIC  cytokine  cocktail  as  a  maturation 
stimulus  and  analysed  after  overnight  culture.  Live  cells  have  been  gated  on 
forward  and  side  scatter.  The  uptake  of  fluorescent  Bio-CCL3  and  Bio-CCL1  9  is 
shown  in  the  upper  histogram  plots  and  the  surface  antibody  staining  is  shown  in 
the  lower  dot  plots. 
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Figure  6-2d  Fluorescent  chemokine  uptake  and  surface  phenotype  of  X4 
matured  DC 
Antigen  loaded  DC  were  give  the  X4  cytokine  cocktail  as  a  maturation  stimulus 
and  analysed  after  overnight  culture.  Live  cells  have  been  gated  on  forward  and 
side  scatter.  The  uptake  of  fluorescent  Bio-CCL3  and  Bio-CCL19  is  shown  in  the 
upper  histogram  plots  and  the  surface  antibody  staining  is  shown  in  the  lower  dot 
plots. 
In  chapter  4,  DC  and  antigen-loaded  DC  were  found  to  strongly  express  CCR5  (a 
CCL3  receptor)  by  surface  antibody  staining  (Table  4-1).  However,  using  the 
experimental  conditions  optimised  for  use  with  transfected  cell  lines,  the  uptake  of 
Bio-CCL3  was  poor  (Figure  6-2a+b).  In  contrast,  there  was  significant  uptake  of 
Bio-CCL1  9  by  the  matDC,  with  61  %  of  the  X4  (Figure  6-2d)  and  37%  of  the 
MIMIC  (Figure  6-2c)  matured  cells  becoming  positive  indicating  that  these  cells 
were  expressing  CCR7  or,  less  likely,  CCR1  1,  another  receptor  capable  of  binding 
CCL1  9.  A  small  number  (17%)  of  antigen-loaded  DC  were  positive  for  Bio-CCL1  9 
uptake,  whilst  still  being  CCR5  positive  by  surface  antibody  staining  (Figure  6-2b). 
This  indicated  that  turnour  lysate  alone  was  sufficient  to  initiate  the  up  regulation  of 
CCR7  activity,  but  a  stronger  signal  is  required  to  complete  the  process  of  DC 
maturation,  a  matter  discussed  earlier. 
With  regard  to  the  suitability  of  biokine  usage,  it  is  first  clear  that  the  Bio-CCL1  9 
approach  provides  a  sensitive  method  for  detecting  CCL1  9  receptors,  which  is Dr  Simon  J  Harrison,  2005  Chapter  6-164 
arguably  better  than  CCR7  antibodies.  CCL3  uptake  was  disappointing,  as  there 
was  little  BioCCL3  uptake  despite  the  presence  of  surface  CCR5,  as  indicated  by 
anti-CCR5  antibody  staining. 
The  amount  of  fluorescence  accumulated  by  a  cell  during  the  biokine  uptake 
assay  is  dependant  upon  receptor  activity  during  the  assay,  biokine  concentratiQn 
and  time.  In  order  to  optimise  the  Bio-CCL3  uptake  in  primary  human  material,  I 
fluorescent  Bio-CCL3  assay  was  performed  with  an  increased  incubation  time  of 
4hrs.  A  second  assay  was  performed  with  an  increased  concentration  of 
fluorescent  Bio-CCL3,  by  reducing  reaction  volume  of  the  assay  from  500pl  to 
200pl. 
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Figure  6-3  Reducing  the  reaction  volume  from  500pl  to  200pi  significantly 
improves  Bio-CCL3  uptake  by  CD14  selected  monocytes  (n=3) 
Normal  monocytes  were  obtained  by  CD14  selection  and  suspended  in  DC 
medium  at  1X106/Ml 
. 
Fluorescent  chemokine  assays  were  performed  on  200pl  and 
500pl  aliquots  of  cells.  The  500pl  aliquot  samples  were  incubated  for  2  (plot  shown 
in  Figure  6-2a)  or  4hrs  (above),  the  200pl  samples  were  incubated  for  2hrs. 
Controls  (Strep-PE  alone)  were  performed  for  each  culture  condition,  and  each 
condition  was  set  up  in  triplicate.  Samples  were  analysed  by  flow  cytometry  with  a 
negative  gate  set  on  99%  of  cells  in  each  control  sample. Dr  Simon  J  Hardson,  2005  Chapter  6-165 
Reducing  the  reaction  volume  to  200pl  improved  the  fluorescent  chemqkine 
uptake  (Figure  6-3),  to  a  level  more  in  keeping  with  results  from  surfacT  antibody 
staining.  Increasing  the  incubation  time  from  2-4hrs  for  the  200pl  assayp  only 
served  to  increase  the  level  of  non-specific  uptake  of  the  control.  It  was  decided  at 
this  point  that  all  further  assays  would  be  performed  in  200pl  for  both  Bio-CCL3 
and  Bio-CCL19  uptake  assays,  as  there  was  no  significant  change  in  the  Bio- 
CCL19  uptake  using  200pl  samples  (data  not  shown). 
6.1.3  Specificity  of  fluorescent  chemokine  uptake  by  competitive 
blocking  with  non-biotinylated  chemokines 
As  previously  discussed,  chemokine  receptor-ligand  binding  is  uniquely 
promiscuous  in  the  way  ligands  and  receptors  can  bind  in  a  number  of 
combinations.  In  order  to  determine  whether  the  uptake  of  Bio-CCI-19  was  via 
CCR7  or  CCR1  1,  a  blocking  step  was  added  to  the  assay.  Aliquots  of  matDC  were 
pre-stimulated  with  either  non-biotinylated  CCL1  9,  to  block  uptake  via  CCR7  and 
CCR1  1,  or  CCI-25,  which  should  specifically  block  uptake  via  CCRI  1.  These 
unlabelled  chemokines  were  added  at  a  concentration  A0  greater  than  the 
concentration  of  CCL1  9  used  in  the  fluorescent  biokine  uptake  assay.  Cells  were 
incubated  at  370C  for  1  hour,  and  then  washed  twice  in  warm  DC  medium.  A 
fluorescent  biokine  uptake  assay  was  then  performed  as  previously  described  with 
a  negative  control  and  an  untreated  sample  of  matDC  (Figure  6-4). Dr  Simon  J  Harrison,  2005 
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Figure  6-4  Pre-stimulation  of  matDC  with  CCL19  and  CCL25  shows  that  Bio- 
CCL19  uptake  is  mediated  by  CCR7 
Mature  DC,  generated  from  CD14  selected  monocytes,  cultured  in  GM-CSF  and 
IL-4  supplemented  DC  medium  for  4  days.  The  DC  were  pulsed  with  U266  tumour 
cell  lysate  overnight  and  then  matured  overnight  with  the  X4  cytokine  cocktail.  Two 
aliquots  of  matDC  were  pre-stimulated  for  1  hour  with  non-biotinylated  CCL1  9  to 
block  uptake  via  CCR7  and  CCR1  1,  or  CCL25  to  block  uptake  via  CCR1  1. 
Unblocked  cells  were  incubated  for  1  hour  in  medium  alone.  All  cells  were  then 
washed  in  warm  medium  and  the  fluorescent  chemokine  assay  was  performed  on 
blocked  and  unblocked  matDC.  Repeat  experiments  gave  similar  results. 
The  CCL19  and  CCL25  pre-blocking  experiment  confirmed  that  Bio-CCL19  uptake 
was  mediated  via  CCR7.  Pre-stimulation  with  CCL25  had  no  effect  on  Bio-CCL19 
uptake  (79.22  +  1.0%,  positive,  MFI  54.55)  as  compared  to  the  unblocked  positive 
control  (75  +  0.85%,  MFI  47.66).  Pre-stimulation  with  CCL19  significantly  reduced 
Bio-CCL19  up-take  (8.74  +  0.2%  positive,  MA  9.67)  (p<  0.001). 
The  task  to  determine  receptor  specificity  for  Bio-CCL3  uptake  is  a  more  complex 
one,  as  CCL3  can  bind  to  CCR1,  CCR3,  CCR5  and  the  decoy  receptor  D6.  To 
attempt  to  address  this,  fluorescent  Bio-CCL3  uptake  assays  were  set  up  as 
normal  with  the  addition  of  a  ten  times  excess  of  unlabelled  human  (h)CCL31-1, 
murine  (m)CCL3,  hCCL3L1  -2,  hCCL3L1  -4  and  hCCL4.  There  are  two  naturally Dr  Simon  J  Hanison,  2005  Chapter  6-167 
occurring  isoforms  of  CCU  in  humans,  called  CCU  and  CCI-31-1.  CCL3LI  is 
viewed  as  the  true  human  homologue,  and  binds  CCRI,  CCR3,  CCR5  and  D6 
(Nibbs,  et  al  1999).  Confusingly,  CCI-31-1  is  also  the  true  functional  homologue  of 
murine  CCL3.  The  truncated  form  CCI-31-1  -2  is  missing  the  final  2  amino  acid 
residues  from  the  N  terminal,  and  has  increased  specificity  for  CCRI  and  CCR5, 
and  no  ability  to  bind  CCR3  and  D6.  The  CCI-31-1-4  protein  is  missing  the  N 
terminal  4  amino  acid  residues.  It  retains  its  ability  to  bind  CCL1,  has  reduced 
specificity  for  CCR-5  and  no  ability  to  interact  with  CCR3  or  D6.  Finally,  CCL4  was 
included  because  it  binds  to  CCR5  and  D6.  The  results  are  shown  in  Figure  6-5 
and  it  was  hoped  that  the  use  of  these  chemokines  would  give  an  indication  of  the 
Bio-CCL3  receptors  present  on  the  cells.  The  amount  of  blocking  of  Bio-CCL3 
uptake  in  each  assay  was  calculated  using  Equation  2-1. 
Significant  inhibition  was  achieved  with  all  CCL3  variants,  mCCL3  (mean  57.05  + 
16.24),  hCCL3L1  (mean  48.68  ±  13.53),  hCCL3L1  -2  (mean  45.64  ±  15.64)  or 
hCCI-31-1-4  (mean  36.86  +  12.54).  Overall,  these  data  suggest  that  Bio-CCL3 
uptake  was  mediated  by  either  CCR5  or  CCR1.  To  further  elucidate  which  of  these 
two  receptors  was  responsible  for  Bio-CCL3  uptake,  blocking  would  need  to  be 
performed  using  CCU,  which  has  specificity  for  CCR1,  and  CCL8,  which  only 
binds  CCR5.  Another  method  would  be  to  use  cell  that  genetically  lack  one  of  the 
receptors,  such  as  A32  homozytes  who  do  not  express  CCR5.  None  of  these 
reagents  was  available  at  the  time  these  assays  were  performed.  Interestingly, 
competition  with  CCI-4  did  not  block  Bio-CCL3  uptake  but  rather  induced  a 
significant  up  regulation  of  Bio-CCL3  uptake  (mean  116.78  +  17.57,  p<  0.005)  and 
the  mechanisms  that  may  induce  this  phenomenon  will  be  discussed  later. Dr  Simon  J  Harrison,  2005 
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Figure  6-5  Competitive  blocking  of  Bio-CCL3  with  non-biotinylated 
chemokines,  which  have  varying  CCR  specificities,  suggests 
uptake  is  mediated  by  CCR5 
Monocytes  from  normal  individuals  (n=4)  were  purified  by  density  gradient 
centrifugation  and  CD14  magnetic  bead  selection.  The  fluorescent  chemokine 
uptake  assay  was  performed  for  Bio-CCL3  uptake  with  the  addition  of  12.5ul  of 
0.1  ug/ml  (x1  0  excess)  of  the  non-biotinylated  blocking  chemokines  hCCL3L1, 
mCCL3,  hCCI-31-1-2,  hCCL3L1-4  and  hCCL4.  Samples  were  incubated  for  2 
hours  and  analysed  by  flow  cytometry.  Samples  were  set  up  in  duplicate  and  the 
results  represent  4  separate  experiments.  The  data  shown  is  the  mean  percentage 
blocking  of  the  positive  control  MFI  induced  by  each  chemokine  and  was 
calculated  as  shown  in  Equation  6-1. 
The  competitive  blocking  experiments  for  Bio-CCL3  uptake  shown  in  Figure  6-5 
did  not  show  complete  inhibition,  as  seen  when  matDC  were  pre-stimulated  with 
CCL1  9,  prior  to  a  Bio-CCL1  9  assay  being  performed  (Figure  6-4).  Thus,  the 
impact  of  CCL3  pre-incubation  prior  to  Bio-CCL3  uptake  was  assessed.  Pre- 
stimulation  induces  receptor  desensitisation,  making  the  cells  refractory  to 
subsequent  ligand  interactions.  A  pre-stimulation  blocking  experiment  of  Bio-CCL3 
uptake  was  performed  in  triplicate  using  normal  monocytes,  cultured  with  a  ten Dr  Simon  J  Harrison,  2005  Chapter  6-169 
times  excess  of  hCCL3Ll,  mCCL3,  hCCL3Ll-2,  hCCL3Ll-4  and  hCCL4  for  an 
hour  at  370C.  The  fluorescent  Bio-CCL3  uptake  assays  were  performeq  as 
previously  described.  The  data  in  Figure  6-6  shows  that  pre-stimulation  with 
CCL3Ll  (mean  86.03  +  2.78%,  p<0.03)  and  CCL3Ll-2  (mean  77.94  +  1.80%,  p 
0.03)  increased  the  degree  of  inhibition  of  Bio-CCL3  uptake  compared  to 
competitive  co-blocking  (Figure  6-5).  There  was  also  a  higher  level  of  blocking 
with  mCCL3  (mean  88.0  +  1.15%)  and  CCL3Ll  -2  (mean  81.62  +  1.01  %)  pre- 
stimulation  compared  with  the  competitive  blocking,  but  this  failed  to  achieve 
statistical  significance.  Pre-stimulation  with  CCL4  again  increased  the  Bio-CCL3 
uptake  (mean  20.54  +  10.54%),  but  this  was  significantly  less  than  that  seen  witý 
competitive  blocking  alone  (p  <  0.03). 
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Figure  6-6  Pre-stimulation  of  normal  monocytes  with  non-biotinylated 
chemokines  further  reduces  Bio-CCL3  uptake 
Aliquots  of  normal  monocytes  used  in  one  of  the  experiments  in  Figure  6-8  and  6- 
9  were  incubated  with  a  X10  excess  of  non-biotinylated  CCL31-1,  mCCL3, 
CCI-31-1  -2,  CCL3L1  -4  and  CCL4.  They  were  incubated  for  1  hour  and  then  a  Bio- 
CCL3  uptake  assay  was  performed  in  triplicate,  in  the  presence  of  the  non- 
biotinylated  chemokines.  The  assays  were  then  incubated  at  37'C  for  2  hours  and 
analysed  by  flow  cytometry.  The  assays  were  set  up  in  triplicate  and  compared 
with  the  results  of  the  assays  incubated  at  370C  to  calculate  the  inhibition  of  Bio- 
CCL3  uptake  as  shown  in  Equation  6-1. Dr  Simon  J  Hanison,  2005  Chapter  6-170 
In  summary,  biokines  can  be  used  to  assess  the  capacity  of  primary  hu1nan  cells 
to  take  up  chemokines  such  as  CCL3  and  19,  giving  an  indication  of  aclive, 
functional  receptor  expression  on  these  cells.  Pre-stimulation  blocking  Issays, 
using  CCL1  9  and  25,  showed  that  the  uptake  of  Bio-CCL1  9  was  mediaýed  by 
CCR7.  Of  the  possible  receptors  that  could  have  mediated  the  uptake  qf  Bio- 
CCL3,  CCR1  and  5  are  the  most  likely  candidates.  However,  the  lack  of  receptor 
specificity  in  the  Bio-CCL3  assay  may  have  advantages.  It  may  be  useq  to 
simultaneously  probe  for  the  presence  of  all  pro-inflammatory  CCL3  receptors 
(CCL1,3,5)  on  target  cells,  avoiding  the  use  a  number  of  reagents,  as  would  bq 
the  case  when  using  antibodies.  Indeed,  in  many  cases,  particularly  in  species 
other  than  humans,  high  quality  antibodies  are  often  unavailable  for  chemokine 
receptors.  Biokines  may  represent  a  suitable  alternative.  More  over,  the  biokine 
methodology  is  a  useful  approach  when  examining  the  shift  from  an  iDC  to  a 
matDC  phenotype,  as  it  will  give  a  better  overall  view  of  the  changes  in  the  cell's 
capacity  to  interact  with  CCL3. 
6.1.4  Tracking  Chemokine  Receptor  activity  in  normal  and  MM 
MoDC  production  using  the  fluorescent  chemokine  uptake 
assay 
As  discussed  previously,  DC  migrate  under  the  control  of  different 
chemokine/receptor  interactions  at  various  stages  of  development.  These 
mechanisms  are  vital  to  the  DCs  ability  to  generate  an  immunogenic  response. 
They  encounter  antigen  at  sites  of  inflammation,  then  mature  and  migrate  to  lymph 
nodes,  where  DC  present  these  antigens  to  immune  effector  cells  in  the  context  of 
appropriate  co-stimulation.  The  fluorescent  chemokine  uptake  assay  was  used  to 
track  changes  in  CCR7  and  CCL3  receptor  activity  during  the  different  phases  of 
MoDC  production.  Monocytes  were  collected  from  MM  patients  and  ND 
undergoing  stem  cell  mobilisation,  and  purified  by  density  gradient  centrifugation Dr  Simon  J  Harrison,  2005  Chapter  6-171 
and  CD14  magnetic  bead  selection.  Immature  DC  were  produced  from  monocytes 
by  4-day  cultures  in  DC  medium  supplemented  with  GMALA  or  GMAL-13. 
Immature  DC  were  simultaneously  matured  and  loaded  with  antigen  by  overnight 
culture  in  medium  supplemented  with  either  the  X4  or  MIMIC  maturation  cocktail, 
and  U266  tumour  cell  lysate.  This  study  has  revealed  a  number  of  fundamental: 
changes  in  CCR7  and  CCU  receptor  expression  during  MoDC  development  ano 
maturation  that  vary  between  ND  and  MM  patients. 
A  significant  number  of  monocytes  isolated  from  ND  following  stem  cell 
mobilisation  were  found  to  have  CCR7  activity  using  the  chemokine  uptake  assay 
(mean  31.37  +  9.91%)  (MFI  10.93  +  5.75),  shown  in  Figure  6-7.  This  expression  is 
maintained  by  iDC  and  up  regulated  following  maturation  (mean  49.35  +  6.12%) 
(p:  ý  0.05).  The  MFI  of  CCR7  activity  is  markedly  up  regulated  during  maturation 
(mean  27.86  +  4.12%)  (p:  ý  0.001).  The  activity  of  CCL3  receptors  progressively 
down  regulates  during  MoDC  production  (monocytes  44.28  +  8.22%,  iDC  19.41  + 
4.00%  and  mat  DC  15.8  +  3.9%)  (p<  0.01). 
Figure  6-8  shows  the  MFI  and  percentage  positive  cells  for  monocytes,  iDC  and 
mat  DC  produced  from  MM  patients  undergoing  chemotherapy  and  G-CSF  stem 
cell  mobilisation.  Monocytes  from  MM  patients  show  a  reduced  level  of  CCL3 
receptor  activity  (mean  20.12  +  4.26%)  as  compared  to  monocytes  from  normal 
donors  (*p:  ý  0.01).  The  pattern  of  change  seen  in  the  OC  and  mat  DC  is  similar  in 
MM  patients  compared  to  normal  donors.  However,  the  level  of  expression  of 
CCR7  in  MM  mat  DC  (30.33  +  6.81  %) is lower  than  that  seen  in  matDC  from 
normal  donors  (mean  49.35  +  6.12%),  but  this  fails  to  achieve  statistical 
significance  (+  p=0.055). Dr  Simon  J  Harrison,  2005 
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Figure  6-7  CCL3  receptor  and  CCR7  activity  during  MoDC  production  from 
normal  stem  cell  donors,  measured  using  the  fluorescent 
chemokine  uptake  assay 
The  chemokine  uptake  assays  were  performed  using  monocytes  (n=9),  iDC 
(n=  12)  and  matDC  (n=  18)  isolated  from  normal  donors  (n=9)  undergoing  stem  cell 
mobilisation  with  G-CSF  1  Opg/kg  for  5  days.  Plot  A  show  the  mean  fluorescence 
intensity  and  plot  B  shows  the  percentage  of  positive  cells.  *  Denotes  significant 
difference  from  MM  patients,  +  denotes  a  trend  towards  a  difference. Dr  Simon  J  Harrison,  2005 
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Figure  6-8  CCL3  receptor  and  CCR7  activity  during  MoDC  production  from 
MM  patients  undergoing  stem  cell  mobilisation,  measured  using 
the  fluorescent  chemokine  uptake  assay 
The  chemokine  uptake  assays  were  performed  on  monocytes  (n=9),  iDC  (n=12) 
and  matDC  (n=  18)  isolated  from  MM  patients  (n=9)  undergoing  stem  cell 
mobilisation  with  chemotherapy  and  G-CSF  5-1  Opg/kg  for  5  days.  Plot  A  shows 
the  mean  fluorescence  intensity  and  plot  B  shows  the  percentage  of  positive  cells. 
*  Denotes  significant  difference  from  ND,  +  denotes  a  trend  towards  a  difference. Dr  Simon  J  Harrison,  2005  Chapter  6-174 
Immature  DC  analysed  in  the  above  analyses  had  been  produced  using  one  of 
two  cytokine  cocktails,  GM-CSF  combined  with  either  IL-4  or  IL-13.  Thus,  they 
were  examined  separately.  The  OC  produced  from  ND  (n=9)  showed  no 
significant  difference  in  chemokine  receptor  activity  between  the  cells  produced  by 
GM/IL-4  (n=5)  (mean  38.1  +  6.9%)  (MFI  9.8  +  1.7)  and  GM/IL-13  (n=7)  (mean  26.2 
1.6%)  (MFI  8.0  +  0.8).  However,  the  percentage  of  cells  positive  for  Bio-ELC 
uptake  and  the  level  of  activity,  as  indicated  by  the  MR,  were  significantly  lower  in 
the  MM  patient  (n=9)  DC  produced  with  GMAL-13  (n=5)  (mean  7.56  +  2.67%) 
(MFI  5.05  +  1.33)  as  compared  to  those  produced  with  GM/IL-4  (n=4)  (mean  23.79 
5.29%,  p<0.01)  (MFI  10.95  +  1.16,  p<0.05),  (Figure  6-9). 
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Figure  6-9  CCR7  activity  on  iDC  from  MM  patients 
Immature  DC  were  produced  from  MM  patient  (n=9)  monocytes  collected  following 
stem  cell  mobilisation.  Samples  were  cultured  for  4  days  in  DC  medium 
supplemented  with  GM-CSF  and  either  IL-4  (n=4)  or  IL-13  (n=5).  CCR7  activity 
was  analysed  using  Bio-CCL1  9  uptake  as  a  marker  of  receptor  activity. 
pý  0.01 Dr  Simon  J  Harrison,  2005  Chapter  6-175 
In  order  to  assess  the  quality  of  the  rnatDC  induced  by  the  X4  and  MIMIC 
maturation  stimulus,  we  compared  the  results  of  Bio-CCI-19  uptake  in  cplls  that 
had  been  matured  with  the  two  maturation  cocktails.  Samples  from  all  nine  ND 
were  matured  with  both  MIMIC  and  X4,  and  results  are  shown  in  Figure  6-10.  A 
lower  proportion  of  ND  MIMIC  matured  matDC  exhibited  CCR7  activity  (mean 
38.63  +  6.33%)  compared  to  those  matured  with  X4  (mean  58.86  +  9.3%,  p<0.05). 
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Figure  6-10  CCR7  activity  is  lower  in  normal  matDC  matured  with  the  MIMIC 
cytokine  cocktail  compared  to  those  matured  with  X4 
Mature  DC,  produced  from  normal  donors  (n=9),  were  analysed  to  ascertain 
whether  the  maturation  stimulus  they  received  influenced  the  level  of  CCR7 
activity.  Aliquots  from  all  Nine  ND  were  matured  with  MIMIC  (n=9)  and  X4  (n=9). 
The  majority  of  samples  from  MM  patients  were  matured  with  X4  (8/9).  Thus  we 
compared  the  level  of  CCR7  activity  in  these  cells  with  those  from  normal  donors 
that  had  been  matured  with  X4  (n=9)  (Figure  6-11).  This  analysis  showed  the  MM 
matDC  matured  with  X4  had  a  significantly  lower  percentage  of  Bio-CCL1  9 
positive  cells  (mean  30.32  +  6.81)  as  compared  to  the  normal  donor  controls 
(mean  58.86  +  9.3%,  p<0.02). Dr  Simon  J  Harrison,  2005 
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Figure  6-11  CCR7  activity  is  higher  in  normal  matDC  matured  with  X4 
cytokine  cocktail  compared  to  MM  matDC  matured  with  X4 
The  uptake  of  Bio-CCI-19  by  normal  donor  matDC  matured  with  X4  (n=9)  was 
compared  with  MM  matDC  matured  with  X4  (n=8)  in  order  to  assess  the  quality  of 
MM  matDC. 
These  experiments  have  shown  that  the  biokine  uptake  assay  can  be  used  to 
monitor  the  level  of  CCR7  and  CCL3  receptor  activity  during  MoDC  development. 
The  level  of  receptor  activity  can  vary  depending  upon  the  method  of  DC 
production,  and  between  cells  from  ND  and  patients  with  malignant  disease,  such 
as  MM.  DC  produced  with  GM/IL-4  and  matured  with  X4  may  be  of  better  quality, 
with  regards  to  CCR7  activity  and  homing  to  lymphoid  tissue,  than  those  produced 
with  GM/11-1  3  or  matured  with  MIMIC.  However  it  will  be  important  to  correlate 
these  findings  with  those  from  migration  and  chernotaxis  assays  before  deciding 
whether  this  is  the  preferred  method  for  DC  production  for  patients  with  MM. 
Monocytes  were  found  to  express  a  significant  level  of  CCR7  activity  in  these 
assays.  The  level  of  CCR7  activity  on  MM  monocytes  is  much  more  variable  than 
that  seen  on  ND  monocytes.  This  could  be  due  to  the  different  regimes  used  to 
mobilise  cells,  or  to  inherent  differences  in  MM  monocytes Dr  Simon  J  Harrison,  2005  Chapter  6-177 
6.1.5  Analysis  of  the  expression  of  the  chemokine  receptors 
CCR5,  CCR7  and  D6  by  reverse  RT-PCR 
Intriguingly,  the  fluorescent  chemokine  uptake  assay  indicates  that  monocytes, 
collected  during  stem  cell  mobilisation,  and  OC  have  some  detectable  CCR7 
activity.  This  is  at  odds  with  the  data  in  the  published  literature  generated  by 
surface  antibody  staining,  which  suggest  that  these  cells  do  not  express 
detectable  CCR7.  In  order  to  confirm  this  data,  RT-PCR  was  used  to  determine 
CCR5  and  CCR7  gene  expression  in  monocytes,  OC  pre  and  post  antigen  loading 
and  matDC.  In  addition,  parallel  CCR5  expression  was  gauged. 
Dendritic  cells  were  generated  from  ND  monocytes  with  GM/11-4  and  X4.  At  each 
stage  of  production  process,  5xI  05  cells  were  stored  at  -800C  as  a  concentrated 
cell  pellet.  RNA  was  isolated  from  cells  and  used  to  synthesise  cDNA.  The  relative 
expression  of  chemokine  mRNA  was  then  analysed  using  a  single  set  of  primers, 
within  a  single  PCR  reaction.  The  products  of  the  PCR  reaction  were  analysed  by 
conventional  gel  electrophoresis  and  visualised  by  UV  light. 
The  PCR  gel  shown  in  Figure  6-12  shows  that  in  keeping  with  the  cytokine  uptake 
assay,  there  was  expression  of  CCR7  in  monocytes  collected  at  the  time  of  stem 
cell  mobilisation,  as  well  as  in  OC  pre  and  post  antigen  loading.  Although  the  PCR 
that  was  performed  was  not  quantitative,  this  expression  seemed  to  up  regulate  in 
mature  DC.  The  monocytes  used  in  this  experiment  were  >93%  pure,  so  it  is 
possible  that  the  CCR7  mRNA  detected  was  due  to  T  cell  contamination. 
However,  expression  was  maintained  in  iDC,  which  were  in  culture  for  4  or  5  days 
in  the  absence  of  any  cytokine  that  would  maintain  T  cell  viability.  Alongside  the 
Bio-CCL19uptake  data,  these  experiments  suggest  CCR7  expression  by 
monocytes. Dr  Simon  J  Harrison,  2005 
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Figure  6-12  Gel  electrophoresis  of  PCR  products  for  CCRS,  CCR7  and  D6 
RT-PCR  reactions  for  CCR5,  CCR7  and  D6  were  performed,  with  and  without 
reverse  transcriptase  (RT),  on  monocytes  harvested  at  the  time  of  stem  cell 
mobilisation  (Gel  A),  OC  produced  by  culture  in  DC  medium  supplemented  with 
GM/lL-4  (Gel  B),  DC  post  antigen  loading  with  U266  tumour  cell  lysate  (Gel  C) 
and  matDC  following  the  X4  maturation  cocktail  (Gel  D). 
The  expression  of  CCR5  appeared  highest  in  monocytes  and  iDC,  with  apparent 
down  regulation  in  OC  following  antigen  loading,  and  matDC.  These  findings  need 
to  be  interpreted  in  light  of  the  contamination  in  the  CCR5  -RT  control  lane.  This 
could  be  due  to  contamination  of  the  sample  with  DNA  that  has  not  been 
completely  destroyed  by  the  DNAse  neutralisation  step.  This  emphasises  the 
importance  of  -RT  controls,  which  are  often  omitted  by  others.  Finally,  there  was 
no  evidence  of  D6  expression  in  any  of  the  test  cells  in  this  experiment.  Thus  the Dr  Simon  J  Harrison,  2005  Phapter  6-179 
Bio-CCL3  uptake  observed  in  the  experiments  discussed  in  6.1.4  is  unlikely  to  be 
mediated  by  the  D6  decoy  receptor. 
6.1.6  CCR8  expression  during  MoDC  production  meafured  by 
surface  marking  with  blotinylated  CCL1 
There  is  recent  evidence  that  CCR8,  as  well  as  CCR7,  has  a  role  in  the  migratign 
of  CD40  licensed  matDC  from  peripheral  tissues  to  lymph  nodes.  The  CCL1  (I- 
309)  Fluorokine  kit,  (R  and  D  systems)  was  used  to  examine  the  expression  of 
CCR8  on  monocytes  and  DC  during  MoDC  production.  CCL1  is  the  main  ligand 
for  CCR8.  The  molecules  employed  in  this  method  had  been  biotinylated  after 
production.  As  a  result,  each  CCL1  molecule  has  multiple  biotin  sites,  and  they 
form  large  complexes  when  streptavidin-bound  fluorochromes  are  added.  This 
prevents  this  type  of  molecule  from  being  pre-labelled  with  streptavidin-bound 
fluorochromes  and  so  they  are  not  suitable  reagents  to  measure  ligand 
internal  isation.  However,  it  does  allow  sensitive  and  specific  surface  quantification 
of  the  cell  surface  receptor  expression. 
Aliquots  of  cells  were  suspended  in  cold  PBS,  and  labelled  with  Bio-CCL1  or 
negative  control.  The  samples  were  incubated  for  1  hour  at  40C,  the  Strep-FITC 
was  then  added  and  the  samples  incubated  for  a  further  30mins,  in  the  dark,  at 
40C.  Samples  were  then  washed  twice  and  analysed  immediately  by  flow 
cytometry.  The  specificity  of  the  staining  was  tested  by  pre-blocking  Bio-CCL1  with 
anti-human  CCLI  antibody,  and  performing  a  competitive  binding  assay  by  pre- 
incubating  test  cells  with  a  ten  times  excess  of  non-biotinylated  CCL1  for  1  hour. 
The  assays  were  then  completed  as  normal  (Figure  6-13).  All  assays  were 
performed  in  triplicate. Dr  Simon  J  Harrison,  2005 
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Figure  6-13  CCR  8  surface  marking  with  Bio-CCLI  is  blocked  by  anti-human 
CCL1  antibody,  and  partially  inhibited  by  competition  with  un- 
biotinylated  CCLI 
Normal  monocytes  were  prepared  by  density  gradient  centrifugation  and  CD14 
selection.  Samples  were  analysed  for  CCR8  expression  by  CCLII  surface  staining 
(plot  B)  and  compared  with  negative  control  samples  (A).  Blocking  with  an 
antihuman  CCL1  anti-body  (C)  and  pre-stimulation  with  x1O  excess  of  un- 
biotinylated  CCL1  (D)  determined  specificity  of  marking.  Samples  were  analysed 
by  flow  cytometry.  The  M1  contains  99%  of  the  negative  control  cells  and  M2  is 
the  positive  gate. 
Monocytes  were  positive  for  CCR8  (mean  95%  +  1.14%)  and  this  was  completely 
blocked  by  anti-human  CCL1  antibodies.  Pre-stimulation  with  un-biotinylated 
CCL1  reduced  the  MFI  by  a  mean  of  50%  +  2%.  This  suggested  that  the  Bio-CCL1 
surface  staining  was  both  a  sensitive  and  specific  method  for  detecting  CCR8  on 
the  surface  of  primary  human  cells  (Figure  6-13). 
We  went  on  to  examine  the  CCR8  levels  on  monocytes,  DC  and  matDC 
generated  from  normal  donors  (n=6)  and  MM  patients  (n=6),  who  were  undergoing 
stem  cell  collection.  Monocytes  from  normal  donors  had  a  lower  MFI  (mean  28.34 
10.80)  and  percentage  of  CCR8  positive  cells  (mean  43.17  +  5.80%)  compared 
to  MM  monocytes  (mean  124.69  +  54.0,  p<0.001)  and  (mean  64.79  +  13.90%, 
p<0.03)  (Figure  6-14).  There  was  no  statistical  difference  between  CCR8  levels 
on  normal  donor  or  MM  patient  iDC.  However,  the  expression  of  CCR8  on  MM 
matDC  (163.0  +  18.5)  was  statistically  higher  than  on  ND  matDC  (163.0  +  18.5,  p 
0.01). Dr  Simon  J  Harrison,  2005 
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Figure  6-14  CCR8  levels  on  normal  and  MM  monocytes,  MC  and  matDC 
CCR  8  levels  were  assessed  using  the  Bio-CCL1  surface-marking  assay. 
Monocytes  were  isolated  from  normal  donors  and  MM  patients  undergoing  stem 
cell  collection.  Immature  DC  were  produced  by  culture  in  DC  medium 
supplemented  with  GM/IL4  or  GM/IL13.  Maturation  was  induced  using  the  MIMIC 
or  X4  maturation  cocktails.  Plot  A  shows  the  MFI  data  and  plot  B  shows  the 
percentage  of  cells  that  were  CCR8  positive.  Samples  were  analysed  from  6  ND 
(n=12)  and  6  MM  patients  (n=6). 
The  difference  in  the  level  of  CCR8  expression  on  cells  from  MM  patients  and  ND 
may  be  constitutive,  or  due  to  the  differing  stem  cell  mobilisation  regimes.  This 
may  be  the  case  for  monocytes,  but  it  is  much  less  likely  to  be  the  explanation  for 
the  different  levels  of  expression  seen  on  matDC.  Thus  it  is  more  likely  that  cells 
from  MM  patients  have  an  inherently  higher  expression  of  CCR8.  This  may  be 
further  clarified  by  measuring  CCR8  levels  on  cells  from  ND  and  MM  patients 
obtained  under  steady  state  conditions. Dr  Simon  J  Harrison,  2005  Chapter  6-182 
6.1.7  Discussion 
Chemokines  and  their  receptors  are  crucial  for  the  efficient  function  of  the  immune 
system.  They  provide  a  homeostatic  mechanism  by  which  cells  such  and  DC  and 
T  cells  can  migrate  from  the  bone  marrow  to  the  periphery  and  then  on  to 
lymphoid  tissues.  Chemokines  also  play  a  role  in  the  regulation  of  the 
inflammatory  response,  by  recruiting  cells  through  the  up  regulation  of  inducible 
chemokines  and  then  facilitating  APC  antigen  priming  of  na*fve  T  cells,  through 
their  co-localisation  in  lymph  nodes,  mediated  by  CCR7  expression.  Unfortunatqly 
turnours  can  use  the  chemokine  system  to  down  regulate  the  immune  system 
either  directly  or  by  recruiting  regulatory  cells  into  the  tumour  site. 
We  have  shown  that  the  fluorescent  biokine  uptake  assay  is  a  sensitive  and 
specific  method  of  detecting  chemokine  receptor  activity  on  immune  cells  such  as 
monocytes  and  DC  from  normal  donors  and  patients  with  malignant  disease,  such 
as  MM. 
The  uptake  of  Bio-CCL-3  was  mediated  via  CCR1  or  CCR5,  and  uptake  generally 
decreased  as  cells  differentiated  into  matDC.  This  is  consistent  with  the  reported 
reduction  of  pro-inflammatory  chemokine  receptors  reported  as  DC  mature. 
Interestingly,  the  level  of  Bio-CCL-3  uptake  activity  was  lower  on  MM  monocytes 
as  compared  to  ND.  This  could  be  simply  due  to  the  fact  that  MM  patients  have 
stem  cells  mobilised  following  chemotherapy,  rather  than  growth  factor  alone  as  in 
ND.  However,  there  may  be  an  underlying  effect  due  to  the  malignant  disease, 
and  it  may  be  possible  to  differentiate  between  the  two  by  analysing  monocyte 
expression  of  CCRII  and  CCR5  on  cells  from  MM  patients  or  ND  collected  under 
steady  state  conditions.  It  is  known  that  CCL3  levels  are  elevated  in  the  serum  and 
BM  supernatants  of  MM  patients.  These  levels  also  correlated  with  the  severity  of 
MM  bone  disease  and  prognosis,  and  increase  with  as  the  disease  progresses Dr  Simon  J  Harrison,  2005  Chapter  6-183 
(Abe,  et  a/  2002,  Choi,  et  at  2000,  Hashimoto,  et  at  2004,  Magrangeas,  et  a/  2003, 
Terpos,  et  a/  2003)We  postulate  that  these  elevated  levels  of  CCL3  may  directly 
induce  the  down  regulation  of  pro-inflammatory  chemokine  receptors  by 
desensitisation,  preventing  efficient  monocyte  recruitment  to  sites  of  inflammatiqn. 
Strangely,  the  level  of  Bio-CCL3  uptake  was  dramatically  increased  by  co- 
stimulation  with  CCL4.  This  observation  is in  keeping  with  a  number  of  recent 
reports  that  have  shown  that  some  chemokines,  such  as  CCL21  and  CXCI-13,  and 
CXCLB  and  CXCL6,  may  produce  synergistic  effects  on  target  cell  migration 
(Paoletti,  et  al  2005,  Struyf,  et  al  2005).  In  addition  Paoletti  et  al  have  suggested 
that  these  effects  may  be  mediated  by  the  formation  of  chemokine  heterodimers.  It 
is  already  known  that  CCL3  and  CCL4  are  secreted  in  the  form  of  heterodimers  by 
monocytes  (Guan,  et  al  2001),  and  we  postulate  that  these  two  mechanisms  may 
be  responsible  for  the  increase  in  Bio-CCL3  uptake  observed  by  co-stimulation 
with  CCL4.  These  observations  are  of  interest  to  those  who  are  designing 
immune-based  therapies,  as  it  is  clear  that  receptor-ligand  interactions  alone  are 
not  enough  to  trigger  functions  such  as  migration  (Randolph,  et  a/  2005).  Dendritic 
cell  migration  also  requires  cells  to  be  primed  with  a  balance  of  other  stimuli,  such 
as  PgE2  and  CD40L,  in  order  for  migration  and  not  cytokine  production  to  be 
tfiggered. 
Interestingly,  this  assay  showed  some  CCR7  activity  on  monocytes  collected 
during  stem  cell  mobilisation,  which  was  similar  in  cells  collected  from  MM  patients 
and  ND.  This  expression  was  confirmed  on  PCR  analysis.  To  my  knowledge, 
CCR7  expression  has  not  been  previously  reported  on  monocytes.  It  is  possible 
that  this  receptor  expression  may  allow  limited  monocyte  access  to  lymphoid 
tissue,  where  they  could  differentiate  into  macrophages  or  DC,  known  to  be 
present  in  these  organs.  The  biokine  assay  was  also  used  to  track  the  up 
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It  is  not  surprising  that  that  the  chemokine  receptor  profile  of  MoDC  may  be 
influenced  by  the  cytokines  used  to  generate  them.  Immature  DC  from  MM 
patients  generated  using  GMIIL-13  had  a  lower  expression  of  CCR  7  compared  to 
those  generated  by  GM/IL-4.  The  maturation  cocktail  also  influenced  the  level  of 
CCR7  expression.  Normal  donor  DC  matured  with  X4  had  higher  level  of  CCR7 
expression  compared  with  normal  donor  cells  matured  with  MIMIC  and  MM  DC 
matured  with  X4,  again  suggesting  an  inherent  difference  between  MM  and  ND 
dedved  cells. 
CCR8  expression  could  be  measured  using  the  Bio-CCL1  surface-marking  assay, 
and  this  expression  was  shown  to  up-regulate  during  MoDC  production. 
Monocytes  and  matDC  from  MM  patients  were  shown  to  have  a  significantly 
higher  expression  of  CCR8  as  compared  to  normal  donors.  This  observation 
suggests  that  cells  from  MM  patients  may  be  more  sensitive  to  the  potential 
immunosuppressive  effects  of  CCL1  reported  recently  (Batten,  et  a/  2005) 
.  Batten 
et  al  showed  that  mesenchymal  stem  cells  (MSC)  directly  inhibited  T  cell 
proliferafive  responses  to  allo  PBMCs,  and  failed  to  induce  the  proliferation  of 
primary  and  primed  T  cells,  through  the  production  of  CCL1.  Furthermore,  MSCs 
also  induced  T  cell  production  of  Th2  cytokines  and  chemokines  (IL-3,  IL-5,  IL-10, 
IL-15  and  CCU),  accompanied  by  down  regulation  of  Thl  cytokines  (IL-1  a,  IL-P, 
IFNy  and  TNFa). 
A  greater  understanding  of  how  malignant  diseases  and  their  therapies  interact 
with  the  chemokine  system  is  required  if  the  DC  system  is  to  be  used  to  produce 
effective  immune  therapies  for  patients.  The  changes  in  the  MoDC  system 
detected  in  cells  from  MM  patients  suggest  that  monocytes  are  unable  to  home  to 
sites  of  inflammation,  matDC  have  impaired  ability  to  home  to  LN  and 
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MM  monocytes  and  DC.  The  correlation  between  the  expression  of  CCPs  on  MM 
patient  cells  With  the  level  of  chemokines  in  the  plasma  and  bone  marrqw  may 
provide  further  insights  into  these  processes. 
Observations  such  as  these  may  help  to  explain  why  DC  used  in  immunotherapy 
trials  have  failed  to  home  effectively  to  lymph  nodes,  or  have  any  major  impact  qf 
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7.  Discussion  and  Conclusions 
The  field  of  tumour  immunotherapy  is  still  in  its  infancy.  It  is  becoming  clear  that 
the  human  immune  response  is  the  result  of  highly  complex,  continuously  evolving 
interactions  between  cells  of  the  adaptive  and  innate  arms  of  the  immune  system, 
the  internal  and  external  environments,  and  normal  and  abnormal  cells  (i.  e. 
malignant  or  virally  infected  cells).  Despite  the  considerable  advances  in  our 
knowledge  over  the  past  30  years,  we  still  seem  to  have  only  scratched  the 
surface  of  the  complexities  of  the  immune  system  and  it's  interaction  with 
malignant  disease.  It  is  therefore  not  surprising  that  the  results  from 
immunotherapy  trials  have  so  far  been  disappointing.  Although  we  and  others  are 
able  to  generate  immune  effector  cells  in  the  laboratory  that  are  capable  of  killing 
tumour  cells  in-vitro,  with  the  notable  exception  of  PTLD  (Bollard,  et  a/  2003),  this 
has  not  translated  into  improved  outcomes  for  patients  with  malignant  disease  who 
have  participated  in  clinical  trials  of  tumour  specific  immunotherapy.  There  are  a 
number  of  factors  that  are  likely  to  contribute  to  this  situation: 
1.  As  with  most  new  therapies,  the  majority  of  immunotherapy  trials  have  been 
conducted  in  patients  who  have  advanced  malignant  disease.  Given  that 
patients  who  undergo  allo  HSCT  have  improved  survival  when  transplanted 
early  in  the  disease  course  (Gratwohl,  et  a/  1998),  and  respond  best  to  DLI 
when  it  is  given  for  relapse  at  the  molecular  level  (van  Rhee,  et  a/  1998)  the 
poor  results  so  far  in  the  immunotherapy  trials  are  hardly  surprising.  It 
remains  unclear  whether  the  negative  impact  of  disease  burden  is  the  result 
of  disease  suppression  of  the  immune  system  or  if  the  increased  amount  of 
treatment  that  these  patients  will  have  received  also  contributes  to  their 
poor  outcomes.  Clearly  it  will  be  advantageous  to  use  immunotherapy 
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tumour  burden  is  at  its  lowest  (Hsu,  et  al  1997),  such  as  following 
autologous  HSCT. 
2.  Thus  far  it  has  been  difficult  to  identify  tumour  specific,  immunogenic 
antigens  with  which  we  can  direct  the  immune  system  against  the  malignant 
clone.  The  success  of  immunotherapy  in  the  treatment  of  PTLD  is  largely 
attributable  to  the  fact  that  the  immune  therapy  is  direct  against  a  few  well 
characterised,  highly  immunogenic  viral  (i.  e.  EBV)  Ags.  In  the  majority  of 
other  malignancies  in  which  immunotherapy  is  being  explored,  the  potential 
target  antigens  that  have  been  employed  so  far  are  normal,  often  early 
developmental  antigens,  that  are  expressed  in  an  aberrant  location  and  to  a 
much  higher  degree  than  normal  (i.  e.  wrong  place,  wrong  time  and  wrong 
amount),  such  as  MUC-1,  NY-ESO-1  and  Id  protein  (Barratt-Boyes  1996, 
Timmerman,  et  al  2002,  van  Rhee,  et  al  2005a).  Many  groups,  including  our 
own,  have  opted  for  a  simpler  approach.  Rather  than  trying  to  identify 
tumour  specific  antigens  with  which  to  prime  the  immune  system,  whole 
tumour  cell  preparations  can  be  used,  such  as  freeze  thaw  tumour  cell 
lysates  and  apoptotic  tumour  cells  (Hayashi,  et  al  2003,  Kotera,  et  al  2001), 
leaving  the  APC  and  immune  effector  cells  to  identify  the  most 
immunogenic  epitopes.  While  this  method  runs  the  risk  of  potentially  useful 
antigens  being  ignored  by  the  immune  system  because  of  the  antigen 
immuno-dominance  phenomenon  (Berkower,  et  al  1982,  Gapin,  et  al  1998, 
Milazzo,  et  a/  2003),  it  is  less  likely  that  a  broad  based  approach  such  as 
this  will  allow  the  tumour  to  escape  immune  based  therapies  by  simple 
down-regulation  or  deletion  of  a  single  target  antigen.  This  approach  does 
not  get  around  the  theoretical  problem  of  the  potential  anti-tumour  Ags 
being  only  weakly  immunogenic,  due  to  the  fact  that  the  host  may  have 
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in  Figure  5-9,  it  was  shown  that  this  type  of  antigen  preparation  is  capable 
of  producing  tumour  cell  kill  at  relatively  low  effector  target  ratios  in-vitro.  It 
remains  to  be  seen  whether  this  success  can  be  replicated  in-vivo. 
In  diseases  such  as  MM,  which  induce  a  hostile  environment  in  which  to 
attempt  to  generate  an  immune  response  (Brown,  et  a/  2001,  Cook,  et  a/ 
1999),  it  is  unclear  when  and  how  the  cells  that  are  to  be  used  to  generate 
APC  should  be  collected.  Furthennore,  there  is  still  debate  about  which 
cells  should  be  used  i.  e.  circulating  blood  DC,  MoDC  or  indeed  whether  the 
whole  of  this  process  can  be  conducted  in-vivo  via  antigen  vaccination  with 
the  addition  of  adjuvants  to  attract  APC  to  the  vaccination  site  and  then 
promote  maturation,  migration  and  immunogenic  antigen  presentation  to 
immune  effectors  (Adams,  et  a/  2005).  In  order  to  reduce  the  negative 
impact  of  the  tumour  on  the  immune  based  therapy,  it  would  again  seem 
logical  to  collect  the  cells  and/or  vaccinate  at  a  time  when  the  tumour 
burden  is  at  Ws  lowest  (Hsu,  et  a/  1996).  In  the  treatment  of  the  majority  of 
patients  with  myeloma  this  would  be  after  the  patients  had  recovered  from 
autologous  HSCT  (Attal  and  Harousseau  1999). 
4.  In  order  to  generate  a  cytotoxic  immune  response,  vaccinated  DC  need  to 
migrate  from  the  vaccination  site,  i.  e.  the  skin,  to  secondary  lymphoid 
tissues  such  as  draining  lymph  nodes.  There  is  evidence  that  matDC  used 
in  clinical  studies  fail  to  migrate  in  significant  numbers  (Blocklet,  et  al  2003) 
despite  seemingly  adequate  expression  of  chemokine  receptors  that  are 
thought  to  mediate  DC  migration  to  LN,  such  as  CCR7.  Recent  evidence 
suggests  that  the  factors  governing  DC  migration  are  not  as  straight  forward 
as  originally  thought.  Other  chemokine  receptors  ,  such  as  CCR8,  and  the 
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to  LN  (Qu,  et  a/  2004,  Randolph,  et  a/  2005).  Some  groups  have  tried  to 
circumvent  this  process  by  direct  intranodal  injection  of  DC  (Yi,  et  al  2003). 
However,  these  approaches  have  thus  far  not  produced  significant 
improvements  in  the  potency  of  the  anti  tumour  effect  in  the  treatment  of 
patients  with  MM.  A  greater  understanding  of  how  the  chemokine  system 
controls  DC  and  effector  cell  migration,  and  how  the  hostile  tumour  induced 
environment  may  inhibit  this  process  is  required  if  we  are  to  translate  the 
encouraging  in-vitro  anti-tumour  effects  demonstrated  in  Figure  5-11  into 
effective  therapies  for  MM  patients.  Tools  such  as  the  fluorescent 
chemokine  uptake  and  staining  assays  described  in  Chapter  6  will  prove 
useful  in  this  process.  They  provide  a  rapid,  straight  forward,  direct 
functional  measure  of  chemokine  receptor  activity  on  target  cells.  Thus  it  is 
no  longer  necessary  to  rely  upon  phenotypic  data  alone  or  undertake 
complex  migration  experiments  in  order  to  assess  chemokine  receptor 
expression  and  activity. 
5.  Immune  effector  cells  are  also  suppressed  in  malignant  diseases  such  as 
MM  (Campbell,  eta/  2001,  Cook,  eta/  1999).  Data  from  studies  such  as 
those  described  in  Chapter  5  and  the  XcellerateTm  trial  (Vij,  et  a/  2003) 
should  help  us  decide  whether  it  is  possible  to  improve/boost  any  inherent 
anti-tumour  immune  response  (as  shown  in  Figure  5-8),  or  reverse  any 
turnour  induced  suppression  of  effector  cells  in  order  to  improve  the  efficacy 
of  immune  base  therapies  (as  suggested  by  Figure  5-9).  It  would  also 
seem  sensible  to  collect  immune  effectors  for  use  in  immune  therapies  at  a 
time  when  the  disease  burden  is  at  its  lowest.  Given  that  this  cytotoxicity 
data  showed  the  best  tumour  cell  kill  was  achieved  using  MM  T  cells 
collected  after  cyclophosphamide  and  G-CSF,  it  would  be  reasonable  to 
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keeping  with  published  data,  which  suggest  that  G-CSF  alone  is  associated 
with  a  greater  proportion  of  DC2  as  compared  with  chemotherapy  and  G- 
CSF  mobilisation  (Bolwell,  et  a/  2003),  and  G-CSF  mobilised  cells  contain 
an  increase  propotion  of  TRgs  (Vela-Ojeda,  et  a/  2005).  It  is  not  known 
whether  the  improved  cytotoxicity  data  was  as  the  result  of  altering  the 
proportions  of  T  cell  subsets  that  were  collected,  i.  e.  suppressing  TRegs.  It 
remains  to  be  seen  whether  this  method  is  preferable  to  collecting  cells 
under  steady  state  conditions,  without  any  formal  mobilisation.  These 
questions  warrant  further  investigation,  as  the  cellular  composition  of  the 
starting  material  with  which  an  immunotherapy  is  built  may  have  a  dramatic 
impact  on  the  end  results.  There  is  good  experimental  evidence  to  suggest 
that  depleting  subjects  of  TRgs  prior  to  vaccination  with  DC  based 
immunotherapy  may  improve  the  effectiveness  of  these  approaches 
(Ghiringhelli,  et  al  2005,  Sakaguchi,  et  a/  2001).  Whether  this  can  be 
achieved  using  a  simple  in-vivo  T  cell  suppressive  therapy  such  as 
cyclophosphamide  (Rosenberg,  et  a/  1994a),  or  requires  a  more  specific 
approach  using  an  anti-CD25  monoclonal  antibody,  such  as  denileukin 
diftitox  (Ontak)  (Olsen,  et  al  2001),  to  specifically  deplete  the  subject  of 
CD25+  cells  remains  to  be  seen. 
When  designing  immune  therapies  for  use  in  patients,  it  is  important  to  consider 
that  the  building  blocks  of  the  treatment,  i.  e.  the  cells  of  the  immune  system,  may 
be  numerically  and  functionally  abnormal.  The  blood  DC  system  in  MM  and  MGUS 
patients  is  compromised  at  diagnosis  (Brown,  et  a/  2001,  Ratta,  et  a/  2002)  and 
Figure  3-6.  However,  following  autologous  HSCT  or  thalidomide  therapy  for  the 
treatment  of  relapse,  there  is  an  improvement  in  the  numbers  of  circulating  blood 
DC,  albeit  short  lived  (Figure  3-8  and  3-9).  This  would  suggest  that  the  best  time 
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chemotherapy  and  stem  cell  rescue.  This  is  in  keeping  With  other  published  data, 
which  suggest  that  the  best  time  to  use  immune  base  therapies  is  a  time  when  the 
disease  burden  is  at  its  lowest  (Hsu,  et  a/  1997,  Stevenson,  et  a/  2004).  The 
immune  system  in  MM  patients  follovving  these  types  of  therapies  does  not  return 
to  non-nal,  in  that  the  B  cell  and  pDC  numbers  remained  suppressed  (Data  not 
shown  and  Figure  3-8).  Along  with  the  data  from  other  groups  which  has  shown 
that  the  blood  DC  do  not  mature  normally  (Brown,  et  al  2001,  Ratta,  et  al  2002),  it 
is  becoming  clear  that  blood  DC  are  not  ideal  for  use  as  immune  therapies  for  MM. 
Generating  DC  from  monocytes  is  a  more  encouraging  prospect.  Monocytes  are 
more  readily  available  than  blood  DC,  and  the  use  of  CD34*  cells  is  more 
technically  demanding,  with  respect  to  the  collection  and  purification  of  CD34" 
cells  in  sufficient  quantity,  and  Ag  loading  of  CD34*  derived  DC.  However,  even 
when  monocytes  were  collected  following  a  course  of  anti-MM  induction  therapy 
and  stem  cell  mobilisation,  MoDC  generated  from  MM  patients  were  still  found  to 
be  phenotypically  and  functionally  abnormal  at  all  stages  of  development  (Figure 
4-2,4-4,4-6  and  4-8).  Cells  that  were  matured  with  the  X4  cytokine  combination 
were  found  to  be  superior  to  those  cells  matured  with  the  MIMIC  combination,  in 
that  a  higher  proportion  of  X4  matured  cells  expressed  CD83  (Table  4-2)  and  had 
greater  CCR7  activity  (Figure  6-10).  It  is  also  likely  that  prior  to  being  used  as 
therapy,  MoDC  would  need  to  be  matured  for  48  hours  in  order  to  fully  up  regulate 
chemokine  receptors,  such  as  CCR7,  and  efficiently  migrate  to  lymph  nodes  in 
order  to  interact  with  T  cells  (Figure  4-10).  It  is  currently  unclear  whether  the 
increase  in  CCR8  expression  on  MM  matDC  has  a  negative  or  a  positive  impact 
on  MoDC  migration  following  vaccination  (Figure  6-14).  Overall,  these  findings 
suggest  that  it  may  be  crucial  to  optimise  MoDC  production  for  each  disease  state 
in  which  they  are  to  be  used,  in  order  to  maximise  the  chances  of  inducing  an 
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best  be  studied  using  a  combination  of  ligand  uptake,  surface  antibody  staining 
and  in-vWtn-vivo  migration  assays  to  determine  the  optimal  timing  of  MoDC  Ag 
loading,  maturation  and  administration. 
Despite  the  limitations  imposed  by  using  functionally  abnormal  cells,  MM  patient 
MoDC  can  be  used  to  generate  anti-MM  cytotoxic  T  cells  in-vitro.  The  cytotoxic 
activity  of  unprimed  MM  patient  T  cells  was  better  than  that  observed  with  ND 
cells,  and  this  may  be  related  to  the  fact  that  the  MM  cells  were  collected  after 
cyclophosphamide  and  G-CSF,  while  the  ND  cells  were  collected  following  G-CSF 
alone  (Figure  5-8)  and  the  potential  differences  in  the  T  cell  populations  in  the 
respective  collections,  as  discussed  above.  The  proliferative  response  to  IL-2  + 
matDC  and  the  cytotoxic  activity  of  MM  T  cells  was  boosted  by  pre-stimulating  with 
T  cell  activating  beads  and  IL-2,  prior  to  antigen  presentation  (Figure  5-2  and 
Figure  5-9).  This  was  despite  the  fact  that  this  process  seemed  to  render  the  T 
cells  IL-2  dependant,  in  that  they  did  not  proliferate  or  secrete  cytokines  in  the 
presence  of  DC  alone  (Figure  5-2  and  5-5).  It  remains  to  be  seen  whether  these 
effects  can  be  transferred  in-vitro  given  the  difficulties  that  surround  the  use  of  IL-2 
in  patients  (Escudier,  et  a/  1994,  Farag,  et  at  2002). 
The  observations  described  above  could  form  the  basis  for  a  novel  clinical 
immunotherapy  trial  in  MM  patients,  using  both  autologous  moDC,  pre-stimulated 
T  cells  and  followed  by  low  dose  IL-2  as  consolidation  immunotherapy  following 
inducUon  chemotherapy  and  autologous  HSCT  (Figure  7-1).  Monocytes  and  T 
cells  could  be  collected  by  formal  cyclophosphamide  and  G-CSF  mobilisation, 
following  autologous  HSCT,  at  a  time  when  the  disease  burden  is  at  its  nadir. Dr  Simon  J  Harrison,  2005 
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Figure  7-1  Total  Immunotherapy  for  Multiple  Myeloma  using  antigen  loaded 
autologous  DC,  pre-stimulated  T  cells  and  SCI  IL-2 
Collecting  immune  cells  after  induction  chemotherapy  and  auto  HSCT  should 
reduce  the  tumour  burden  to  its  lowest  level,  reducing  any  immunosuppressive 
effects  on  the  immune  system  and  the  therapeutic  cells  when  given  back  to  the 
pabent.  Monocyte  derived  DC  generated  with  GIVI-CSF  and  IL-4,  loaded  with 
autologous  tumour  cell  antigen  and  matured  with  X4  could  then  be  given  in  2 
weekly  aliquots  by  intra-dermal  injection.  T  cells  collected  during  the  same 
procedure,  marked  to  allow  tracking  studies,  pre-stimulated  with  activating  beads 
and  IL-2  would  be  administered  simultaneously  by  IN.  infusion.  This  should 
enable  the  antigen  loaded  matDC  and  pre-stimulated  T  cell  to  migrate  to  lymph 
nodes  in  the  same  time  frame.  IL-2  would  be  administered  by  SCI  the  next  day 
and  daily  for  the  next  2  weeks  to  provide  cytokine  growth  support  to  the  pre- 
stimulated  cells. Dr  Simon  J  Hanison,  2005  Chapter  7-194 
The  aim  of  collecting  cells  at  such  a  late  time  point  in  the  treatment  of  MM  is  to 
minimise  any  disease  related  immunosuppressive  effects  on  the  collected 
monocytes  and  T  cells.  A  secondary  effect  of  collecting  T  cells  at  this  point  may  be 
a  relative  depletion  of  memory  and  regulatory  T  cells,  whilst  enriching  for  nawe  T 
cells  as  the  immune  system  repopulates  itself  folloWng  autologous  HSCT.  These 
hypotheses  foffn  the  rational  basis  for  the  use  of  autologous  HSCT  for  the 
treatment  of  autoimmune  diseases  such  as  rheumatoid  arthritis  and  Immune 
thrombocytopaenic  purpura  (Huhn,  et  a/  2003,  Snowden,  et  a/  2004).  Monocytes 
would  be  cultured  with  IL-4  and  GM-CSF,  primed  with  an  autologous  tumour  cell 
preparation  (i.  e.  tumour  cell  lysate)  collected  at  the  time  of  diagnosis,  and  matured 
with  the  X4  cytokine  combination.  At  the  same  time  T  cells  could  be  pre-stimulated 
with  anti-CD2,3  and  28  coated  beads  and  IL-2,  in  order  to  reverse  T  cell  anergy 
and  regain  T  cell  responsiveness  to  IL-2.  Both  cell  types  could  be  administered  on 
the  same  day,  DC  by  ID  and  T  cells  by  IV  injection,  in  order  to  promote  rapid  co- 
localisation  in  lymph  nodes.  Subcutaneous  low  dose  IL-2  would  be  given  the 
following  day  to  maintain  T  cell  viability,  increase  the  T  cell  proliferation  stimulus 
and  stimulate  the  adaptive  and  innate  immune  systems  (Aladdin,  et  a/  2000, 
Dudley,  et  a/  2002,  Gonzalez-Barca,  et  a/  1999). 
In  a  similar  vein,  although  MM  is  susceptible  to  the  GVL  effect,  and  patients  who 
have  relapsed  following  allo  HSCT  do  respond  to  DLI.  However,  it  is  far  less 
potent  strategy  for  patients  with  MM  when  compared  to  other  diseases,  such  as 
CIVIL  (Verdonck,  et  a/  1998).  This  may  be  in  part  due  to  the  timing  of 
administration,  as  it  is  known  that  patients  with  molecular  relapses  from  CIVIL 
respond  better  to  DLI  as  compared  to  patients  with  haernatological  relapse.  Up 
until  now  it  has  been  difficult  to  monitor  MM  with  this  level  of  sensitivity,  but  the 
use  of  techniques  such  as  serum  free  light  chain  quantification,  high  sensitivity 
chimerism  assays  and  rapid  PCR  MRD  monitoring  may  improve  this  situation Dr  Simon  J  Hanison,  2005  Chapter  7-195 
(Rasmussen,  et  al  2004).  As  previously  discussed,  it  is  also  likely  that  the  donor 
lymphocytes  are  being  infused  into  a  hostile  immunosuppressive  environment 
induced  by  the  MM  tumour  cell.  Pre-stimulation  of  donor  lymphocytes  may  render 
the  cells  less  sensitive  to  the  effects  of  the  MM  turnour  cells.  When  given  in 
combination  with  IL-2  to  provide  cytokine  support  to  these  pre-stimulated  cells, 
there  may  also  be  more  generalised  immuno-stimulatory  effects  on  the 
transplanted  immune  system,  which  may  promote  an  increase  in  the  GVL  effect 
(Kiss,  et  al  2003,  Slaviin,  et  a/  1996).  This  combination  may  warrant  further 
investigation,  and  could  form  the  basis  of  a  more  potent  treatment  for  MM  relapse 
following  allo  HSCT. 
We  are  about  to  enter  an  exciting  phase  in  the  development  of  immune  based 
therapies  for  malignant  diseases  such  as  MM  when  we  can  build  on  the  results  of 
the  phase  I  studies  and  the  advances  in  basic  immunology.  A  greater 
understanding  of  how  the  adaptive  and  innate  arms  of  the  immune  system  interact 
and  regulate  each  other  may  be  crucial  in  this  process  and  form  the  basis  of  some 
of  the  next  generation  of  clinical  immunotherapy  studies  (Ritchie  D,  personal 
communication).  It  may  also  be  possible  to  engineer  our  cellular  therapies  so  that 
a  number  of  different  cell  types  are  administered  in  the  correct  state  of  maturation, 
allowing  them  to  rapidly  co-localise  in  lymph  nodes  and  interact  efficiently,  whilst 
being  resistant  to  the  suppressive  effects  of  the  tumour. 
Ultimately,  it  may  be  possible  to  avoid  having  to  process  cells  in-vitro  by  using 
cytokines  and  chemokines  to  manipulated  cells  of  the  immune  system  in-vivo.  In 
theory,  it  should  be  possible  precondition  an  area  of  skin  so  as  to  attract  or 
generate  APC  ready  to  receive  tumour  specific  antigen  delivered  by  simple 
vaccination.  The  addition  of  adjuvant  compounds  would  then  promote  efficient 
APC  maturation  and  migration  to  lymph  nodes  where  they  would  present  antigen Dr  Simon  J  Hanison,  2005  Chapter  7-196 
to  immune  effector  cells,  such  as  naive  T  cells.  A  CD8  cytotoxic  T  cell  response 
could  be  promoted  by  further  administration  of  cytokines,  such  as  IL-2.  Mowever, 
while  we  are  developing  and  testing  the  next  generation  of  immunotherapies  we 
should  remember  that  even  if  the  disease  burden  is  reduced  to  a  very  low  level,  it 
may  still  have  a  disproportionate  suppressive  effect  on  the  host  immune  system. 
Thus  these  in-vivo  approaches  would  seem  to  be  a  very  long  way  off  for  the 
treatment  of  diseases  such  as  MM. 
In  summary,  the  results  described  in  this  thesis  have  confirmed  that  the  DC 
system  is highly  abnormal  in  MM  patients,  but  does  recover  to  some  degree 
following  autologous  HSCT.  Although  the  mature  MoDC  produced  from  MM 
patients  seem  to  be  of  poorer  quality  than  those  from  ND,  when  combined  in-vitro 
with  pre-stimulated  autologous  T  cells,  the  resultant  cytotoxic  T  cells  had  superior 
killing  ability  compared  to  ND  and  un-stimulated  T  cells.  However,  the  CCR7  and  8 
chemokine  activity  of  mature  MoDC  when  measured  using  the  fluorescent  ligand 
uptake  and  staining  assays  was  abnormal,  suggesting  that  when  administered  in- 
vivo,  MM  matDC  may  not  migrate  as  efficiently  to  lymph  nodes  and  be  more 
susceptible  to  immunosuppressive  chemokines  as  compared  to  normal  DC.  These 
results  should  help  in  the  development  of  effective  immune  based  therapies  for  the 
treatment  of  MM  and  other  malignant  diseases. Dr  Simon  J  Harrison,  2005 
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